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Abstract 
Yersinia pestis, an organism endemic in much of the world, is the causative agent of 
pneumonic and bubonic plague. The disease is severe with a high mortality rate. Most 
plague vaccines are formalised whole cells, which give limited and short-lived immunity. 
An acellular vaccine could prove to be more effective than using killed whole cells, 
without the associated side effects. 
The 17.5kDa PI antigen of Y. pestis has been shown to be immunogenic and protective in 
mice (Simpson et at., 1990) and therefore it might be a suitable component of an acellular 
vaccine. In this study, the conditions for the production and purification of Fl from 
culture of Y. pestis were examined with a view to increasing the yield of FI antigen. The 
optimal conditions were to grow Y. pestis MRE 1447 in a chemically defined medium at 
pH7.4 for 48h at 37°C and these conditions were transferred to a 25-litre fermenter for the 
larger-scale production ofFI antigen. Typically, 40mg ofFI antigen of~90% purity was 
obtained from lL of culture supernatant. The purified Fl was characterised using 
biochemical, structural and immunological methods to confirm the integrity of the 
purified antigen. Immunological methods using anti-Fl monoclonal and polyclonal 
antibody identified the purified antigen as Fl. Structural studies on the glycosylation of 
the protein showed that no post-translational glycosylation of the protein could be 
detected by the methods used in this study. The cafl sequence was successfully cloned 
into Escherichia coli to produce a recombinant Fl antigen. This recombinant antigen 
proved to be both immunogenic and protective but yields of recombinant protein were 
consistently low. 
Purified culture-derived native Fl and a recombinant V antigen (produced at CBD, 
DERA) were used to assess controlled-release vaccine delivery systems in poly(lactide-
co-glycolide) PLG micro spheres and liposomes. Recombinant V was used in addition to 
FI to assess a combination subunit vaccine with FI given alone as an acellular vaccine. 
FI antigen encapsulated in PLG microspheres induced high serum antibody titres when 
injected i.p. in mice; mucosal IgA was also detected. Mice immunised with Fl in 
Alhydrogel or PLG micro spheres were protected against sub-cutaneous challenge with Y 
pestis. FI antigen surface-labeled onto liposome vesicles stimulated high serum titres in 
Balb/c mice; a mucosal response was also induced and mice were protected against sub-
cutaneous challenge with up to 1 x 105 organisms. This strongly indicated that 
immunising with Fl formulated in PLG micro spheres and liposomes induced a potent 
immune response and that protection was achieved after only one dose. However, 
increased protection was observed when a combination vaccine of Fl and rV was 
administered in PLG microspheres, liposomes or Alhydrogel given in multiple doses. 
The efficacy of different delivery routes against sub-cutaneous Y. pestis challenge was 
also investigated. Administration by the i.p. route gave consistent protection against sub-
cutaneous plague challenge. The i.n. route also proved effective for both PLG 
microspheres and liposomes when multiple doses were used. Oral delivery failed to give 
adequate protection against sub-cutaneous infection, even after multiple doses. 
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Chapter 1 
General Introduction 
1.1 The Genus Yersinia 
The genus Yersinia is part of the family Enterobacteriaceae. Y. pestis, Y. pseudotuberculosis 
and Y. enterocolitica are the three most important species of the genus with respect to 
pathogenicity for animals and humans. Y. intermedia, Y. kristensenii, Y. fredericksenii, Y. 
aldovae and Y. rohdei are widespread environmental bacteria, not usually associated with 
disease. Y. mollaretti and Y. bercovieri have been separated from Y. enterocolitica (Wauters 
et al., 1987), although they formerly belonged to biogroups 3A and 3B respectively and their 
importance in pathogenesis is undetermined, but they seem to be devoid of virulence-linked 
properties. Another species, Y. ruckeri, is an important fish pathogen responsible for the red 
mouth disease in rainbow trout and some other fishes (Carniel and Mollaret, 1990). 
The members of the genus Yersinia are facultatively anaerobic Gram-negative short rods 
which grow better at 25°C than at 37°C on media commonly used for Enterobacteriaceae 
(figl.l). Colonies are lactose negative and only appear after 48h of growth. The bacteria have 
the ability to grow at 4°C (cold enrichment); however, this property seems to be more 
beneficial for environmental species than for pathogenic ones (Carniel and Mollaret, 1990). 
1.1.1 Diseases caused by Yersinia 
Y. pestis, Y. pseudotuberculosis and Y. enterocolitica are the three species of the genus 
Yersinia that cause disease in humans. These three species differ considerably in invasiveness 
and vary in infection route; they also cause diseases of contrasting severity. However, they 
exhibit a common tropism for lymphoid tissue and are able to avoid lysis by complement, 
aVoid phagocytosis by polymorphonuclear leucocytes or macrophages (Rodrigues et al., 
1992) and are capable of forming extracellular microcolonies in the infected tissues 
(Cornelius et al., 1987). Y. enterocolitica and Y. pseudotuberculosis can cross the 
gastrointestinal mucosa to infect underlying tissue, but infections usually remain localised in 
the sub-mucosal area (portnoy and Martinez, 1985; Bolin and Wolf-Watz, 1984). Y. 
pseudotuberculosis is essentially a rodent pathogen which can be transmitted orally and 
causes diarrhoea, emaciation and death as a result of septicaemia. Y. enterocolitica is a 
common human pathogen which causes gastrointestinal disorders of varying severity, from 
mild self-limiting diarrhoea to mesenteric adenitis resembling appendicitis; systemic 
involvement is unusual. Transmission is usually by consumption of contaminated food or 
water. Several cases of septic shock due to transfusion of blood 
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Fig. 1.1 Electron micrograph of Y. pestis strain MRE 1447 
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Strain MRE 1447 was grown in YPMH chemically defined media (Table 2.1). A 48h 
culture was diluted with YPMH containing 0.0 1 % formaldehyde, after confirmation of 
non-viability cells were washed and resuspended in PBS. Bacteri al suspensions were 
coated onto an electron micrograph grid and stained with 1 % (w/v) PTA (pH7.2) and 
viewed by transmission electron microscopy using a magni fication of x70 000. 
contaminated with Y. enterocolitica have been reported (Tipple et al., 1990). In Europe, pork 
was reported to be a source of infection by Y. enterocolitica (Tauxe et at., 1987). Only a few 
well-defined serotypes of Y. enterocolitica are pathogenic, serotype 0:8 is often associated 
with disease. 
Y. pestis, the causative agent of plague, is nonnally injected into the body by an insect bite 
and therefore does not have to penetrate a body surface unaided. However, after infection by 
this route, bacteria disseminate throughout the body and can eventually reach the lungs. 
Bacteria can then be spread from person-to-person via the respiratory route which is referred 
to as pneumonic plague (Bartelloni et al., 1973) therefore, Y. pestiS has the potential to cause 
epidemics. 
1.1.2 Pathogenic mechanisms 
Environmental effects on growth differ between species of Yersinia as they occupy their own 
environmental niche. Some pathogenic organisms become rapidly killed in nature following 
separation from their host. However, gastro-intestinal parasites are typically more sturdy and 
can often survive without net increase in cell number for prolonged periods of time. The 
enteropathogenic Yersinia are excellent examples of this, whereas Y. pestis is more fastidious 
and has evolved a distinct strategy of survival. The enteropathogenic Yersinia generally cause 
gastrointestinal disease in their natural hosts. As a consequence organisms are excreted for 
prolonged periods of time, thereby favouring ingestion by new hosts. This is not the case with 
Y. pestis which usually kills its host. Bubonic plague is manifested as an acute, intransigent 
and lethal disease which is dependent on mounting an immediate and overwhelming attack 
on the host before the immune system becomes capable of providing significant defence. 
Man sometimes becomes part of this cycle. Yersinia are known to interact with phagocytic 
cells of the host and they are obligate intracellular parasites which can multiply within the 
phagosome; in fact some virulence factors are only expressed after the bacteria have been 
phagocytosed. 
In the first stages of Y. enterocolitica and Y. pseudotuberculosis infections, the bacteria attach 
to the intestinal mucosa followed by infection of underlying tissue. A toxin similar to the ST 
toxin of enterotoxigenic Escherichia coli, called Yst, is produced by Y. enterocolitica and 
may be responsible for the diarrhoea that is a common symptom of Y. enterocolitica 
infections. However, when Y. enterocolitica is grown in vitro, the gene for Y st is expressed 
only at temperatures lower than 30°C (Amirrnozafari and Robertson, 1993; Mikulskis et al., 
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1994), therefore there has been a tendency to dismiss Yst as the cause of diarrhoea. 
Nevertheless, sufficient Y st could be present in bacteria entering the host to cause symptoms. 
There is also recent evidence to suggest that the pattern of temperature regulation of virulence 
factors may be different at different pH values (Straley and Perry, 1995). It is assumed that 
the bacteria cross the intestinal mucosa by first binding to the apical surface of gut epithelial 
cells; the cells in this region then engulf the bacteria, enabling them to cross the mucosa 
inside the phagocytic vesicle to reach the basal surface where bacteria are released by 
exocytosis. Such a model seems reasonable when bearing in mind the ability of these 
organisms to adhere to and be engulfed by cultured mammalian cells in vitro (Brubaker, 
1991a). It remains unclear, however, as to the exact role of proteins that mediate invasion of 
cultured cells (invasion factors). 
All three pathogenic species of Yersinia are serum resistant. In Y. enterocolitica and Y. 
pseudotuberculosis, serum resistance is an inducible trait, and bacteria become serum 
resistant only at 37°C (Salyers and Whitt, 1991). In Y. pestis, a protease, plasminogen 
activator (PIa) confers serum resistance (Sodeinde et al., 1992). Among other functions, this 
extracellular protease can degrade the C3b and C5a components of complement. Therefore, 
PIa could contribute to serum resistance by preventing formation of the membrane attack 
complex (MAC) which damages the membrane of the pathogen, leading to lysis of the 
bacteria. In addition, PIa may have an anti phagocytic role in preventing opsonisation of 
bacteria by C3b and attraction ofphagocytes by C5a. 
Since iron is essential for bacterial growth and survival, Yersinia spp., like other bacterial 
species, have evolved strategies to obtain iron from the host. Pathogenic Yersinia spp. have 
multiple iron-acquisition systems which are induced at 37°C and anow the bacteria to obtain 
iron from haemin and transferrin, two abundant sources of iron in the human body. Among 
the first authors to provide evidence of the virulence-enhancing effect of iron in strains of Y. 
pestis were Jackson and Burrows (1956). They studied non-pigmented mutants of virulent 
strains of Y. pestis which were unable to absorb haemin from defined medium and 
consequently were non-virulent in mice and unable to proliferate freely in vivo because they 
were unable to derive iron from the host. However, the growth of these mutants could be 
augmented in vivo and virulence increased by injection of iron compounds with the organism. 
Many animal hosts can be infected by Yersinia spp., including mice, and developing animal 
models of infection has not been difficult, although these models do not necessarily mimic 
the human disease. 
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Yersinia spp. readily invade many types of cultured mammalian cells, including HeLa, Hep-2 
and Henle cell lines. This trait has been intensively studied as a model for invasion of 
mammalian cells by bacteria (Isberg, 1989). However, results of tissue culture studies are not 
always consistent with the behaviour of bacteria in vivo. 
1.1.3 Genetics of Yersinia 
Yersinia spp. exhibit a complex virulence regulatory network which is partially controlled 
by temperature. The clinically significant Yersinia can mUltiply on appropriate media at 
temperatures ranging from about 5 - 24°C. However, marked physiological differences occur 
upon an increase in growth temperature from 26°C to 37°C, including the need for additional 
nutritional requirements and expression of virulence functions. The organisms possess novel 
regulatory functions that respond to temperature and to the presence of calcium and these are 
involved in virulence. Research into the molecular biology of this genus has shown that Y. 
pestis and Y. pseudotuberculosis exhibit nearly identical chromosomal DNA relatedness 
(Bercouvier et al., 1980; Brubaker, 1972) and distinctions are mainly represented by 
differences in plasmid content (Ben-Gurion and Shafferman, 1981; Brubaker, 1991a). The 
chromosomal DNA of Y.enterocolitica has significantly less relatedness, indicating 
evolutionary divergence prior to that separating Y. pestis and Y. pseudotuberculosis. The fact 
that Y. pestis is very closely related to the much less invasive Y. pseudotuberculosis (90% 
DNNDNA homology) has made it possible to look for genes expressed in Y. pestis but not in 
Y. pseudotuberculosis and vice versa, thus providing an insight into which factors might 
account for the greater invasiveness of Y. pestis in humans. 
Yersinia as a genus are known to possess certain virulence factors, some of which are 
chromosomal and others are plasmid-mediated (table 1.1). A shared feature of all pathogenic 
Yersinia strains is the presence of 70- to 75-kbp Lcr (low calcium response) plasmids. Many 
of the genes necessary for virulence are encoded on these plasmids and have been cloned and 
identified. The products of these plasmid genes fall into four general categories: (i) adhesin 
protein (YadA), (ii) secreted antiphagocytic proteins and Yersinia outer proteins (Yops), (iii) 
proteins involved in processing and secretion of Yops (Ysc), and (iv) regulatory or Lcr 
proteins. Strains that have been cured of these plasmids are much less virulent. Y. pestis has 
three additional plasmids not found in Y. enterocolitica or Y. pseudotuberculosis. One is the 
110-kbp plasmid (Fra) which encodes the fraction l( FI ) protein and murine toxin. The FI 
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Table 1.1 Virulence factors of Y.pestis, Y.pseudotuberculosis and Y.enterocolitica 
VIRULENCE FACTOR Y.PESTIS Y. PSEUDOTUBERCULOSIS Y. ENTEROCOLITICA 
ca. 10-kb pst plasmid Present Absent Absent 
Plasminogen activator + 0 0 
Posttranslational + 0 0 
degradation of Yops 
ca. 70-kb Lcr plasmid Present Present Present 
Yops + + + 
YadA 0 + + 
V, Wantigens + + + 
ca. lOO-kb tox plasmid Present Absent Absent 
Fraction 1 + 0 0 
Murine exotoxin + 0 0 
Chromosomal + 0 0 
pigmentation (haemin 
storage at 26<>C) 
- ----
Host cell invasions 
inv product 0 + + 
ail product 0 0 + 
pH6antigen + + 0 
Catalase + + 0 
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protein is a component of an antiphagocytic protein capsule, whilst the murine toxin kills 
mice but has not been shown to have a role in human disease (Brubaker, 1991a). The second 
Y. pestis specific plasmid, is a 10kbp plasmid that encodes a plasminogen activator protease 
(pIa). PIa aids the dissemination of Y. pestis within the body and may also have a role in the 
insect-mediated transmission of the bacteria. The third Y. pestis specific plasmid is the Pst 
plasmid encoding the pesticin virulence determinant. 
In Y. enterocolitica and Y. pseudotuberculosis, two invasion factors have been identified, 
invasin (encoded by the inv gene) and Ail (attachment-invasion locus) (Isberg and Leong, 
1990; Miller, 1989, 1992). Both inv and ail are chromosomal genes. More recently, a 
plasmid-encoded protein originally identified as an adhesin, YadA (Yersinia adherence), has 
been shown to mediate invasion of cultured cells and can thus be added to the list of potential 
invasion factors (Bliska et aI., 1993). Virulence factors which are shared by Y. pestis and 
either or both Y. pseudotuberculosis and Y. enterocolitica, include PsaA (a pilus adhesin), 
Yops (only a few of these have assigned functions) and LcrV or V antigen. These virulence 
mechanisms will be discussed later as Y. pestis virulence factors. 
The medically significant Yersinia are closely related, therefore it follows that the genetic 
differences known to occur between them are likely to mediate the two distinct forms of 
infection. Table 1.1 summarises the similarities and differences in virulence factors in the 
three pathogenic species of Yersinia. 
1.2 Yersinia pestis 
1.2.1 The history of plague 
Y. pestis is the causative agent of bubonic and pneumonic plague and the disease has a long, 
documented history. One of the first documented accounts of plague was when the disease 
struck the Roman empire and Western Europe during the time of the emperor Justinian in 542 
A.D. and it raged on throughout the next century. Then for unknown reasons the disease 
disappeared until 1348, when it was reintroduced from the East. The disease was believed to 
have been introduced from Asia via trade routes to Europe. The first outbreaks of human 
plague are thought to have occurred in Russia, from where it spread down to the Black Sea. 
Bubonic plague then seems to have been transported aboard ships to the Mediterranean ports 
of Europe. The plague then spread further and most of Europe was affected before the 
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epidemic finally subsided in 1352 (Figure 1.2). Statistics are unreliable but it is generally 
supposed that about a third of the population of Western Europe perished during this 
epidemic. After this, episodes occurred into the late 17th and early 18th centuries and one of 
the last great outbreaks of bubonic plague occurred in 1894 in Hong Kong. Plague also broke 
out in Bombay in 1898 and in San Francisco in 1901. The latter incidences were presumably 
imported by merchant ships carrying plague-infected rats and fleas. Following this, the 
popUlation of wild rodents in California and other western states may have become infected 
with the plague bacillus as a result of contact with imported rats and plague is still endemic in 
North America today. 
Alexandre Yersin isolated the plague bacillus during the 1894 pla$lle epidemic in Hong 
Kong. This epidemic was regarded as the return of an ancient, unpredictable, little understood 
and incurable disease, much as it is still regarded today. In June of 1894, Hong Kong was 
under quarantine after the first plague victims had been diagnosed. A number of scientists 
arrived to investigate the epidemic, including Alexandre Yersin, a little known bacteriologist 
at the time. They were tasked with isolating and identifying the organism that was causing 
the bubonic plague. 
Yersin was the first scientist to look for the causative agent of plague in excised buboes and 
found them teeming with Gram-negative bacilli. There was some controversy, however, as 
another scientist, Kitasato, also working in Hong Kong investigating bubonic plague, claimed 
that the organism he had isolated was the plague bacillus. He, however, examined the heart, 
lungs, liver and spleen of plague victims and not the buboes characteristic of the disease. 
Kitasato insisted that his Gram-positive bacillus, and not Yersin's Gram-negative bacillus was 
the causative agent of plague. However, by 1898 Yersin's isolate was widely accepted as the 
plague bacillus and in France research commenced into the development of a vaccine. During 
his work in Hong Kong, Yersin established plague as a zoonosis transmitted from rat-to-rat 
and rat-to-human. However, he was not aware of the central role of the flea. This was 
discovered by another scientist from the Institut Pasteur, Paul-Louis Simond in 1897. Yersin 
also tested soil in plague-stricken areas and discovered that the bacteria are capable of lying 
in the ground for long periods without significant loss of viability. 
In 1937, the plague bacillus was classified in the genus Pasteurella, following a proposal 
made by Rahn. However, Van Loghem (1945) reasoned that this classification was 
inappropriate because it placed the plague and pseudotuberculosis bacilli among the 
Fig. 1.2 Map showing the spread of plague during the mid-14th century 
1347 - 1348 
1349 - 1350 
1351 - 1352 
McEvedy (1988) 
The spread of plague was rapid, the disease originated in central Asia and was 
transmitted to Europe via the "Silk road", reaching Kaffa in about 1347. It was 
then carried by ship to the major ports of Europe and northern Africa. Most of 
Europe was affected before the epidemic finally subsided in 1352. Milan was the 
only major city at the time to escape plague. 
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Parvobacteriaceae, characterised by their exceptionally small size, whereas Y. pestis and Y. 
pseudotuberculosis are closely related and stand apart from the genus Pasteurella in general. 
Yersin studied at the Institut Pasteur for some of his career and because of this, Yersin's 
plague bacillus was originally named Pasteurella pestis, but, Van Loghem proposed to 
classify these two species in a new genus called Yersinia, in honour of the discoverer of the 
plague bacillus (Bendiner, 1989). 
Cases of plague continue to be reported throughout the world in places such as South Africa, 
Argentina and India (Ampel, 1991). The most recent epidemic of plague was seen in India in 
the latter half of 1994 (Jacob John, 1994; Chand, 1994), in which the disease was spread in 
the pneumonic form, and prior to this in Vietnam during the Vietnam war (Marshall, 1967). 
These cases continue to occur because in many parts of the world Y. pestis is endemic in the 
rodent population. In the western United States for example, up to fifteen cases of plague 
occur annually in hikers or hunters who have acquired the disease from wild animals. There 
is some evidence to suggest that people such as hunters may acquire the disease whilst 
skinning infected animals and therefore the disease may be transmitted in aerosols from the 
dead animals as well as by insect bite. With antibiotics available in modem times, the disease 
is treatable but administration must be immediate as the disease progresses rapidly. Mis-
diagnosis and the consequent delay in the appropriate treatment mean that the disease is still 
often fatal; the most effective antibiotics in vitro are ceftriaxone and ciprofloxacin (Smith et 
al., 1995). 
1.2.2 Pathogenesis of plague 
The classical model of plague is that the disease exists in a primary animal reservoir, 
generally one of wild rodents. This epizootic spreads to the black rat (Rattus raltus), which is 
very sensitive to plague, and on its death its flea, Xenopsylla cheopsis, attaches itself to 
another available host, sometimes human. Inter-human transmission is possible, via the 
respiratory route in the case of pneumonic plague or via the human flea, although humans 
generally acquire the disease from rat fleas. Plague cannot persist endemically in human 
populations, though it does so in wild rodents. Rats which survive infection often become 
"carriers" and the rat fleas survive for long periods in the nests passing infection to new 
generations. As a result, occasional epidemics occur among the rodents greatly reducing their 
numbers. It is at such times that the two species of rats associated with man, the brown rat 
(Rattus norvegicus ) and the black rat (R . rattus), become involved in epidemics; the black 
rat is more often associated with the great plague pandemics, possibly because it is more 
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inclined to invade ships and therefore extend the spread of disease, or because its fleas are 
more aggressive to man. The fleas which infest brown rats are Ceratophyllus fasciatus; those 
of the black rat are X cheopsis, X astia and X brasiliensis. X cheopsis is the flea usually 
associated with rat-to-man transmission of plague. 
Y. pestis infections are therefore acquired in two ways, by transmission from rats or other 
wild animals to humans by flea bite, or by direct human-to-human transmission via aerosols. 
The flea bite injects the bacteria into the bloodstream and bacteria then travel in blood to the 
nearest lymph nodes. In the lymph nodes, Y. pestis is ingested by fixed macrophages, but the 
bacteria can survive and grow in normal inactivated macrophages and thus proliferate in the 
lymph nodes (Williams et al., 1972). The inflammatory respons~ to this proliferation 
produces the characteristic swelling, or bubo, that gives bubonic plague its name. Bacteria 
growing in the lymph nodes leak into the bloodstream; this stage of the disease is called 
septicaemic plague and lysis of the bacteria releases lipopolysaccharide (LPS), which causes 
septic shock. Eventually the bacteria reach the lungs, where they parasitise the lung 
macrophages and once the disease has reached this stage (called pneumonic plague) it can be 
transmitted by aerosols. Direct inhalation of the organisms in such aerosols produces a form 
of the disease that progresses much more rapidly than the flea-transmitted bubonic form, 
possibly because the aerosolised bacteria, in contrast to the flea-bite bacteria, already express 
all the virulence factors needed for colonisation of the human body and so provide a more 
overwhelming challenge to the host defence system. The fatality rate for pneumonic plague 
is high and death can occur within days. Humans with plague often develop necrotic lesions 
in peripheral blood vessels (probably as a result of LPS-induced intravascular coagulation) 
giving the skin a blackish appearance and leading to the term black plague or black death. 
Wild-type strains of Y. pestis exhibit a consistent pattern of virulence in both natural and 
experimental hosts. The ability of Y. pestis to cause a fatal disease from peripheral sites of 
infection is an important characteristic of the species. In mice, Y. pestis is rapidly removed 
from the vascular system and emerges to colonise the liver, spleen and lungs. The bacteria 
then return to the bloodstream which results in pronounced bacteraemia. The number of Y. 
pestis organisms required to cause fatal infection in mice is significantly less than that for the 
enteropathogenic Yersina. This enhanced virulence may be due to the expression of virulence 
factors, not present in the enteropathogenic Yersillia. 
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1.3 Y. pestis Virulence Factors 
Pathogenic bacterial species are adapted to multiply at the expense of a living host which 
simplifies the problem of nutrient acquisition for the bacteria but poses the problem of 
escaping from the response of the immune system of the host. To succeed in this, bacterial 
pathogens use a number of specific functions that they have evolved or acquired from other 
organisms. A bacterial infection is a sequential process in which the infecting organism must 
be able to withstand the different environmental conditions and host defence mechanisms it 
will encounter. To survive, the invading bacteria must therefore express their virulence 
functions at the appropriate time. Successful pathogens have therefore not only acquired 
virulence factors but must also subject these to a regulatory network. Therefore the virulence 
factors depend on the appropriate environmental stimuli to initiate expression. 
Proof that a given determinant serves as a virulence factor requires demonstration that its 
mutational loss from the bacterium results in a loss or reduction in virulence. This definition 
becomes more difficult when virulence is mediated by two or more proteins encoded on a 
plasmid or within a chromosomal region known to undergo loss or deletion at high 
frequency; both of these situations occur in Y. pestis. However, research in recent years has 
made progress towards identifying the individual proteins involved in the disease process and 
their importance in virulence. Y. pestis harbours three plasmids that are required for the 
expression of virulence; a 9.5kb Pst plasmid which encodes the outer membrane protein PIa, 
a 75kb Ler plasmid encoding the V antigen and Yops and the 1l0kb pFra plasmid which 
encodes the Fl antigen and murine toxin (table 1.1). Most of the mutant strains used to study 
virulence in Y. pestis show only a reduction in virulence and not a total loss of virulence, 
suggesting that the determinants m<!y act in concert to contribute to full virulence. The most 
important virulence factors that contribute to disease will be discussed here. 
1.3.1 Fl antigen 
The F 1 antigen is encoded on a 11 Okb plasmid and is a 17 .5kDa surface protein, sometimes 
referred to as the capsular antigen. It is reported to be glycosylated, bearing galactose and 
fucose residues (Bennet and Tornabene, 1974; Glosnicka and Gruszkiewicz, 1980) and 
because a recombinant Fl antigen has been shown to induce a protective immune response in 
Balb/c mice (Simpson et al., 1990) it might be a suitable component in an acellular vaccine 
to Y. pestis. Fl antigen is thought to consist of two sub-units, a protein linked to a 
polysaccharide (fraction I A) and a free protein (fraction I B). fraction I A, a 17.5kDa protein, 
and fraction 1 B, a 15kDa protein, are complexed to form a series of serologically similar 
aggregates (Glosnicka and Gruszkiewicz, 1980; Bennet and Tornabene, 1974; Baker et al., 
1952). 
Fl may have a role in the ability of Y. pestis to evade phagocytosis. Janssen et al. (1958) 
showed that both virulent and avirulent organisms grown at 26°C were capable of surviving 
inside neutrophil polymorphonuclear leukocytes and macrophages after inoculation into the 
peritoneum of guinea pigs. They reasoned that the survival and multiplication of bacteria 
inside phagocytic cells was more important than resistance to phagocytosis. Their 
experiments may resemble the conditions occurring in nature when Y. pestis lacking FI 
antigen are injected into the mammalian host from a flea bite. It i~ only after the initial 
multiplication inside the host that the bacteria express the FI antigen, enabling them to resist 
phagocytosis and disseminate throughout the body. However, Cavanaugh and Randall (1959) 
showed that Y. pestis lacking Fl, when injected into an animal model, were ingested by 
neutrophil polymorphonuclear leukocytes which kill the bacteria but mononuclear 
phagocytes (these differentiate into macrophage) permitted intracellular multiplication. 
Burrows (1963) found that virulence of naturally occurring FI- mutants was significantly 
reduced in guinea pigs. However, with advances in molecular biology it is possible to 
construct specific FI- strains to study virulence and this may have advantages over the use of 
naturally occurring mutants used in the past. Worsham et al. (1994) reported that mutants 
lacking the Fl antigen still had partial virulence and loss of it did not decrease the mouse 
lethality of Y. pestis but may have delayed time-to-death in mice that were infected with FI-
recombinant strains. It is not known whether F I is important in determining the high 
virulence of Y. pestis in humans but the fact that the time-to-death was delayed in mice when 
infected with FI- strains, indicates that FI is important for invasiveness in the early stages of 
infection and possibly acts by preventing phagocytosis by neutrophils and monocytes. There 
is evidence that the FI antigen as a surface component effectively protects bacteria in vivo 
against phagocytosis (Burrows and Bacon, 1956; Williams et al., 1972). The mechanisms of 
the anti phagocytic action ofFI antigen have been investigated by Williams et al. (1972) who 
found that FI interfered with the action of the complement components, C4 and C2. 
Complement proteins act together in a complex regulatory pathway that results in 
inactivation or efficient phagocytosis of bacteria and so any disruption of this could lead to 
prevention of phagocytosis, which in tum would aid dissemination of bacteria throughout the 
host. 
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1.3.2 V and W antigen 
The V and W antigens of Y. pestis were first discovered by Burrows and Bacon (1956). 
Burrows (1958) showed that V strains were avirulent for mice and guinea pigs whereas V+ 
strains were fully virulent. Une and Brubaker (1984), showed that virulence in Y. pestis was 
correlated with the expression in vitro of a temperature-dependent nutritional requirement for 
calcium (Ca2+), associated with the ability to produce maximal levels of V and W antigens 
(Vwa +). This phenotype is regulated by the Lcr plasmid which also promotes the synthesis of 
temperature-dependent Y ops (Wong and Elberg, 1977). 
V antigen induced in Y. pestis in vitro is found within the cytoplasm as a 37kDa protein; 
however, the origin of the W antigen, reported to be a 140kDa lipoprotein, has not yet been 
determined. The V antigen has been more intensively studied to determine its role in 
virulence and, more recently, its potential as a candidate vaccine antigen, but the 
physiological role of V in promoting disease is still not well understood. Straley and 
Brubaker (1981) isolated peptides associated with these virulence determinants by using 
methods of cell disruption and separation into cytoplasmic and outer membrane fractions 
using sucrose gradient centrifugation. Because they are not expressed on the cell surface, V 
and W antigens probably do not interact directly with host cell membrane surfaces during 
infection. However, Une and Brubaker (1984) concluded that V may facilitate intracellular 
growth because Vwa+ strains plus anti-V serum or Vwa- strains did not grow significantly 
within organs or appear in the vascular system; the bacteria had apparently been cleared. This 
hypothesis is supported by the fact that concentrations of Ca2+ and Mg2+ optimal for the 
synthesis of V antigen are similar to those in mammalian intracellular fluid (Straley and 
Brubaker, 1981). It is unclear how cytoplasmic V is released into the extracellular 
environment and whether the antigen is protective in vivo in man. Leary et al. (1995) and 
Williamson et al. (1995) have shown that V acts as a very effective protective antigen in 
mice when used as a vaccine antigen. 
A commonly used method for detecting V antigen in Y. pestis is to culture the bacteria on 
agar that contains magnesium oxalate and is calcium-free. Virulent bacteria will express V 
antigen and not grow on this medium at 37°C. Zahorchak and Brubaker (1982) studied Y. 
pestis grown under calcium-free conditions at 37°C and showed that nucleic acid and protein 
synthesis had ccased. The calcium-deprived cells started growing again when placed at a 
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temperature of 26°C, but at 37°C, after the arrest of growth, even after the addition of 
calcium, growth could not be restored. Synthesis of these antigens is suppressed by cell 
division that occurs in the presence of calcium ions. After phagocytosis, however, the Vand 
W antigens are synthesised because the cytoplasm of mammalian cells contains insufficient 
calcium ions to support bacterial division. It is the V antigen that has been the focus of recent 
efforts to purify and characterise the protein, whereas, relatively little is known about the W 
antigen. 
1.3.3 Plasminogen activator (PIa) 
The primary sequence of PIa has been ddined (Sodeinde and Goguen, 1989). PIa is a 
protease located in the outer membrane of the bacterial cell and probably has multiple 
functions. It has a fibrinolytic activity which prevents blood clotting and breaks down clots, 
thereby increasing invasiveness at the site of the flea-bite. PIa activates plasminogen by 
proteolytic activation to form plasmin, the blood protein that dissolves fibrin clots. A fibrin 
clot would limit the spread of bacteria by trapping them at the site of infection. Plasminogen 
would normally be activated only after the bacteria have been eliminated and the clot can 
safely be cleared. By prematurely activating plasminogen, the bacterial enzyme PIa prevents 
the fibrin clot from forming and removes one of the barriers to bacterial spread. Y. pestis 
lacking PIa are avirulent if injected in mice sub-cutaneously, but retain virulence if injected 
into the bloodstream (Sodeinde et al., 1988). 
PIa may also playa role in the ability of the flea to inject the bacteria into the new host. 
When a flea feeds, it ingests blood and the mouth parts of the flea trap clots causing a 
blockage that prevents the flea feeding again. At the surface of the human body, the 
temperature is high enough (35°-37° C) for PIa and flea proteases to co-operate in dissolving 
the clot thereby disseminating plague bacteria trapped in the clot. 
In addition to this, PIa degrades some of the Yops (section l.3.4) and has the effect of 
limiting the amount ofYops on the surface and in the vicinity of the bacterial cell (Sodeinde 
et al., 1992). This apparently self-defeating activity could be important if Yops are essential 
to protect Y. pestis from phagocytosis by polymorphonuclear neutrophils (PMNs) but need to 
be at a level which will allow uptake by circulating monocytes or macrophage that do not kill 
Y. pestis. PMNs are important short-lived phagocytic cells which engulf bacteria, dcstroy 
thcm and thcn dic. Monocytcs, in contrast, arc long-livcd phagocytic cells, that also 
intemalise and destroy infectious agents. They migrate out into the tissues where they 
become tissue macrophages. It is advantageous for Y. pestis to be engulfed by these 
monocytes as Y. pestis is known to be able to survive within these cells and to express 
additional virulence factors within the phagosome (Straley et al., 1993; Straley and Brubaker, 
1981). Therefore, modulating the amount of active Yops at the site of infection could be a 
means of balancing protecting bacteria from phagocytosis by PMNs yet still allowing them 
to be ingested by monocytes, which would further protect them from host defences and 
promote dissemination. 
1.3.4 Yersinia outer proteins (y ops) 
Y ops are potentially important surface antigens that may be species specific or common to 
all three Yersinia spp. There are eleven Yops expressed by the Lcr virulence plasmid of Y. 
pestis (Straley and Cibull, 1989, Straley et al., 1993). Yops were originally thought to be 
located in the outer membranes of Yersinia spp.(Straley and Brubaker, 1981; Portnoy et aI., 
1981). However, research suggests that that they are not outer membrane proteins but are 
excreted proteins that can be membrane associated under some conditions (Straley et aI., 
1993). Purification of Y ops from Y. pestis has proved difficult when the organism was grown 
in vitro and may have been due to degradation of Y ops in Y. pestis by PIa (Straley and 
Brubaker, 1981; Sodeinde et al., 1992); however, when the Ler plasmid of Y. pestis was 
transferred to E. coli or Y. pseudotuberculosis, several Yops were expressed that cross-
reacted serologically with those of Y. enterocolitica (Wolf-Watz et al., 1985; Portnoy et al., 
1984). Furthermore, a plague convalescent-phase serum recognised two of these cross-
reactive Yops, indicating that Y. pestis expresses Yops during human infection (Bolin et al., 
1985). 
Y ops can be placed into two functional categories; those that interfere with signal 
transduction in host cells (i.e. the ability of host cells, particularly phagocytes to respond to 
environmental signals) and those that attack the host cell cytoskeleton (Salyers and Whitt, 
1994), Yops M, K and L are unique to Y. pestis (Straley and Bowmer, 1986). Measurement 
of the LDso of Y. pestis insertion mutants showed that at least two Yops (E and K) were 
necessary for virulence, whereas Y ops J and L were not found to be essential for full 
virulence. The operons encoding Yops and V antigen are widely separated on the Lcr 
plasmid (Perry et al., 1987). These co-ordinately regulated virulence genes probably 
represent a virulence regulon. 
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The genes that mediate the co-ordinate regulation of V and Y ops lie within a 17kb region 
often called the Ca2+ -dependence region, because transposon insertions result in loss of the 
cl+ requirement for growth and have a greatly decreased expression of V and Y ops 
(Goguen et ai., 1984). The maximal expression of Yops in the absence of ci+ and weak 
expression of Y ops in its presence suggested that at least some of these proteins might be 
made when Yersinia are intracellularly located in a similar manner to the V antigen (pollack 
et ai., 1986). However, there is evidence that two Yops, YopE and YopH are directly injected 
into the host cell cytoplasm by adherent bacteria. Purified Y ops were not toxic when added 
exogenously to cultured mammalian cells, whereas, bacteria producing these proteins were 
cytotoxic when attached to these cells (Salyers and Whitt, 1994). The exact mechanism by 
which the proteins are "injected" is unknown. 
Yops are highly heterogeneous with respect to both molecular weight and iso-electric point. 
This heterogeneity suggests possible multiple functions contributing towards the pathogenic 
properties of Y. pestis. The functions of some Yops are known and are summarised in table 
1.2. 
1.3.5 Pigmentation 
Iron is essential for bacterial growth and survival, and an important host defence mechanism 
is to make iron unavailable to invading bacteria (Bullen et ai., 1978). To counteract this 
defence mechanism, pathogenic bacteria grow and survive in the low-iron environment of the 
tissues by possessing specific, high affinity mechanisms for obtaining iron. Organisms can 
obtain iron in several ways; (i) Production of high-affinity iron-chelating agents 
(siderophores, normally phenolate or hydroxamate compounds) which compete directly with 
host iron-binding proteins e.g. transferrin and lactoferrin; (ii) removal of iron from iron-
binding proteins by direct interaction with bacterial surface receptors and (iii) degradation of 
iron-binding proteins. Furthermore, iron may become freely available to an organism 
following trauma in which there is haemolysis and/or a drop in tissue oxidation-reduction 
potential. Some organisms that produce haemolysis in vivo may thus liberate haem which 
could then be utilised as a source of iron. 
In Y. pestis, the iron acquisition mechanisms are unclear and seem to depend upon growth 
conditions. Y. pestis has the ability to absorb exogenous haemin or the dye, Congo Red, at 
26°C from solid medium and thereby grow as coloured or pigmented colonies. This is 
1 g 
Table 1.2 
Known functions of some Y. pestis outer proteins (Yops) 
Yop Molecular Protein Function Cellular 
Weight location 
YpkA 80kDa Serine threonine Secreted protein, thought Extracell ular 
kinase to interfere with phagocyte 
signal transduction 
YopE 26kDa Cytotoxic when injected Injected directly into 
directly into host cells; host cell cytoplasm 
destroys actin by adherent bacteria 
mono filaments and host 
cell cytoskeleton 
YopH 45kDa Tyrosine Interferes with phagocyte Injected directly into 
phosphatase signal transduction and host cell cytoplasm 
therefore with the process by adherent bacteria 
of phagocytosis 
YopN 34kDa Membrane-associated Extracellular 
. C 2+ • protem, a - sensmg 
protein in vitro; function in 
vivo is unclear. This 
protein is involved in the 
regulation of expression 
and secretion of Y ops and 
V antigen 
YopM 44kDa Inhibits platelet Extracellular 
aggregation, anti-
inflammatory 
19 
referred to as Pgrn + phenotype. In contrast Pgrn- mutants form white colonies on the same 
media and are avirulent in mice by sub-cutaneous infection unless animals receive sufficient 
iron to saturate serum transferrin. These Pgrn- isolates are typified by the Y. pestis EV76 
strain which has been found to be avirulent in other animals and is used as a live plague 
vaccine in humans (pollitzer, 1954). Pgrn- mutants are fully virulent in mice via the 
intravenous route. 
Several researchers have examined siderophore production in Y. pestis. Wake et al. (1975) 
found evidence of siderophore production in Y. pestis by plating pgnt and Pgm- strains of Y. 
pestis onto deferrated brain heart infusion (BHI) agar. An activity diffused from some of the 
colonies which promoted growth of neighbouring organisms, whi~h was interpreted as 
evidence of release of siderophores. These findings were disputed by Perry and Brubaker 
(1979). They found that on iron-limited media, Y. pestis failed to stimulate growth of S. 
typhimurium LT2 enb-7, a mutant capable of utilising numerous exogenous siderophores 
(Lucky et al., 1972; Pollack et al., 1970). In addition to this, when growth was limited in 
iron-deficient liquid medium (0.1 to 0.3JlM Fe3+), the organisms failed to produce detectable 
soluble phenolate or hydroxamate compounds. Decreasing the incubation temperature and 
further reducing the iron concentration failed to induce production of these compounds on 
solid medium. The organism exhibited significant growth under all but the most stringent 
conditions of iron deficiency, which suggested that iron was accumulated by some alternative 
process. Furthermore, they found that iron-starved Y. pestis were unable to utilise exogenous 
siderophores. Added Fe3+ was unable to promote growth of Y. pestiS unless the haemin 
precursor protoporphyrin IX was present (perry and Brubaker, 1979). The reasons for 
protoporphyrin requirement were not clear but the evidence suggested that haemin was the 
most effective nutritional source of iron and could serve as the sole source of iron for Pgm + 
Y. pestis. 
Sikkema and Brubaker (1989) demonstrated the presence of outer-membrane peptides, 
peptide F and iron-repressible peptides IrpA - IrpE, that were involved in assimilation of 
iron; spontaneous mutation to Pgm- resulted in loss of peptide F and IrpB - E. Recent 
research has provided evidence that assimilation of iron differs according to temperature, this 
is in common with other Y. pestis virulence factors. Straley and Perry, (1995) reported that at 
26°C, iron-deprived cells over-express HMWP 1, HMWP2 proteins and the receptor for iron, 
ycrsiniabactin. Yersiniabactin in Y. pestis is iron-regulated protein C (IrpC). However, cells 
can also absorb exogenous haem at 26°C and therefore be haem-loaded before infection and 
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not have an immediate requirement for iron at 37°C. The full functioning of this iron-
scavenging mechanism at 26°C has not been verified and the iron acquisition mechanisms 
appear to be different at 26°C compared to 37°C. The exact mechanisms of iron acquisition at 
37°C are unclear and may involve receptors for iron-binding proteins. 
1.3.6 Pesticin 
The pesticin virulence factor is encoded on a small 9.5kb Pst plasmid. Pesticin is a 
bacteriocin which is produced by wild-type cells of Y. pestis and exerts an inhibitory effect 
on certain strains of E. coli, Y. pseudotuberculosis, Y. enterocolitica and non-pestinogenic 
strains of Y. pestis (Hu and Brubaker, 1974). It is a monomeric protein with a molecular 
weight of about 63kDa and is located in the cytoplasm. Hall and Brubaker (1978) showed 
pesticin acts by converting sensitive bacteria to non-viable osmotically stable spheroplasts. 
Pesticin is thought to enzymatically hydrolyse mureinlipoproteins in the walls of sensitive 
bacteria. 
Loss of pesticin typically prevents dissemination from peripheral sites of infection (Brubaker, 
1970) but pesticin-specific mutations on the Pst plasmid do not reduce virulence. Pesticin 
may have a role in iron assimilation. Pigmented (Pgm +) Y. pestis cells which have 
spontaneously become non-pigmented (Pgm") because of a large deletion are resistant to 
pesticin (Perry et al., 1990). These Pgm" cells, as well as a specific pgm+, Ps{ mutant, no 
longer express the outer membrane iron-repressible proteins (IrpB-E) (Sikkema and 
Brubaker, 1989). Since the receptors for a number of bacteriocins and bacteriophages are 
outer membrane proteins which serve as receptors for high-affinity iron transport systems 
(Neilands, 1982), the above observations ma..~e the pesticin receptor a likely ca..'1didate for 
regulation of iron metabolism. 
1.3.7 pll6 antigen (Psa A) 
A pilus adhesin found in Y. pseudotuberculosis and Y. pestis but not in Y. enterocolitica is 
Psa A, s,ometimes referred to as a pH6 adhesin because it is produced maximally at pH6. Psa 
A was first characterised by Ben-Efraim et al. (1961) who found that the protein was 
expressed in all strains of Y. pestis, but only at temperatures above 34°C and at a pH below 
6.7. Lindler et al. (1990) described two loci, psaA and psaE, necessary for the expresssion of 
Psa A. The structural gene was found to be psaA, while psaE was required for the maximal 
expression of the antigen. Insertion mutations of these genes resulted in no expression or 
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greatly diminished expression of the antigen and a concomitant decrease in the virulence of 
Y. pestis. Lindler and Tall (1993) concluded that Psa A was the monomer of yersinial 
fimbriae and that other psa genes were involved in expression of this fimbrial structure. 
Computer analysis of the primary and secondary structure of the protein predicted a p-sheet 
structure (Zav'yalov et al. 1996). 
Price et al. (1995) tried to detennine whether expression of psaA was controlled at the 
transcriptional or post-transcriptional level. He examined PsaA + and PsaA- strains of Y. pestis 
grown under PsaA-inducing (PH6, 37°C) or non-inducing conditions (pH7.4, 26°C) (Ben-
Efraim et al., 1961) by probing Northern blots for the a_32 P-Iabelled psaA gene. Expression 
of the psaA transcript was found only in the induced cultures, suggesting that expression of 
psaA is regulated at the level of transcription by pH, temperature and psaE. 
Proteins extracted from cultures were analysed by Western blot with absorbed anti-Psa A 
serum (Lindler et al., 1990) and Psa A was detected only in the psaA + strain grown under 
inducing conditions. Their findings implied that pH was the initial stimulus for expression of 
psaA but that increased temperature was required for full expression of the Psa A gene. The 
antigen is associated with the two most invasive species of Yersinia suggesting that it may 
have some role in the disease process, perhaps as an adhesin (Straley, 1993). Psa A fonns 
virulence-associated fimbriae on the surface of Y. pestis at pH6.7 in host phagolysosomes or 
extracellularly in abscesses such as buboes, characteristic of bubonic plague (Zav'yalov et al., 
1996). It is also possible that it may have a role as an adhesin in Y. pseudotuberculosis 
infection as this is an enteropathogenic organism which can cross the mucosal epithelium. 
Zav'yalov et al. (1996) produced a recombinant E. coli strain expressing Psa A and studied 
the binding of this recombinant antigen to human, rabbit, sheep and mouse IgG. Different 
subclasses and whole IgG were used, also binding to Fab and Fc fragments was examined. 
The protein was found to react specifically with human IgG; it bound to IgG 1,2 and 3 but not 
IgG4 and only bound to Fe fragments. Therefore, PsaA is a novel bacterial Fe receptor with 
limited species specificity. Earlier workers proposed that the primary function of Y. pestis 
fimbriae composed of Psa A was the mediation of specific attac1mlent to macrophages 
(Straley, 1993). However, Zav'yalov's findings suggest that in humans, the specific 
attachment of Y. pestis to Fc-receptors of macro phages may be mediated by the fonnation of 
pseudo-immune complexes on the surface of the bacteria between Psa A fimbriae and normal 
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IgG. This covering of bacterial surface structures by nonnal IgG could prevent bacteria from 
recognition by specific antibodies, therefore enabling them to evade the immune system of 
the host. 
1.3.8 Lipopolysaccharide (LPS) 
Bacterial endotoxins are components of the Gram-negative outer membrane and include 
LPS, an amphipathic molecule, which represents an important virulence factor in Gram-
negative infections. The lipid component of the LPS molecule, Lipid A, is the primary 
endotoxic structure and has immunomodulatory properties. In the disease process LPS causes 
intravascular coagulation, leading to septic shock. 
The LPS of Y. pestis was first isolated in 1956 by a phenol-water extraction procedure and 
purified by precipitation with ethanol which resulted in relatively protein-free LPS (Davies, 
1956; Luderitz, 1977). Since then the structure of Y. pestis LPS has been further investigated 
and debated. Hartley et al. (1974) examined hydrolysates ofLPS and showed that the total 
carbohydrate content of the LPS consisted of glucose, heptose sugars, glucosamine and 2-
keto-3-deoxyoctonate (KDO). These sugars are generally found in the core region of LPS 
from the Enterobacteriaceae. When applied to a Sepharose 4B column, the LPS was eluted 
with the void volume, indicating that the native LPS fonned large aggregates. Some 
researchers reported that Y. pestis produced smooth LPS with long polysaccharide chains and 
demonstrated long, thread-like structures, 8-9nm in diameter when the LPS of Y. pestis was 
examined by electron microscopy. Smooth LPS is generally associated with intestinal 
pathogens, such as E. coli and Salmonella and is effective in protecting the bacterial surface 
from complement, as complement is activated by the lipid A of LPS which is embedded in 
the outer membrane of the bacterial cell. Some E.eoli strains have both smooth LPS and a 
capsule and this may act together to shield the bacteria from the immune system (Michalek et 
al., 1982), in Y. pestis the LPS and Fl antigen may have a similar role. However, other 
researchers examining the LPS of Y. pestis found that it possessed core components but 
lacked extended O-group structures and would therefore be classed as rough LPS (Porat et 
al., 1992). More recent research confirmed this and also found that Y. pestis did not express 
long-chain LPS, this was in contrast to Y. pseudotuberculosis LPS (Chart et at., 1995). The 
latter migrated as discrete bands, producing a "ladder pattern" on SDS-P AGE gels and it was 
possible to differentiate the two by SOS-PAGE and silver staining. 
Y. pestis is an invasive organism and generally invasive pathogens have rough LPS, whereas, 
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enteric bacteria possess smooth LPS which may protect the orgamsm from the harsh 
environment in the gut. 
1.3.9 Murine toxin 
Murine toxin, a polymer of 12kDa protein sub-units, is also encoded on the 110-kb plasmid 
but less is known about its structure and mode of action. It is lethal for mice and rats but 
essentially non-toxic in other hosts. The significance of murine toxin in promoting disease is 
not well understood but it probably accounts for the more rapid death of mice infected with 
Y.pestis than when infected with the enteropathogenic Yersinia (Protsenko et al., 1991). 
1.3.10 Components required for full virulence of Yersinia 
Some of the virulence factors described above are shared with Y. pseudotuberculosis and Y. 
enterocolitica which poses the question, why is Y. pestis so much more invasive than the 
other pathogenic Yersinia? Y. pestis has additional plasmids, one of which (Fral) encodes the 
antiphagocytic capsular Fl protein, described earlier. Two other Y. pestis-specific virulence 
factors that may explain its greater invasiveness are haemin storage and plasminogen 
activator. In addition to being able to use haemin as an iron source, Y. pestis actively stores 
haemin and accumulates concentrations which are high enough to change the colour of 
colonies on agar plates containing haemin. Haemin storage occurs maximally at 26°C, so that 
Y. pestis injected by flea-bite would be haemin loaded. The stored haemin may act as an iron 
reserve, but it is also possible that a haemin coat could give the bacteria some initial 
protection from the host's defences by making the bacteria appear like a host component. 
Another unique protein of Y. pestis is PIa which clearly has an important role in survival and 
dissemination of the bacteria in the body. 
The virulence factors described are an example of the principle that the most successful 
pathogens have evolved virulence strategies that are successful in preventing the host 
clearance of bacteria but do not kill the host (balanced pathogenicity). It can be argued that a 
pathogen such as Y. pestis, with a high mortality rate, produces virulence factors that do not 
kill the host immediately but aid the spread of bacteria throughout the body to contribute to 
the spread of the disease and eventually kill the host. This would account for Y. pestis having 
occasional devastating effects on human popUlations. Whereas other pathogenic Yersinia, 
such as Y. enterocolitica, do not kill their hosts and thus maintain themselves at a constant 
level in the environment. The disease process in Y.pestis infection is summarised in fig. 1.3 
and shows where the different virulence factors are considered to play a major role. 
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Fig. 1.3 Schematic summary of Y. pestis infection and the 
role of virulence factors 
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Certain of the virulence determinants described above have been found to be major antigens 
of Y. pestis. For high virulence, strains must be capable of producing not only FI antigen but 
at least V and/or Pgm antigens in addition to Fl. These antigens would seem to be the most 
important antigens determining virulence and certainly FI and V antigen in native or 
recombinant form are capable of eliciting high titre antisera in mice and rabbits. 
1.4 Regulation of Virulence 
The behaviour of microbial pathogens IS determined by genetic structure and by 
environment. When producing infection, the pathogens grow in the changing environment of 
the host tissues, and they produce the full complement of virulence determinants that are 
required to accomplish successive steps of infection; survival on and penetration of mucosal 
surfaces, multiplication in the tissues, interference with host defences and damaging the host. 
Therefore, study of the genetic control and expression of these antigens may provide much 
useful information about bacterial invasiveness. 
Many Y. pestis virulence genes are regulated by temperature. For example, FI antigen, is 
produced on incubation at 37°C but not at 26°C, and expression of some genes such as psa is 
affected by a combination of temperature and pH. However, little is known about the 
regulation of chromosomal genes. Most information about the regulation of virulence genes 
comes from studies of regulation of yap genes on the virulence plasmids. These genes are 
regulated not only by temperature but also by calcium concentration. Y ops are expressed 
maximally at 37°C in the absence of calcium. Calcium in millimolar concentrations (i.e. 
similar to those found in body fluids) considerably down-regulates transcription of the Yops 
genes at 37°C, but expression is still greater than at lower temperatures. "When bacteria are 
shifted from 2SoC to 37°C in calcium-free medium (optimal conditions for Yops expression), 
growth of bacteria decreases considerably. During this period of growth restriction, Yops and 
V antigen (LcrV) are produced. Addition of calcium to the medium allows growth to resume 
at a normal rate. Therefore, growth at 37°C is calcium dependent. 
However, there is no proof that this phenomenon occurs in vivo and there is the possibility 
that calcium-dependent growth restriction is an in vitro artefact. The regulation of virulence 
genes in Y. pestis ill vivo begins with initial colonisation, where the tissues surrounding a flea 
bite form an iron chclated environment for an invading bacterium. The transition in 
temperature on entering the mammalian host should tum off the 26°C iron transport system 
and the second iron-transport system that is active at 37°C would be induced to levels higher 
than those in the flea (Straley and Perry, 1995). After initial colonisation but early in 
infection, macrophages would not be fully activated and might support intracellular growth 
of bacteria. In the acidic phagosomal environment, Y. pestis might express the 
chromosomally encoded Psa A which could promote subsequent survival in the presence of 
PMNs attracted to the focus of infection. In enteropathogenic yersinia production of Yad A 
aids survival in PMNs; however, Y. pestis does not express Yad A because of a frame-shift 
mutation and is protected against phagocytosis by its capsular protein Fl, which is regulated 
by increase in temperature from 26° to 37°C. 
Subsequently, growth of Y. pestis in peripheral tissues is primarily extracellular. Proteins 
expressed by the Lcr plasmid, especially V antigen, are important in inhibiting phagocytosis 
and also temper the inflammatory response and delay the development of an effective cell-
mediated immune response (Straley and Perry, 1995). At 37°C, millimolar concentrations of 
Ca2+ prevent full transcriptional upregulation at high temperatures and block the secretion of 
V antigen and Y ops. This negative control may be overridden by Y. pestis becoming attached 
to a macrophage by an adhesin, possibly the Psa A adhesin, but this process is not well 
understood. Therefore wastage is prevented by blocking secretion and inhibiting full 
transcriptional upregulation until the proteins are needed. Dissemination to deeper tissues 
might be provided by the expression of proteins such as Fl and PIa. 
1.4.1 Regulation of expression of Fl antigen 
Most strains of Y. pestis possess the ca.llOkb virulence plasmid pFra which mediates the 
expression of the Fl antigen as capsular material at 37°C. The genes encoding the Fl 
structural protein are located in the /1 operon which contains four loci, cafl R, cafl M, cafl A 
and cafl (Figure 1.4) that have been assigned putative functions. The cafl gene which 
encodes the Fl subunit, has been cloned and sequenced by Galyov et al. (1990). The caflR 
gene encodes a regulatory protein (Karlyshev et at., 1992) which seems to induce caflM gene 
transcription leading to the production of the CaflM and CaflA proteins involved in capsule 
formation. The Cafl R protein may be involved in transduction of signals which might be 
temperature and/or other environmental factors, such as Ca2+ and Mg2+ ions concentration. 
The cajl A genes encode an assembly protein Cafl A (Karlyshev et al., 1991) which was 
found to have a molecular weight of 93.2kDa. From the DNA sequence and deduced amino 
acid sequence, Can A has been found to have regions of homology with protein Fa cD, PapC 
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and FimD involved in the assembly of E. coli fimbriae. Deletion of the caflA gene results in 
bacteria incapable of agglutinating with anti-plague anti-serum, implying that Fl has not been 
produced and that the CaflA protein may be involved in capsule assembly. The CaflA 
protein is located in the outer membrane and binds Fl antigen sub-units during the 
extracellular secretion process and is therefore important for anchoring the capsular protein to 
the cell surface. 
The caflM gene was sequenced by Galyov et al. (1992) who showed that the effective 
synthesis of the capsule layer of Y. pestis is mediated by the expression of the caflM gene. 
CaflM protein and the PapD protein of E. coli have homology in their primary structures and 
conserved amino-acid sequences. PapD acts as a chaperone protein i!1 Pap pilus biogenesis, 
acting as a periplasmic transport protein, implying that CaflM acts as a chaperone protein in 
capsule layer biogenesis (Zav'ylov et al., 1995). More recent research has suggested that 
caflM is important for the correct folding of FI, for aggregation of the antigen in the 
periplasm and transport of the Fl protein to the cell surface (Zav'ylov et al., 1995). 
Examination of the structure of caflM has defined two immunoglobulin-like domains, which 
is a characteristic feature of chaperone proteins. 
1.4.2 Regulation of expression of V antigen 
The low calcium response which leads to the production of the V antigen is mediated by a 
75kb Ler plasmid. This plasmid contains "Ca2+ dependence" genes that are thought to be 
responsible for detection of temperature and cl+ important in the regulation of expression of 
both V antigen and Yops, maximal expression of both V antigen and Yops occurs at 37°C in 
the absence of cl+. Perry et al. (1986), using insertion mutagenesis, identified the IcrGVH 
operon encoding the V antigen and is regulated at the transcriptional level by temperature 
and Ca2+. The genes encoding the Yops proteins are arranged in multiple operons dispersed 
over the Ler plasmid. The arrangement of V and Yaps genes on the Ler plasmid raises the 
possibility of co-ordinate regulation which was suggested by comparison of V antigen 
activity with expression of beta-galactosidase from the operon fusion phage Mu dI (Ap lac) 
inserted in Yop operons (Straley and Bowmer, 1986). The maximal expression of V at 37°C 
in the absence of ci+ suggests that during infection V is synthesised when Yersiniae are 
resident within a macrophage which would provide such an environment (Pollack et al., 
1986~ Straley and Brubaker, 1981). Yops are also expressed under these conditions, some 
Yops are expressed within the phagosome and others by adherent cells (section 1.3.4). 
Therefore, the low ci+ response (Lcr) of Yersinia includes a regulatory cascade and a set of 
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virulence-related proteins. The regulatory genes modulate both bacterial growth and 
expression of the virulence-related proteins in response to temperature and the presence of 
C 2+ a . 
As a consequence of the Ler, Y. pestis, when shifted from 26 to 37°C, growth ceased within 
two generations, indicating growth restriction (Zahorchak and Brubaker, 1982). Reinitiation 
of growth occurred when the cultures were returned to 26°C; at 37°C, growth restriction was 
prevented ifCa2+ was present in the growth medium. Certain nuc1eotides, such as ATP, were 
also found to have a similar effect. However, the effects ofCa2+ and ATP on growth were not 
identical, as ATP, unlike Ca2+, never fully restored maximal growth at 37°C. Barve and 
Straley (1990) found that ci+ -independent mutants were unable to in~uce strong expression 
of V antigen, therefore, Ca2+ depletion was the primary factor in V antigen expression. The 
genes involved in the regulation by ci+ are found on a region of the Lcr plasmid, called the 
ci+ - dependence region. In Y. pestis this region contains at least five Icr genes that are 
thermally induced. to different extents and function in the regulation of Yop and Vantigen 
expression. Fig. 1.5 shows the regulation ofthe Ler and where the genetic loci are believed to 
participate. However, there is no proof that this phenomenon actually occurs in vivo, 
calcium-dependent growth restriction may be an in vitro artifact. It is possible that the true 
signal recognised by the Icr genes is not calcium but some other signal that is mimicked by 
calcium. Another possibility is that interaction with phagocytic cells is the trigger for V 
antigen and Y ops expression. 
1.5 Plague Vaccines 
1.5.1 The history of plague vaccination 
Research into producing an effective plague vaccine has a long history. In 1897, Haffkine 
developed a killed plague vaccine, which was very crude and caused severe side-effects. 
During World War II, servicemen were certain to be deployed to areas in which they would 
be exposed to plague. At this time, before the use of antibiotics, an effective plague vaccine 
was urgently required. The problem was approached by studying the metabolism and 
physiology of the bacillus to ascertain the best method for obtaining an adequate yield of 
micro-organisms for a vaccine. The main approach was to disrupt the plague bacillus and 
investigate the component antigens. Animal models were designed for reliable potency 
testing. Serological tests were developed that would enable evaluation of the antibody 
response to vaccination with various preparations and promising vaccines were studied in 
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volunteers. In the meantime killed vaccines were prepared for immediate requirements. The 
approach remains much the same to date. 
Live attenuated and killed vaccines were studied with equal intensity and during the 1940's 
and 50's more was probably discovered about plague and the plague bacillus than had been 
known previously. Most important, perhaps from the vaccination standpoint, was the 
isolation and characterisation ofa crystalline protein antigen from the capsular material of the 
plague bacillus. 
This antigen, the fraction 1 or Fl antigen, was shown to be the specific major antigen of Y. 
pestis. The Fl antigen could be used in several serological tests ~at were invaluable in 
evaluation of antibody responses to vaccination, for diagnosis of plague and for use in serum 
surveys to detect plague in wild rodent populations. This still remains the case today and 
Meyer's work led to the development of the plague vaccine in use today (Meyer et ai., 
1974a). 
1.5.2 Types of Plague Vaccine 
1.5.2.1 Killed plague vaccines 
Killed vaccines comprising inactivated micro-organisms have certain advantages in that they 
can be inexpensive to manufacture and require only cultivation and recovery of the infectious 
agent, followed by simple chemical or thermal inactivation. However, in the case of plague 
vaccines procedures would have to be carried out in containment, increasing the production 
costs. Because they are made from whole bacteria or viruses, killed vaccines are composed of 
more than one immunogen. However, adverse side-effects may be more common with this 
type of vaccine. Furthermore, inactivated micro-organisms may not induce cell-mediated 
responses and will induce mucosal responses only when delivered in sufficient quantity 
through multiple doses (Clemens et aI., 1990). 
Haffkine (1898) initially established the dosage of his killed plague vaccine which needed to 
be administered in a single inoculation as "that amount of a particular brew necessary to 
produce a temperature reaction up to 102°F in the majority of those inoculated". The 
Haftkine vaccine was injected sub-cutaneously and administration of this early vaccine was 
associated with localised pain, swelling and erythema, with peak intensity at 24-48hr; 
regional lymphadenopathy was also frequent. Systemic responses were also recorded 
mani resting as generalised weakness, headache and anorexia. These severe side-effects led to 
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the value ofthe Haffkine vaccine being seriously questioned. 
During the decade preceding World War II, research on killed plague vaccines was limited 
until the work by K.F. Meyer. During 1941 the Subcommittee on Tropical Diseases National 
Research Council Committee on Medical Research passed the following resolution :- " Even 
though the available knowledge does not seem to afford definite evidence of the benefits 
from the use of plague vaccine, it is considered advisable to vaccinate with plague bacillus of 
an approved strain, all military or naval personnel under serious threat of exposure to 
bubonic plague". On the basis of this recommendation, vaccination with killed plague 
vaccine was initiated in the forces. This formalin-killed Y. pestis plague vaccine and the way 
in which it is inoculated produces less frequent systemic and milder local reactions than the 
earlier killed vaccines. 
There is little evidence in humans that vaccination with Plague Vaccine USP elicits an 
antibody response which is similar to that observed in animals proven by challenge to be 
immune. However, no military personnel in the armed forces vaccinated with killed vaccine 
contracted plague during World War II, although many personnel were located in areas 
where plague was occurring (Meyer et al., 1974 ). Similar observations were made in 
Vietnam where the potential for exposure to plague was great (Butler et al. 1974; Marshall, 
1967). 
1.5.2.2 Live attenuated vaccines 
Live attenuated vaccines are composed of living viruses or bacteria that are avirulent either 
because of attenuating mutations or because of replication restrictions associated with their 
range of hosts. In theory, a single inoculation with a small dose of a live vaccine can expand 
by replication to a larger (and therefore more immunogenic) dose of vaccine within the 
recipient. During the course of this replication, the live vaccine must express all or most of 
the important target immunogens that ordinarily lead to protection after the natural infection. 
Live vaccination in this way more closely mimics natural infection. The infection with live 
vaccine can induce the production of cytokines which in tum can recruit elements of the 
immune system, such as macrophage and other antigen-presenting cells, that may not 
respond to inactivated or sub-unit vaccines. When the live vaccine is a virus or intracellular 
micro-organism, it is capable of inducing both humoral and cell-mediated responses e.g. 
cytotoxic T lymphocytes. Because the live vaccine replicates in a manner analogous to the 
target agent, it promotes the processing and presentation of antigens in a way that is most 
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similar to the natural infection. For a live vaccine to induce a mucosal response, it must be 
administered to a mucosal surface and adhere to antigen sampling cells, such as M cells in 
the gut (Owen, 1977). The fact that some viruses and bacteria naturally target the lymphoid 
tissue of the mucosal epithelium suggests that attenuated mutants of these agents might make 
excellent mucosal vaccine carriers. 
Live attenuated vaccines for plague were first developed and introduced by Girard and Robic 
in 1933 and by Otten in 1934. Both the E.V. (Girard) and the Tjiwidej (Otten) vaccines were 
considered to have been highly effective in producing immunity to plague. The unpleasant 
side-effects of live plague vaccines were first reported by Rotman in 1945 as severe systemic 
and local reactions. In the USSR in the 1940's adverse reactions were also reported and the 
Russians tried many different routes of administration in attempt to overcome these adverse 
side-effects. By the 1970's these problems had still to be overcome and Meyer confirmed 
that mass vaccinations with the E.V. strain 76 was inadvisable because of the adverse side-
effects (Reisman, 1970). 
Other factors influence the efficacy of attenuated plague vaccines. Great difficulties have 
been encountered in maintaining seed material for these vaccines. When several strains of 
E.V. used for vaccine production in France, Vietnam and the USSR were studied by the 
criteria of Burrows (1963) and Surgalla (1960) to ascertain virulence determinants, great 
variation was observed. The E.V. strains varied as to presence or absence of fibrinolytic 
activity, pigment and dependence on an exogenous source of uracil. In terms of vaccine 
potency, the E.V. strains vary from poor to fair in mice and from fair to good in guinea pigs. 
It was also noted that the "residual" virulence of the standard Girard E.V. 76 isolate could be 
enhanced by passage through rats and guinea pigs, making it a potentially dangerous vaccine 
candidate. 
Therefore, mass inoculations against plague present serious dangers in terms of adverse side-
effects and in the case of attenuated vaccines, a potential return to full virulence. Measures to 
eliminate these complications are therefore required, but attempts to avoid them have so far 
proved unsuccessful. Although mass immunisations with plague vaccines are often required 
to prevent epidemics, little information has been assembled on which to base an evaluation of 
the relative merits of the plague vaccines in current use. Although both live attenuated and 
killed vaccines have been developed, these carry with them the dangers of adverse side-
effects. The live EV76 vaccine induces good protection against Y. pcstis infection but the 
34 
vaccine still has the inherent problem of adverse side-effects. EV76 grown at 3fc to induce 
expression of the FI antigen appears to induce a greater protective response in mice than 
when grown at 28°C, in that time to death is greatly extended (Russell et al., 1995), 
presumably because there is an enhanced anti-Fl reaction induced as part of the primary 
response. A comparison of the immune responses induced by these vaccines, and the effect 
of the presence ofFl antigen in the administered dose, could indicate how a subunit vaccine 
could be developed. 
Oyston et al., (1995) produced a live attenuated recombinant AroA mutation of Salmonella 
thypimurium expressing Fl antigen and found that it gave protection against challenge with 
virulent plague. However, there were problems in that the organisms were not cleared 
efficiently from the tissues of the mouse model. 
1.5.2.3 Subunit vaccines 
Subunit vaccines are composed of purified proteins, carbohydrates or peptides and are 
generally considered to be the safest form of vaccine because of their well-defined 
biochemical makeup. The ability to manipulate these vaccines chemically also provides a 
means of altering the immune response in specific ways. 
It was generally considered in areas where the risk of contracting plague was high, that the 
benefits of the whole cell vaccine outweighed the risks. However, there are a number of 
reasons for the development of an acellular vaccine; (i) to reduce the adverse side-effects of 
the killed whole cell and live attenuated vaccine, (ii) to improve and prolong the degree of 
protection against plague, especially compared to whole cell vaccines, and (iii) to improve 
vaccine safety, as there is a risk of a return to full virulence oflive attenuated vaccines. 
Ideally, an acellular vaccine should aim to inhibit more than one stage of the disease process. 
Candidate antigens for inclusion in an acellular vaccine must meet with certain criteria. They 
must elicit a protective immune response in the host, have a well-defined, demonstrable role 
in the infection process and be non-toxic. Other characteristics to consider are the properties 
that make a vaccine practical to deliver, particularly in developing countries where use of a 
plague vaccine might be more important. There is no effective plague subunit vaccine to 
date. The first attempt at producing a sub-unit vaccine was by Meyer in 1974, who 
immuniscd mice with the Fl antigen of Y. pestis (Meyer el al.. 1974c). 
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More recent research into an acellular vaccine has demonstrated that recombinant Fl antigen 
(Simpson et aI., 1990) and and a recombinant V antigen (Leary et a/., 1995) are protective in 
mice. In addition to this, Williamson et al. (1995) used a combination of native Fl and 
recombinant V antigens as an acellular vaccine in mice. F 1 or V antigen alone gave 
protection against challenge with virulent plague; however, this protection was increased 
considerably when the antigens were administered as a combination vaccine. Why V should 
be such a protective antigen is unclear as it is expressed as a cytoplasmic protein, although it 
is secreted after the bacteria have been phagocytosed. 
Other antigens that might elicit a protective immune response are outer membrane proteins, 
such as plasminogen activator (PIa), Y ops and the surface protein, pH6 antigen. Native PIa 
would present problems, as it is a fibrinolytic enzyme and might damage the host, therefore 
outweighing any advantage it might have as a protective antigen. The pH6 antigen, on the 
other hand, might be an effective component in an acellular vaccine. It is a protein expressed 
on the surface of the bacteria and is thought to have a role in adhesion. Antibodies against 
this antigen might prove effective in protecting against pneumonic plague. To assess the use 
of Y ops in a sub-unit vaccine, the protective efficacy of the individual Yops would need to 
be studied. Studies have shown that YopE and H might be protected from neutralisation by 
antibody and therefore it is reasonable to predict that these Y ops would. not be protective 
antigens. In contrast, Yops such as YopM and N, have extracellularly exposed domains and 
so might be suitable components of a subunit vaccine (Straley et a/., 1993). Therefore, a 
combination of purified protective antigens either in the native or recombinant fonn, might 
prove to be an effective acellular vaccine protecting against bubonic and pneumonic plague. 
1.5.3 Vaccine development 
An important development in plague vaccination would be to improve the existing vaccines 
with respect to adverse side-effects and batch-to-batch variation. A major development 
would also be to produce a vaccine which was effective after only one dose against both 
systemic and aerosol infection, and immunised preferably via a non-invasive route, for 
example, oral or intranasal. 
There are a number of new approaches to vaccine development: 
a) The isolation ofre1cvant protective antigens. 
b) The use of anti-idiotype antibody preparations to mimic B cell cpitopcs. 
c) The synthesis of oligo- or polypeptides which may reflect naturally occurring amino-acid 
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sequences in proteins of the pathogen. 
d) The use of recombinant DNA technology to obtain DNA coding for antigens of pathogens 
or other factors, such as cytokines, ~hich could be used: i) To transfect cells in vitro so that 
the inserted DNA is translocated and expressed to produce antigen. (ii) To directly inject into 
the cells in vivo, where it is translated and expressed and an immW1e response initiated. (Ada 
1996). (iii) The use of live vaccine vectors to deliver protective imrnW1ogens, or the DNA 
encoding these proteins, to host target tissues (Schodel, 1994). 
However, of the above approaches, sub-unit peptide or protein vaccines are likely to be 
important in the development of a new generation of plague vaccines. Developments may 
include vaccine formulations, such as combination vaccines where more than one vaccine is 
administered at the same time. This may not be such an important development for plague 
vaccination as its use will probably be limited to people travelling or living in areas where 
plague is endemic. Another possibility is the use of mixed vaccine formulations, where 
different methods of presenting the antigen are used at the same time. This may favour 
priming or boosting an immune response if the antigen is presented in a different way at each 
immunisation and more than one antigen could be given. Another important advancement in 
plague vaccination would be the development of effective vaccine delivery systems that 
could be tailored to meet the requirements of a particular vaccine. For example, a 
combination or mixed vaccine where the antigen is delivered and presented in such a way as 
to optimise the immune response, provide longer-lived protection and ideally be given as a 
single dose vaccination (Ellis and Douglas, 1994). The earlier work on plague vaccination is 
still valid today and to build upon this the use of combination vaccines and novel adjuvants 
may be important in the future development of plague vaccination. 
1.6 Immunity to Plague Vaccination 
In the development of any vaccine, it is important to use relevant animal models as well as in 
vitro models for the evaluation of pathogenicity and protection. Each model should be 
carefully characterised and used to explore only the aspects of infection for which it has been 
proven valid. Historically, numerous animal models have been used to study plague infection 
and its prevention (Burrows, 1963). 
1.6.1 Immunity in mice 
Chen and Meyer (1955) studied the immunogenicity in mice of avirulent variants selected 
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from virulent strains of Y. pestis and were able to demonstrate that, in general, strains 
producing large amounts of FI conferred immunity in smaller doses than those producing 
lesser amounts of this antigen. This was confirmed by Burrows and Bacon (1956) who 
compared the vaccine potential of various live mutant strains of plague derived by single-step 
mutations from a fully virulent strain with killed whole cell vaccines. In all cases Fl+ 
vaccines inununised more effectively than the Fl- strains in mice. However, they also found 
that FI- I VW+ vaccines gave effective inununity, that VW strains were more protective than 
VW and in mice the most protective vaccine formulations contained both Fl and VW. 
Infection of a murine model with plague has shown that the LDso dose of the bacterium was 
lowest when the bacteria were delivered by the subcutaneous route (s.c.), which is not 
suprising since this route most accurately mimics the natural route of infection from a flea 
bite. However, the time to death was significantly greater for bacteria delivered by this s.c. 
route rather than by the i.p. or i.n. routes, possibly because the bacteria require an initial 
phase of multiplication in the dermal tissues before dissemination throughout the body when 
administered s.c. Immunised animals showed side-effects of varying severity and the killed 
vaccine was less effective in terms of dose-protection than the live attenuated vaccine. The 
murine model may not accurately reflect the disease process in man since a murine-specific 
toxin is produced by Y. pestis. However, plague vaccines have been successfully evaluated in 
the mouse model (Burrows, 1963). 
Some of these early studies with mice (Burrows, 1963), found in experimental plague 
infections that the immunity developed depended on the level of Fl antibody in inununised 
animals; animals having high immunity to challenge infection tended to have high levels of 
Fl antibody. Therefore, Fl is important but may not be the only antigen to produce immunity 
to plague in mice. A recombinant Fl (Simpson et ai, 1990), native Fl and recombinant V 
antigen (Leary et al., 1995; Williamson et ai., 1995) have been found to be protective in mice 
and more recently, research has been done to improve the murine model (Russell et ai, 
1996). A recent study (Russell et ai., 1995) has compared protection given by the 
formaldehyde-killed vaccine (Plague vaccine USP) with that given by the live attenuated 
vaccine strain of Y. pestis (EV76). The infectious dose of a virulent strain of Y. pestis, 
delivered to mice by several routes mimicking the natural routes of infection, was determined 
for the challenge of immunised mice. 
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1.6.2 Immunity in guinea pigs 
Historically, immunisation of guinea pigs using killed cells or proteins derived from them, 
has proved more difficult than the immunisation of mice using similar materials. In 
particular, purified F1, effective in mice, proved ineffective in guinea pigs even in large 
quantities. However, live vaccines did confer immunity (Spivack et a/., 1958)~ Various 
researchers tried administering vaccine formulations in different adjuvants and found that 
these formulations increased immunity and protection in guinea pigs. Tests on the efficacy of 
plague vaccines administered in combination with vaccines against other diseases have been 
conducted with guinea pigs (Korobkova et a/., 1958). Dried live plague vaccine was given 
combined with killed cholera vaccine and found to protect better than plague vaccine alone, 
which may have been due to the adjuvant effect of cholera toxin. These findings could still 
be of use in today's plague vaccine research; an acellular vaccine might be more effective 
when administered with material of known adjuvant effect and comparison in mice and 
guinea pigs would provide useful information as to the efficacy of the vaccine. 
1.6.3 Immunity in non-human primates 
Most of the data for immunity to experimental plague has been accumulated mainly from 
studies with mice and guinea pigs and most of the research with extensive use of animal 
models took place between the 1940s and 1970s, particularly the 1950s. However, it is 
questionable as to whether this data would be a true assessment of what would happen in 
man. Most of the research on experimental plague in monkeys again took place during the 
1950s. Ehrenkranz and Meyer (1955) compared three types of vaccine; live avirulent EV76, 
formalin-killed virulent organisms and purified, crystalline F1 antigen. They tested the ability 
of these vaccines to protect against intratracheal challenge in monkeys and doses 
recommended for man were used. Multiple single doses were given at intervals over 6-12 
weeks and full protection was afforded; the proper spacing of vaccine doses was as important 
as the total dose given. Resistance to subsequent challenge was associated with detectable Fl 
antibody; however, live EV76 vaccine was also effective in monkeys, once again suggesting 
that Fl may not be the only protective antigen in animal models. 
The challenge route was different to that used in mice and guinea pigs, therefore comparison 
of results may be misleading. The intratracheal challenge route may be a better model for 
pneumonic plague than the bubonic disease. 
Sub-cutaneous challenge III monkeys was investigated by Meyer (1961) and this work 
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suggested that vaccine fonnulations effective against bubonic plague may not be protective 
against the pneumonic disease. Burrows (1963) compared intratracheal, sub-cutaneous and 
intra-muscular immunisation of plague vaccines in monkeys. He concluded that 
immunisation via the respiratory route may provide the best means of protecting against the 
pneumonic form of the disease. Therefore, it might be possible to develop a plague vaccine 
that can be given by inhalation and by using recently developed adjuvants and novel delivery 
systems it might be possible to protect against bubonic and pneumonic plague. 
1.6.4. Immunity in man 
In past epidemics, vaccination with living, avirulent plague vaccines produced reduction in 
infection rate and in the mortality of vaccinated subjects (Burrows, 1963). Immunisations 
with the Tjiwidej (VW) strain did not decrease the incidence of pneumonic plague, whereas 
no cases of pneumonic plague occurred in people immunised with live EV vaccine (VW+) in 
contrast to non-vaccinated cases. However, in the absence of recent comparisons of 
vaccination against epidemic plague, it is difficult to determine whether advances have been 
made and the strategy of plague vaccination has remained largely unchanged. 
Circulating antibodies can be assessed in animal models but these mayor may not be 
protective in man. In addition, humoral antibodies may not be of sole importance m 
immunity to plague, which is transmitted by the sub-cutaneous and respiratory routes. 
Meyer et al. (1974b; 1974c) compared the USA Anny killed whole-cell, live avirulent 
A1122 and Tjiwidej vaccines and Fl antigen. The serological response was assessed and it 
was found that the concentration of serum antibodies resulting from vaccination declined 
within a few weeks, but was rapidly restored or exceeded by revaccination. Some 
individuals, however, failed to produce detectable antibody, even after repeated inoculations. 
Meyer concluded that even in individuals that responded well to vaccination, booster doses at 
intervals of three to six months were essential to protect against plague infection. This, 
essentially, remains the case today and clearly there is a need for the development of an 
improved plague vaccine. 
1.7 l)roperties and Function of the Different Components of the 
Immune System 
The immune system is, by nature, very complex in order to be able to deal with many 
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different types of infection. Many organisms gam access across the epithelia of the 
gastrointestinal or urogenital tracts. In the case of Y. pestis, it is injected directly into the 
bloodstream via an insect bite, although in the pneumonic form gains access via the 
nasopharynx and lung. The site of infection and type of pathogen largely determines which 
immune responses will be effective. The success of a vaccine depends upon its safety and 
efficacy and on generating immunological memory. 
1.7.1 Adaptive and Innate Immunity 
The innate response in host tissues is mediated by activation of neutrophils and macrophages, 
they recognise the many common constituents of micro-organisms, intemalise the pathogens 
and destroy them. Since these cells use non-specific recognition syste~s which allow them to 
bind to a variety of antigens and do not rely on the antigen-specific receptors of either B cells 
or T cells, they result in innate immune responses. Innate immunity, therefore, acts as a first 
line of defense against infection. 
The adaptive immune response is highly specific for a particular pathogen. Moreover, the 
response improves with each successive encounter with the same pathogen and results in 
immunity from infection. The key factors of the adaptive immune response are specificity 
and memory. 
1.7.2 Humoral and cell-mediated immunity 
Immunity to infectious diseases involves a complex interplay between humoral and cell-
mediated immune responses against antigens on the foreign micro-organism. Humoral 
immunity, either in the form of local 19A antibodies at the site of infection or neutralising 
antibodies in the serum, provides the first line of defense against invading micro-organisms. 
Cellular immunity, mediated by T -cells, also plays a major role in protection against foreign 
pathogens. CD8+ CTLs kill cells infected with viruses or bacteria. CD4+ T helper (Th) cells 
provide "help" for B-cells in antibody production and secrete a range of cytokines that are 
involved in a variety of immunoregulatory functions or have a direct effect on invading 
pathogens. 
Th I cells secrete intcrleukin 2 (IL-2), y-interfcron (lFN-y) and tumour necrosis factor-p 
(TNF-~) and are involved in delayed hypersensitivity and inflammatory responses. This 
population of cells stimulates B-cells to produce IgG subclass immunoglobulin which 
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opsonise invading bacteria, making them more susceptible to killing by activated 
macrophages. Th2 cells secrete interleukins IL-4, IL-5, IL-6 and IL-I0, which playa crucial 
role in immunoglobulin (Ig) class switching and B-cell differentiation, in particular for IgE, 
IgA and IgG antibody production. 
Therefore, Thl cells and CD8+ CTLs mediate cellular immunity against intracellular 
pathogens, whereas Th2 cells stimulate humoral immunity against extracellular pathogens. 
The repertoire ofT- and B-Iymphocytes in the immune system is vast with an almost infinite 
capacity to respond to foreign antigens. In a naive individual, the frequency of lymphocytes 
specific for an individual epitope on a foreign antigen is very low. However, following 
exposure to a micro-organism or antigen expressing that epitop~, clonal expansion of 
precursor lymphocytes occurs and memory T - and B- cells are generated. Therefore, primary 
infection with a micro-organism, or vaccination by exposure to an attenuated or killed virus 
or bacterium, or to a purified native or recombinant antigen, results in the stimulation of a 
small, but specific population of lymphocytes in vivo. In a subsequent encounter with the 
antigen, as through infection with the pathogen, the memory B- and T -cells proliferate 
rapidly and allow the immune system to deal effectively with the invading micro-organism. 
The mechanisms ofB- and T-cell responses are described in sections 1.7.2.1 and 1.7.2.2. For 
vaccine design it is important to induce distinct T-cell responses required for effective 
immunity to different pathogens. (Mills 1996). 
1.7.2.1 B cells 
The role of the antibody produced by mature, differentiated B cells is as a first line of specific 
defense in neutralizing the infectious agent, by opsonisation and subsequent phagocytosis or 
by the production of bactericidal antibody. B cells produce specific antibody that recognise 
specific epitopes. These epitopes may be either continuous or discontinuous and this is 
dependent on the conformation of the antigen. A second role ofB cells is to facilitate lysis of 
cells that display foreign antigens on their surface. A specific antibody that recognises these 
antigens may lyse the cells by one of two mechanisms, antibody-dependent cellular 
cytotoxicity and/or bactericidal antibody, which is mediated by complement. The third role 
of B lymphocytes is to facilitate phagocytosis of cellular debris resulting from the lysis of the 
infecting organism and cytotoxicity during infection. 
1. 7 .2.2 T cells 
T cells are needed to control intracellular pathogens and to activate 13 cell responses to most 
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antigens. Cytotoxic T lymphocytes (CTLs) are almost exclusively class I MHC-restricted 
CDS+ T cells. These lymphocytes are important in viral infections or those involving 
intracellular pathogens as they recognise and are responsible for the lysis of infected cells. 
They also secrete a specific pattern of cytokines, for example, IFN-y which may facilitate the 
clearance of viral infection. 
T lymphocytes with helper activity are class II MHC-restricted CD4+ cells. They interact 
with B cells and help in the process of producing different immunoglobulin isotypes (G, A or 
E) by B cells and in the production of B memory cells. The exact signals promoting these 
activities are not fully understood. T cell-independent antigens do not induce the switch to G, 
A or E immunoglobulin isotypes and do not generate B cell memory. Another group of T 
helper cells interact with phagocytic cells, helping them to destroy pathogens. 
Both CD4+ and CDS+ T-cells recognise a complex between the MHC molecule and a peptide 
from the foreign protein. In the case of CD4+ , the peptide derived from the antigen is 
degraded in the lysosomes, and associates with class II MHC antigens. In the case of CDS+ , 
the peptide is derived from newly synthesised antigen in the cytoplasm and associates with 
class I MHC antigen. Since nearly all cell types in the body express class I MHC molecules, 
the role ofCDS+ CTLs has been described as perfonning a continuous molecular audit of the 
body (Mills, 1996). T cells generate their effects either by releasing cytokines or by direct 
cell-to-cell interaction. (Clark and Ledbetter, 1994). 
1.7.3 Mucosal immunity 
Many pathogens gain entry to the host via a mucosal surface. The response to such infections 
is to produce localised antibodies of the secretory IgA (s-IgA) isotype. This isotype 
constitutes the majority of all antibodies produced at mucosa-associated tissues and results in 
local immune protection. 
It is now established that antigens which are most often encountered by inhalation or 
ingestion, can be taken up into specialised lymphoreticular tissues in the upper respiratory 
tract and gastro-intestinal tract, referred to as BAL T (bronchus-associated) and GALT (gut-
associated) lymphoid tissue. GALT is represented by tissues such as Peyer's patches (PPs) 
and appendix. PPs contain a dome region which is enriched for lymphocytes, macrophages 
and some plasma cells. This is covered by a unique epithelium enriched for specialised 
antigen-sampling cells, rcfen'cd to as microfold (M) cclls. M cclls arc responsible for the 
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uptake and transport of lumenal antigens, which are not degraded but delivered intact to 
underlying lymphoid tissue. All the necessary immunocompetent cells, T-cells (CD4+ Th 
cells and CD8+ CTLs), B-cells and others such as macrophages are present in these 19A 
inductive sites (McGhee, 1992). 
Following stimulation with antigen in the PPs and its presentation to B- and T -cells, the 
antigen-induced B- and T -cells leave the PPs via the efferent lymphatics and reach the 
systemic circulation through the thoracic duct and in this way reach distant mucosal tissue, 
where circulating B-cells are selectively retained. The B-cells clonally expand under the 
influence of antigen, T-cells and cytokines becoming mature 19A-secreting plasma cells 
(Mestecky and McGhee, 1987; McGhee et al., 1989). This cell distribution pathway from 
19A inductive tissues to 19A effector sites (bronchi, genitourinary tract and secretory glands) 
is termed the "common mucosal immune system" (Mestecky et al., 1994) (Figure 1.6). 
However, this is still a subject of some debate and some researchers argue that the mucosal 
immune system is compartmentalised with distinct regional immune tissue (Lewis and 
Hayward, 1996).One of the most effective ways to stimulate PPs to produce effective 
mucosal immunity is by oral delivery of antigens. However, oral administration of proteins, 
including subunit vaccines, may induce a state of unresponsiveness, termed oral tolerance 
(Tomasi, 1980). Oral tolerance may have been a factor when Thomas et al. (1992) 
immunised mice by the intragastric route with Fl antigen and found that it failed to stimulate 
a protective immune response against challenge with Y. pestis. The development of a plague 
vaccine that could induce mucosal immunity as well as systemic immunity would be of great 
advantage in prevention of pneumonic plague infection, but still give protection against the 
bubonic form of the disease. 
Mucosal antibodies have been shown to inhibit microbial adherence and prevent absorption 
of antigen from mucosal surfaces (Abraham et al., 1985). However, when specific IgA reacts 
with the corresponding antigen in the mucosal surface, the absorption of the antigen is 
blocked, but it does not result in complement activation followed by the generation of 
cleavage products ofC3 and C5 components (McGhee et al., 1992). These fragments would 
induce local inflammatory reactions including the influx of polymorphonuclear leukocytes 
and release of substances that enhance the permeability of mucosal membranes due to tissue 
damage. 
The inability of human secretory IgA or serum JgA complexed to antigens to activate 
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Induction of antigen-specific mucosal immune responses by the common mucosal immune system and possible antigen delivery systems 
for the priming of 19A-committed B cells in 19A inductive sites (eg. GAL n 
complement, by either pathway, may be of paramount importance in the maintenance of 
integrity of mucosal membranes. This is important in vaccine development because it is 
unacceptable to give a vaccine that would lead to damage of host tissues and the natural role 
of s-IgA at mucosal sites might be to minimise the inflammatory side-effects produced by 
IgE and IgG isotypes, leading to a balance of the immune response. 
1.8 Vaccine Delivery and Enhancement of the Immune Response 
There are three main natural routes of infection ; a mucosal surface, an abrasion in the skin or 
a biting vector. The immune system must be able to respond effectively regardless of how a 
pathogen enters the host. Different responses would generate a different type of immunity, 
either humoral, mucosal or cell-mediated immunity. It should be possible to deliver a vaccine 
formulation in such a way as to provide the best form of immunity for a particular infection, 
in other words, to have selective induction of different immune responses. 
To achieve high efficacy, a vaccme should ideally fulfill a number of immunological 
requirements. Vaccination should lead to activation and differentiation of the antigen 
presenting cells (APes), synthesis and secretion of cytokines and processing of antigens 
entering the cell to form appropriate peptides. In addition, activation and differentiation of 
specific T and B cells is required resulting in a high yield of memory cells and generation of 
T helper cells and CTLs to several peptide determinants. Long-term persistence of antigen in 
its native conformation is essential to allow continued formation and recruitment of memory 
B cells to form antibody-secreting cells (ASCs), thus ensuring the steady production of 
antibody (Ada, 1996). Many vaccines, including the present plague vaccines do not fulfill all 
of these requirements. A vaccine is required that will provide long term immunity against Y. 
pestis infection both via a flea bite and across a mucosal surface. 
1.8.1 Adjuvants 
Generally, soluble proteins and peptides are poorly immunogenic and must be administered 
with preparations that potentiate the immune response. Adjuvant design evolved from the 
widely held view that the activity of adjuvants is attributable partly to their "depot" effect, 
whereby an antigen is absorbed and slowly released to the surrounding medium over a 
certain period of time. Adjuvants can be grouped as follows : (i) those causing depot 
fonnation at the site of injection, e.g. mineral compounds, oil-based adjuvants, liposomcs, 
biodegradable polymer microspheres, (ii) those acting as delivery vehicles for the antigens 
which may help in targeting antigens to immune competent cells, e.g. liposomes, oil 
adjuvants, biodegradable polymer micro spheres, and (iii) those acting as immunostimulators, 
e.g. Freunds complete adjuvant (FeA), muramyl dipeptide (MDP), lipopolysaccharide 
(LPS), lipid A, monophosphoryllipid A (MPL), pertussis toxin, cytokines (Gupta and Siber, 
1995). 
Alum, aluminium hydroxide or Alhydrogel, first used more than 50 years ago, in addition to 
aluminium phosphate, is still the only adjuvant preparation licensed for general medical use 
in humans. Recent studies have demonstrated the importance of electrostatic attractive forces 
in the adsorption of antigens by aluminium-containing adjuvants (Gupta and Siber, 1995). 
Alhydrogel is a better adsorbent of acidic proteins than basic ones, because it has an 
isoelectric point (IEP) of ca. 11 and is positively charged at pH7.4. Consequently, it is a good 
adsorbent for negatively charged proteins. The surface charge characteristics can be modified 
by adding phosphate ions which are substituted for the hydroxyl ions in the adjuvant. 
Therefore, to some extent, it is possible to optimise the surface charge of aluminium 
hydroxide adjuvant in relation to the antigen by pre-treating with phosphate ion (Gupta and 
Siber, 1995). The mechanism of adjuvanticity of aluminium compounds includes depot 
fonnation at the site of injection and slow release of the antigen. This stimulates immune 
competent cells through activation of complement, activation of macrophages and efficient 
uptake of aluminium adsorbed antigen particles by APCs due to their particulate nature and 
optimal size of less than 1 O~m. 
With so much interest in subunit and peptide-based vaccines, many new adjuvant 
preparations are being investigated. An ideal adjuvant would be chemically defined so that it 
can be manufactured consistently. Adjuvant preparations should enhance a protective 
immune response with a weak antigen. The adjuvant should be stable with regard to 
adjuvanticity and toxicity and without any interaction with the antigen. It should be 
biodegradable and non-immunogenic by itself. In recent years, adjuvants have received much 
attention due to their ability to selectively modulate the immune response to elicit humoral 
and/or cellular immune responses. Humoral response may be further modulated to select 
antibody isotype, IgG subclasses, avidity and affinity of antibodies. Antigen processing can 
be modulated with adjuvants leading to vaccines which can elicit both T -helper cells and 
CTLs (Mills, 1996). 
In addition to aluminium hydroxidc, adjuvants clIITcntly used include oil emulsions, LPS and 
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immunostimulatory complexes.(i) Oil emulsions, such as Freund's adjuvant have a long 
history of use for increasing the immune response in animals. The oil emulsions as adjuvants 
did not receive much attention until Freund, in 1937, demonstrated the adjuvant effect of 
mineral oil mixed with killed Mycobacteria. referred to as Freund's complete adjuvant 
(FCA). The water-in-oil emulsion without Mycobacteria, known as Freund's incomplete 
adjuvant (FIA), has been used in a number of veterinary vaccines. The mode of action of 
Freund's adjuvant is attributed to depot formation at the site of injection and slow release of 
the antigen with stimulation of ASCs. FCA is too toxic to be used as an adjuvant for human 
vaccines. FIA is not currently used in humans because of the side-effects such as local 
reactions at the site of injection, oil-induced neoplasms in mice and Arlacel-A induced 
carcinogenicity in mice. In the 1970s, the minimal structure needed for adjuvanticity of FCA 
was defined as N-acetyl muramyl-alanyl-D-isoglutamine (MDP): However, the most 
promising derivatives of MDP were not pursued as vaccine adjuvants due to lack of 
advantage over aluminium adjuvants. (ii)The adjuvant effect of LPS was described in 1956 
and most of the adjuvanticity and toxicity of LPS are due to the lipid A region of the 
molecule. However, LPS and lipid A are too toxic to use for human vaccines. Incorporation 
into liposomes reduced the toxicity of LPS or lipid A while retaining or even increasing the 
adjuvant effect. (iii) Immunostimulating complexes (ISCOMs) are non-covalently bound 
complexes of Quil-A adjuvant, cholesterol and amphipathic antigen. ISCOMs have been 
shown to stimulate both humoral and cell-mediated immune response particularly CD8+ CTL 
response. The adjuvant properties ofISCOMs have been demonstrated with a variety of viral 
capsid antigens and non-viral antigens of relevance for human vaccination (Gupta and Siber, 
1995). ISCOMs are used in veterinary vaccines and have not been approved for human 
vaccines mainly due to side-effects of Quil-A, although these side-effects were almost absent 
when Quil-A was incorporated into ISCOMs (Morein et al., 1989). (iv) Biodegradable 
microspheres such as liposomes and PLGs (section 1.8.2.1 and 1.8.2.2). 
The basic knowledge of adjuvant action is very important for developing vaccines and for 
subunit or synthetic vaccine antigens, potent adjuvants may be necessary. The practical 
application of peptide-based vaccines depends on their ability to successfully mimic naturally 
occurring antigenic determinants present in the infectious agent and on their capacity to 
stimulate the appropriate response to induce immunity to the natural infection. Unfortunately, 
most of these synthetic peptides are poor immunogens and require the use of adjuvants to 
increase their immunogenicity. Therefore the prospect of using synthetic peptide antigens in 
vaccines will become a reality only if safe and effective adjuvants are developed. 
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1.8.2 Delivery systems 
One approach to adjuvant design incorporates concepts of controlled-release technology, in 
which therapeutic molecules are delivered from vesicles or polymeric systems at a pre-
determined rate for a definite time. In addition, the immune response can be enhanced and 
targeted by appropriate packaging of antigens and use of adjuvants. There have been 
advances ill the packaging of antigens to emulate some of the advantages of live agents, such 
as targeting to particular cells and constructing a mosaic pattern or specific aggregates of 
protein molecules. Three delivery systems are of particular interest; liposomes, ISCOMs and 
biodegradable micro spheres. Liposomes and microspheres were studied during the course of 
this work and are of special interest because they may offer the prosp~t of reducing the size 
of the antigen dose and the number of administrations of some vaccines, whilst still giving 
long-term immunity. Liposomes and micro spheres also give the ability to target the vaccine 
to a particular site in the body and to stimulate a particular response, for example, enhancing 
the immune response via both parenteral and oral vaccination routes. 
1.8.2.1 Biodegradable microspheres 
Spherical, sustained-release polymer particles can be either monolithic, with the antigen 
interspersed throughout the particle (micro spheres) or consist of true core-wall capsule 
structures with a core reservoir of antigen surrounded by an outer polymer shell (reservoir 
microcapSUles). The most studied polymers for controlled-release delivery are poly (lactide-
co-glycolide) (PLG) polymers. The lack of toxicity in these polymers has been established 
and PLG has been used for years as absorbable suture material. 
Scanning electron microscopy (SEM) and gel permeation chromatography (Cohen et al., 
1991) have confirmed that antigen is released from the micro spheres by diffusion through 
matrix pores and by matrix degradation. Monolithic micro spheres release an initial surge of 
antigen from surface pores and then continue to release antigen at a nearly constant rate as 
the matrix of the microsphere degrades (Nuwayser et aI., 1984). Reservoir microcapsules 
will release steady low levels of antigen by diffusion until degradation disrupts the shell 
integrity and the core antigen is released (Morris et aI., 1994). In addition to spontaneous 
degradation of the copolymer matrix, ultrasound, light, magnetism and other external factors 
have been investigated for their potential in influencing polymer breakdown and 
controlling the rate of antigen release (Cohen et al., 1991). Fig. 1.7 shows poly (OL-
lactidc-co-glycolide) structure and degradation. 
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Fig. 1.7 Poly (DL-Iactide-co-glycolide) structure and degradation 
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Chemical structure ofPLG and its hydrolysis to yield lactic and glycolic acids. The rate of 
decay ofPLG microparticles is dependent on the size of the microparticles, the molecular 
weight of the polymer (x + y), and the ratio oflactic:glycolic acids (x:y). 
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The possible mechanisms for enhancement of the immune response by sustained release of 
antigen include a depot effect, analogous to that of alum adjuvants and the delivery of 
antigen directly to antigen-presenting cells such as macrophages. Direct uptake by 
macrophage is possible with micro spheres of up to 10J..1m which are taken up by gut-
associated lymphoid tissue making successful oral immunisation with micro spheres a 
possibility (Jones et al., 1996). 
An ideal vaccine delivery pattern should mimic the profile of antigen concentrations that 
are seen in the course of a natural infection i.e. a high dose of antigen within a few days of 
the injection followed by a period of decreasing amounts of antige~. The initial high load 
of antigen will influence the extent of memory T-cell formation, whereas the subsequent 
steady decrease in antigen load will enhance the development of antibody affinity 
maturation. PLG microsphere technology has the potential benefits of reducing the number 
of inoculations, enhancing the immune response and in reducing the total antigen dose 
required for effective immunisation. In addition, PLG microspheres have the potential to 
protect antigen from the harsh gastric environment and in delivering antigen to lymphatic 
tissues, permitting effective oral primary or booster immunisations. 
To overcome problems encountered using organic solvents during the encapSUlation of 
antigens, the multiple-emulsion method was developed (O'Hagan et al., 1991; Jones et 
al.,1995). This method combines the use of water and organic phases in which protein is 
dissolved in the aqueous solution and is dispersed in the PLG solution by homogenisation 
to create the first inner emulsion of water and oil. This emulsion is then emulsified again in 
a second water phase containing the surface-active material, polyvinyl alcohol (PVA). 
Upon contact with the second water phase PLG precipitates to create embryonic 
microspheres that are further solidified when the organic solvent is removed by 
evaporation. 
The multiple emulsion method produces spherical PLG organic micro spheres with 
diameters between 1 and 1001lm, a parameter easily controlled by the conditions of 
formulation. Microspheres can be injected through a 25-gauge needle, therefore no surgical 
implantation is required. Protein encapSUlation yields may be greater than 90% and most 
impOJ1antly, several vaccine candidates, e.g. tetanus toxoid, pertussis fimbriae and malaria 
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synthetic pep tides retain solubility, activity and immunogenicity following this 
microencapsulation procedure (Jones et at., 1995). Other advantages include simplicity, 
speed, ability to scale-up the procedure and there is special interest in using PLGs for 
delivery of oral vaccines, for which they are considered to be especially suited. 
1.8.2.2 Liposomes 
One approach. to increase the immunogenicity of purified microbial antigens and to 
potentiate the therapeutic action of antimicrobial agents is to employ liposomes as vehicles 
for their delivery. Liposomes are membrane-like vesicles consisting of one or more 
phospholipid bilayers surrounding aqueous compartments.{Figure 1.8) and can be 
multi lamellar or unilamellar. Hydrophobic agents can be embedded in the lipid bilayers 
and hydrophilic agents can be entrapped in the internal aqueous space of the liposomes. 
The charge, rigidity, size and surface properties of liposomes can be varied and controlled 
by incorporating different types of lipids and by varying the preparation method. Therefore 
liposomes are considered as versatile delivery systems and have an advantage in that the 
lipids most often used for liposome preparation are those commonly found in cell 
membranes and so are biodegradable, relatively non-toxic and non-antigenic or weakly 
antigenic. They can also be tailored to avoid the mononuclear phagocyte system, to deliver 
irnmunomodulators (cytokines, such as IFN y ) and liposome-mediated delivery of 
microbial antigens in vaccines. 
The immunological adjuvant action of liposomes was demonstrated by Allison and 
Gregoriadis (1974) and this has been followed by numerous studies on their use for the 
immunopotentiation of a large variety of whole cell, protein and peptide vaccines 
(Gregoriadis, 1991; Alving, 1991). The structural versatility of liposomes has permitted 
tailoring of the system towards optimal adjuvanticity and the appropriate choice of vesicle 
composition with respect to surface charge and phospholipid to antigen mass ratio. It is 
also possible to achieve ligand-mediated targeting of liposomes to immunocompetent cells 
(Garcon et ai., 1989; Mbawuike et ai., 1990) to enhance the immune response and to 
produce cell-mediated and humoral immunity. Small, submicron vesicles can be used as 
can'iers for peptides and proteins. Antimisiaris et ai. (1993) produced giant vesicles, 5.5!-1m 
in diameter, to carry attenuated killed viruses and bactcria in an attcmpt to produce more 
effective live-attenuated vaccines. 
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Fig. 1.8 Schematic diagram of a multilamellar liposome vesicle 
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The rationale of using liposomes to carry antigens for immunisation is based on the known 
preferential uptake by macrophage of parenterally injected liposomes (Wassef et al., 
1994). In vaccine preparations tried to date, the immune response elicited by the liposomal 
vaccines generally has been higher than those obtained with fluid vaccines, but lower than 
those obtained with peptides immunised in Freund's complete adjuvant(Cohen et aI., 
1991). Moreover, at least two injections of antigens in liposomes have been needed to 
elicit an adequate immune response (Davis and Gregoriadis, 1987), which may be 
attributable in part to the inherent instability of liposomes in the host, as they are rapidly 
destroyed by high-density lipoproteins and destructive cells (Cohen et al., 1991). The 
action of liposomes is attributed to depot formation, hydrophobic~ty, rendering soluble 
antigens particulate and efficient targeting of the vesicles to antigen-presenting cells of the 
immune system (Clarke and Stokes, 1992). One influential factor concerns transition 
temperature (Tc) of the lipids used; above the Tc, the major phospholipid molecules that 
form the lipid bilayers become less rigid allowing leakage of contents. Orally administered 
liposomes used as carriers have reportedly increased the intestinal absorption or efficacy of 
entrapped agents such as insulin (Patel and Ryman, 1976), glucose oxidase (Depergolas et 
al., 1976), and coagulation factor VIII (Hemker et al., 1980). Liposomes have also been 
investigated as delivery systems in DNA therapy for conditions such as, cystic fibrosis 
(McLachlan et al., 1995). 
Few studies have investigated the immune response to relevant antigens fed in liposomes. 
Liposome entrapment of streptococcal antigens increased salivary antibody responses in 
rats (Wachsmann, 1985, 1986; Gregory et al., 1986). Many future vaccine preparations are 
likely to be based on relatively pure, low MW proteins. Therefore liposomes may be a 
good vaccine delivery system for such antigens. Aramaki et al. (1994) demonstrated that 
liposomes consisting of distearolphosphatidy1choline (DSPC): phosphatidylserine (Pser) : 
cholesterol (CH) are negatively charged and stable in the gastrointestinal tract and are 
preferentially taken up by PPs following oral administration to rats (Tomizawa et al., 
1993). Other liposomal vaccines include Streptococcus pneumoniae type 3 and 14 (Snippe 
et al., 1989). Oligosaccharides from S. plleul1lolliae type 3 and 14 polysaccharides were 
linked to liposomal membranes which resulted in a T-cell independent response. 
Therefore, to elicit aT-cell dependent response it may be necessary to use additional 
adjuvants to change the immunological characteristics of Iiposomes. Alving el al. (1989) 
investigated an experimental malaria vaccine, lIsing liposomes as a carrier for synthetic 
54 
antigens derived from the structure of the CS protein on the surface of Plasmodium 
falciparum sporozoite. Liposomes were found to be an effective carrier and could be used 
to stimulate higher antibody titres than those elicited by non-encapsulated antigen. 
Liposomes might be especially suited to intranasal delivery of vaccines because the lipid 
membrane will fuse with cells lining the mucosal epithelium, therefore facilitating rapid 
uptake of antigen. However, for effective protection, liposomes given intranasally needed 
to reach the lower respiratory tract and this was done effectively by anaethestising mice 
prior to administration of the liposomes (Aramaki et ai., 1994). 
1.8.3 Enhancement of the immune response using delivery systems 
Using adjuvants and vaccine delivery methods alone or in combination, it is possible to tailor 
the immune response to a particular disease by inducing a stronger cell mediated or mucosal 
response depending on which of these would provide the best protection. However, in the 
case of plague, where infection can be via a flea bite or across a mucosal surface, 
enhancement of the overall response to give a balanced immune response to infection would 
be the most desired effect of administering vaccine antigens using delivery systems. A 
balanced immune response would be one which would induce humoral immunity to give a 
B-cell response and the production of opsonising and bactericidal antibodies as a first line of 
defence. This would be improved if at this stage mucosal immunity could be enhanced to 
protect mucosal surfaces from invasion by the pathogen, if it could also induce a cell-
mediated response, it would be some way towards an ideal vaccine. Therefore, in vaccine 
development, it is important to study the type of immune response that the vaccine 
formulation produces as well as its protective efficacy. 
1.9 Study Aims 
1.9.1 Identification, isolation and characterisation of the native FI antigen of Y. pestis 
The FI antigen has been shown to provide protection against plague. In recent years a 
recombinant F I has been shown to be protective in mice (Simpson et al., 1990). F I antigen 
has also been described as having a major subunit FI (fraction lA) as a 17.5kda 
glycoprotein. This study aimed at purifying native FI antigen, characterising the major 
subunit and determining the glycosylated state of the protein. The study also attempted to 
determine whether any of these factors are important for immunogenicity and protection 
against plague. The study also addressed scaling up the purification of native FI for vaccine 
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production. 
1.9.2 Production and characterisation of rFl antigen 
The nFl antigen has inherent problems in that large volumes of Y. pestis have to be handled 
in order to purify sufficient quantities for immunogenicity and protection studies. In addition, 
problems may arise in proving that it is completely safe for inclusion in an acellular vaccine. 
Development of a suitable rF! antigen would overcome these difficulties and may prove to 
be a more suitable alternative candidate antigen. This study aimed at developing an effective 
process for the production of a rFl and the scaling-up of this process. 
1.9.3 Immunogenicity and protective potency of the nFl and rFl 
The immunogenicity ofnFl and rFl will be assessed and their ability to provide protection 
against challenge with virulent Y. pestis in an experimental animal model determined. The 
aim of this study was directed towards assessing which of these antigens would be most 
suitable for use as an acellular vaccine antigen. 
1.9.4 Evaluation of Fl and V antigens of Y. pestis as protective antigens 
This study also aimed at assessing the V antigen as a protective antigen and as a candidate 
for an acellular vaccine. The protective potency ofFl and V, administered separately and as 
a combined subunit vaccine was examined. 
1.9.5 Development of vaccine delivery systems for the Fl and V antigens of Y. pestis. 
PLG micro spheres and liposomes have been shown to be suitable vaccine delivery vehicles 
for protein subunits and peptides. One of the objectives of this project was to produce PLG 
microspheres and liposomes for delivery of the Fl and V antigens as protective antigens 
administered separately and as a combined vaccine. The novel delivery systems will be 
compared with antigens administered in aluminium hydroxide as adjuvant. 
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Chapter 2 
Materials and Methods 
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2.1 Bacterial strains and growth conditions 
2.1.1 Yersinia pestis strains 
Yersinia strains were stored either as freeze-dried cultures at 4°C or as glycerol stocks at 
-70°C. Y. pestis strains were grown either in chemically defined medium (YPMH) 
(Straley and Bowmer, 1986), the composition of this medium is detailed in table 2.1, or 
blood agar base (Oxoid) for 48h at 37°C or 28°C as required. 
2.1.2 Recombinant E. coli strains 
Recombinant E. coli JM109 strains were stored at -70°C in 15% glycerol. These strains 
containing pGEX plasmids expressing a recombinant F1-glutathione-S-transferase (GST) 
fusion protein (produced as a collaboration between CAMR and CBD, DERA) or a 
recombinant V -GST fusion protein (produced at CBD, DERA) were grown in L-broth 
(table 2.2) or Terrific broth (Sigma Chemical Co., made according to manufacturers 
instructions), both containing 100Jlglml of ampicillin. 
2.2 Expression of Y. pestis antigens 
2.2.1 Expression of native Fl antigen 
Freeze-dried or frozen stocks of Y. pestis MRE 1447 or 1176 were cultured on blood agar 
plates. After 48h incubation at 37°C, single colonies were inoculated into 10ml volumes 
of YPMH in McCartney bottles. These primary cultures were incubated for 24-48h at 
37°C and each 10mi volume used to inoculate lL of YPMH in a polypropylene conical 
flask (Nalgene). After incubation at 37°C for 48h in an Orbital shaking incubator 
(180rpm), the culture was centrifuged (6000 x g for 30min) and the F1 was purified from 
the culture supernatant. 
For larger-scale expression ofFl antigen, two lL YPMH cultures were used to inoculate 
a 35L fermenter (Chemap fermenter with a CBC50 controller) with a running volume of 
25L. Y. pestis was cultured for 48h at 37°C (stirrer speed 400rpm; air, 2L1min; pH 
maintained at 7.4), cells were then harvested by continuous flow centrifugation and the 
supernatant retained. 
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Table 2.1 Components of YPMH medium 
Component 
HEPES 
K2HP04 
MgCl2 
MnCl2 
Na2S203 
NH4CI 
D-Biotin 
Calcium pantothenate 
Thiamine 
Glucose 
DL-Alanine 
L-Arginine hydrochloride 
L-Asparagine 
L-Aspartate 
L-Glutamate 
L-Glutamine 
Glycine 
L-Histidine 
L-Isoleucine 
L-Leucine 
L-Lysine 
L-Methionine 
L-Phenylalanine 
L-Proline 
L-Serine 
L-Threonine 
L-Tryptophan 
L-Tyrosine 
L-Valine 
Amount(mM) 
25.0 
2.5 
20.0 
0.01 
2.5 
10.0 
0.002 
0.004 
0.003 
10.0 
. 2.5 
1.0 
2.5 
1.0 
5.0 
1.0 
5.0 
1.0 
1.0 
1.0 
1.0 
1.0 
1.0 
5.0 
5.0 
2.5 
0.1 
1.0 
1.0 
The above ingredients were added in the appropriate amounts to water, the pH was 
adjusted to 7.4 with O.lM NaOH and the media was filter-sterilised. (Straley and 
Bowmer, 1986). 
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Table 2.2 Components of L-Broth 
Component 
Difco Bacto tryptone 
Difco Bacto yeast extract 
NaCl 
Amount per Litre 
lag 
5g 
lag 
The above ingredients were dissolved in water, the pH adjusted to 7.5 with O.IM NaOH 
and sterilised by autoclaving at 15psi for 15min. 
For L-agar, the above method was used with the addition of 15g per Litre of Difco Bacto 
agar. 
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2.2.2 Expression of recombinant Fl antigen 
A recombinant F1-GST fusion protein was cloned using the pGEX plasmid (Pharmacia). 
A positive clone expressing the fusion protein (E. coli JM109 + pKR4) was selected for 
purification of recombinant F1 (rFl) antigen. 
All media contained ampicillin (lOOJlg mrl) to stabilise the recombinant plasmid within 
the E. coli strain. A stock culture of E. coli JMI09 + pKR4 was used to inoculate L-agar 
plates (table 2.2). After 18h incubation at 37°C, single colonies were used to inoculate 
10ml volumes of L-broth in McCartney bottles, which were incubated for 18h at 37°C. 
These broth cultures were used to inoculate 1 L amounts of the same medium in 2L 
conical flasks, which were incubated in an Orbital shaking incubator (180rpm) until the 
absorbance of the cultures at 600nm reached 0.3 to 0.6. Expression of the recombinant 
antigen was then induced by the addition of isopropylthiogalactopyranoside solution 
(IPTG, manufactured by BCL, final concentration of 0.1 mM in PBS). Incubation was 
continued for a further 5h before the cells were harvested by centrifugation (10000 x g, 
30min, 4°C). All centrifuge pots and buffers were sterilised prior to use to avoid 
contamination with extraneous proteases. 
For larger-scale production of recombinant protein, 2 x 1L L-broth cultures (without 
IPTG) were used to inoculate a 25L fermenter (stirrer speed, 400rpm; air 2L1min; pH 
maintained at approximately 7.5, 5 - 10ml antifoam, PPG 2000, was added after 4h), the 
expression ofrFl was induced using IPTG as described for small-scale cultures. 
2.3 Protein purification 
2.3.1 Purification of native Fl antigen 
Culture supernatant obtained in section 2.2.1 was filtered through a Sartobran capsule 
containing a 0.2Jlm membrane with a 0.45Jlm prefilter. F1 antigen was extracted from this 
cell-free supernatant by precipitation with 40%(w/v) ammonium sulphate. The resulting 
precipitate was sedimented by centrifugation (34000 x g, 30min, 4°C) and resuspended in 
10mM phosphate buffer, pH7.4. Repeated resuspension and centrifugation steps were 
necessary to extract the majority of FI from the precipitated pellet and reduce the size of 
the pellet. 
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Final supernatants were pooled and concentrated using centrifugal concentrators (Filtron) 
or solid polyethylene glycol (PEG, MW 20000) before being dialysed against 4L 10rnM 
phosphate buffer, pH7.4 (3 changes). This material was examined by sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and by Limulus Amoebocyte 
Lysate (LAL) assay (192 Test Kit), according to manufacturer's instructions, for 
lipopolysaccharide content. The concentrated antigen was stored at -20°C. A flow 
diagram representing the F 1 purification process was prepared (Fig. 3.10). 
2.3.1.1 Size exclusion chromatography 
Sephacryl S200 pre-swollen gel (Pharrnacia) was used to prepare a gel filtration column 
(16mm x 100mm) with a packed bed volume of 177m!' The void volume of the column 
was detemlined using a solution of blue dextran (3mg mr!) and found to be 78m!. The 
column was calibrated using the protein molecular weight standards, bovine serum 
albumin (BSA) (66kDa), carbonic an hydrase (29kDa) and cytochrome c (12.4kDa). Fl 
antigen (Smg) was applied to the column in 100mM Tris-HCI, pHS.O at a flow rate of 
0.3ml per min. Fractions (2ml) were collected and elution monitored by absorbance at 
2S0nm. Fractions under the absorbance peak were examined by SDS-PAGE. 
2.3.1.2 Ion exchange chromatography 
A Iml sample ofFl antigen (approximately 200llg) in 20rnM imidazole, pH7.0 (column 
buffer A) was injected onto a MA 7Q anion exchange HPLC column (Pharrnacia). Protein 
was eluted using a sodium chloride gradient applied by adding increasing amounts of 
20rnM imidazole, 1M NaCI (column buffer B). Fractions (Iml) were collected and elution 
was monitored by absorbance at 280nm by the UV monitor on the HPLC system 
(Biorad). Fractions under the absorbance peak were examined by SDS-P AGE. 
2.3.2 Purification of rFl from recombinant E. coli 
Recombinant E. coli strain JM109 + pKR4 was grown under conditions described in 
section 2.2.2. Cells were harvested by centrifugation (10000 x g, 30min, 4°C) and 
resuspended in phosphate buffered saline (PBS) (2g wet weight of cells in 10ml PBS). 
Lysozyme (final concentration, 2S0llg mrl) was added to the cell suspension and 
incubated at 37°C for 30min. Triton X-100 was then added (1% (v/v) final concentration), 
this suspension was mixed gently and placed on ice for 10min. The cold suspension was 
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sonicated (MSE soniprep, 100mm probe) in 50ml amounts for 10 x 30second bursts with 
a lmin pause for cooling between each burst. The sonicate was centrifuged (25000 x g, 
30min at 4°C) to remove cell debris. 
The rFl was purified from the sonicate supernatant by affinity chromatography using 
glutathione 4B Sepharose (Pharmacia) after equilibration of the affinity column (5ml bed 
volume) with PBS (5 column volumes). The sonicate supernatant was incubated with the 
gel at room temperature for 1h. Unbound fusion protein was then removed by washing the 
column (x4) with PBS containing 0.1% (v/v) Triton X-IOO. The rFl antigen was 
separated from bound GST by cleavage with bovine Factor Xa (Enzyme Research 
Laboratories). Factor Xa (5ml) was added to the affinity column (lmg Factor Xa to 
200mg fusion protein) and incubated for 18h at 4°C. Cleaved rFI antigen was eluted from 
the column with 10ml PBS and 2-5ml fractions collected. The protein concentration in 
each fraction was estimated by the Pierce Bicinchoninic acid (BCA) assay according to 
manufacturers instructions, fractions were then pooled and concentrated (section 2.3.1) 
before dialysis against three changes of 4L PBS, samples were stored at -20°C until 
required. 
Samples ofrFI were examined for purity by SDS-PAGE. 
2.3.3 G25 Sepbadex size exclusion chromatography after solubilisation of sonicate 
Bacterial paste (from recombinant E. coli strain JMI09 + pKR4) was dispersed in 
approximately 10 volumes of 50 mM TrisIHCI, 10% (w/v) sucrose, 5mM EDTA, pH7.5, 
lysozyme (final concentration 200~g mr!) was added and the cell suspension frozen at -
20°C. The solution was thawed at 20°C and diluted with 9 volumes of ice-cold lysis buffer 
which contained 150mM diethanolamine, 50rnM NaCI and 5mM dithioerythritol, pH7.5. 
N-Iaurylsarcosine (sarcosyl) was added to 2% (w/v) and the cell suspension sonicated on 
ice for 7 x 30 seconds with 15 second intervals to allow for cooling. The sonicate was 
centrifuged at 27000 x g for 30min to remove bacterial debris and the supernatant applied 
to a Sephadex G25 gel filtration column to remove sarcosyl and exchange the buffer to 
PBS (required for affinity chromatography, section 2.3.2) (Frankel et al.,1991). The 
sephadex G25 column was prepared by swelling enough Sephadex G25-M to make a 
column of approximately 130ml, packed bed volume, in PBS (column buffer). The gel 
was packed into a column (2.5cm x 30cm) and washed with 100ml column buffer. The 
void volume of the column was calculated using blue dextran and found to be 45ml. Cell 
sonicate supernatant was applied to the column at a flow rate of Iml per minute and 
63 
protein eluted with column buffer. Fractions (2ml) were collected and protein was 
detected by absorbance at 280nm on a Pharmacia single path UV monitor and recorded 
using a Pharmacia chart recorder. Fractions corresponding to the absorbance peak were 
analysed by SDS-PAGE and those containing protein were pooled. Fusion protein from 
pooled fractions was finally purified by affinity chromatography on glutathione sepharose 
(section 2.3.2). 
2.3.4 Purification of rV antigen 
A recombinant V-GST fusion protein was cloned using the pGEX plasmid (Pharmacia) 
by colleagues at CBD, DERA, Porton Down, Salisbury. The recombinant strain of E. coli 
expressing this fusion protein was grown as described in section 2.2.2 and purified 
(section 2.3.2). 
2.4 Molecular genetics procedures 
2.4.1 Isolation of DNA from Y. pestis strains 
DNA was isolated from Y. pestis GB strain at CBD, DERA, Salisbury, using Marmur's 
modified method (1961), which extracts all, but mainly chromosomal DNA. The call 
gene encoding the Fl protein is carried on a plasmid, but sufficient plasmid DNA was 
extracted using this method to proceed with the cloning strategy. 
2.4.2 Cloning of the cafl gene 
A GST-Fl sequence map was used to develop a cloning strategy for the production of an 
F1-GST fusion protein using pGEX plasmids (Pharmacia). 
The cloning strategy was to digest the PCR product of F1I5'D and F1I3'C plimers (fig. 
2.1) and the pGEX-5x-2 plasmid vector (Pharmacia) with restriction enzymes, EcoRl and 
BamHl as a forced cloning. Primers were also used to check the clones produced. 
2.4.2.1 PCR 
PCR was used to amplify the call gene from Y. pestis DNA, the predicted size of the PCR 
product was 450 base pairs. The amplified product was suitable for cloning into the 
pGEX-5x-2 plasmid vector. 
64 
Fig. 2.1 peR primers used for cloning the cafl gene 
FlIS'D and F1I3'C primers were constructed to give a predicted PCR product of4S0bp. 
5' Primer: 
FlIS'D 
3' Primer: 
F1I3'C 
BamHI digest site 
ACGCGGATCCCCGCAGATTT AACTGCAAGCACC 33-mer 
EcoRI digest site 
GATCGAATTCTATATGGATTATTGGTTAGATAC 
stop stop 
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(12-mer tail) 
33-mer 
(lO-mer tail) 
Using Y. pestis GB strain DNA as template (approx. 2ng ~rl) and Fl/S'D and F1I3'C 
primers at 12Spmol ~rl of each primer; 2~1 GB DNA, 1 ~l each primer were added to the 
PCR mix containing 20~1 of PCR buffer (xlO concentration, Boehringer Manheim), 2~1 
dNTPs (lOmM each, Phannacia), O.S~1 Taq polymerase (Boehringer Mannheim) and 
made up to 96~1 with distilled water giving a total PCR volume of 1 OO~l. 
The PCR cycle used involved Imin at 96°C for initial denaturation of DNA; 20sec at 
96°C for further denaturation; 20sec at 50°C to allow annealing of DNA; 30sec at 72°C 
for final extension. The PCR product was checked by agarose gel electrophoresis. 
2.4.2.2 Agarose gel electrophoresis 
This was perfonned using a horizontal slab gel electrophoresis system (Biorad 
mini protean II). Gels were fonned using a gel casting tray (7 x 10cm tray for single gels, 
15 x 15cm tray for double gels). Agarose gels were prepared by mixing the appropriate 
amounts of 1 x TAE buffer (appendix 1) with agarose to give 0.7% (w/v) gels for standard 
gels and 1 % (w/v) gels for analysis ofPCR products; this was then heated in a microwave 
oven at low power until the agarose had completely melted. The molten gel was allowed 
to cool until comfortable to the touch before adding ethidium bromide to a final 
concentration ofO.5llg mrl and pouring into the casting tray. 
The gel was placed in the electrophoresis tank and covered with TBE buffer (appendix 1) 
containing 0.51lg mrl ethidium bromide. Samples were mixed with one sixth volume of 
sample buffer containing 0.25% (w/v) bromophenol blue, 40% (w/v) sucrose, 50mM 
TrisIHCI, SmM EDTA, pH7.5, and loaded into the wells. DNA was separated by 
electrophoresis using a voltage across the gel of 80V until the dye front had migrated an 
appropriate distance through the gel. After electrophoresis, DNA was visualised by 
medium wavelength UV transillumination and photographed with a Polaroid camera. 
2.4.2.3 Concentration of the PCR product 
The product of the PCR reaction was concentrated using microconcentrators (Amicon). 
The sample reservoir in the microconcentrator was pre-washed with 0.5ml 0.1 M NaOH. 
After adding 0.5ml sterile distilled water (dH20), the microconcentrator was centrifuged 
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(3000 x g for 3min) and reduced the volume by SO%, lOO1l1 PCR product was added to 
the sample reservoir and O.4ml dH20 was added. This solution was centrifuged (3000 x g 
for Smin at 2SoC), reducing the sample volume to less than 1001l1. This procedure was 
repeated until the sample volume had reduced to 10-20IlL 
2.4.2.4 Ethanol precipitation of DNA 
DNA was precipitated from solution by the addition of one tenth volume of 3M sodium 
acetate, pHS.2 and two volumes of ice-cold absolute ethanoL The solution was mixed and 
incubated at -20°C for ISmins. After precipitation, DNA was recovered by centrifugation 
at 14000rpm for 15min at 4°C, the supernatant was carefully removed and discarded. The 
DNA pellet was washed with Iml of70% (v/v) ethanol and, after carefully discarding the 
supernatant, the precipitate was allowed to air-dry for 10-IS min. The dried DNA pellet 
was finally resuspended in an appropriate volume of TE buffer (appendix I). 
2.4.2.S Preparation of restriction digests 
Restriction digests of the call PCR product and pGEX vector were prepared using EcoRI 
and BamHi restriction enzymes. Appropriate amounts of the restriction enzymes 
(Boehringer Manheim), purified DNA, incubation buffer (Boehringer Manheim) and 
dH20 were mixed according to manufacturers instructions. These restriction enzymes 
gave a double digest and produced cohesive ends in both cafl DNA and the pGEX vector, 
digests were purified as described in section 2.4.2.3 and 2.4.2.4. 
2.4.2.6 Ligation of restriction digests 
A typical ligation reaction consisted of the pGEX and cafl restriction digests, ligation 
buffer, T4 DNA ligase (1 unit per ml) and dH20 using a 1:3 vector:insert ratio. A ligation 
control was prepared including DNA molecular weight markers but without the restriction 
digest. Also, a vector self-ligation control was prepared where the pGEX restriction digest 
was used but not call. The ligation reaction was checked by agarose gel electrophoresis in 
order to visualise the increase in the molecular weight of the ligated DNA. 
2.4.2.7 Transformation of E. coli 
Ligations and controls were electroporated into E. coli JMI09. Cells were grown to mid-
log phase (A6oo = 0.5-l.0) and harvested by centrifugation (10000 x g, 30min at 4°C) 
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followed by washing the pellet with 500ml cold 10% glycerol, this was repeated using 
250mll0% glycerol. The final pellet was resuspended in 1-1.5ml of the glycerol solution. 
This suspension was divided into aliqouts of 50).!1 and stored at -70°C until required. 
Cells were thawed on ice, 40).!1 was mixed with 1-2).!1 DNA and incubated on ice for 
approximately Imin; the mixture was then transferred to a cooled electroporation cuvette 
(Biorad) and the solution pulsed 2.5kV, 25uF and 2000hms. The cuvette was removed 
and immediately Iml SOC broth (table 2.3) was added and the suspension incubated at 
37°C for lh in a polypropylene tube. The suspensions were diluted and plated onto L-
ampicillin agar plates to select for transformed cells. After incubation at 37°C for 18h, 30 
recombinant colonies were picked across onto L-ampicillin plates, marked with a grid, 
using a disposable needle (Nunc), taking care to transfer only one colony at a time. 
Colony lysates were prepared by boiling the inoculated dH20 in a boiling water bath for 
5min. The lysates were cooled and PCR reactions were prepared using F1I5'D and F1I3'C 
primers. PCR products were examined by agarose electrophoresis and positive clones 
identified by a 450bp product. Two positive clones identified in this way, JMI09 + pKR4 
and JMI09 + pKRI0, were selected and stock cultures of these prepared. 
2.4.2.8 Culture Iysates of the recombinant strains 
Culture lysates of induced and non-induced cultures (section 2.3.2) were prepared by 
microfuging a small amount of culture for 4mins at high speed, the pellet was washed in 
0.5ml PBS and the final pellet was resuspended in 50).!1 dH20. One fifth volume of SDS-
PAGE sample buffer was added to give final concentration of 1 %(w/v) SDS, 0.1 %(v/v) 
mercaptoethanol, 10%(v/v) glycerol and lmg mr! bromophenol blue. The suspension was 
heated in a boiling waterbath for 5min to lyse the cells and debris was sedimented by 
microfuging at high speed for 4min. Samples of the supernatant were then examined by 
SDS-PAGE and Western blot for the presence ofFl-GST fusion protein. 
2.4.3 Purification of plasmid DNA 
Plasmid DNA was extracted and purified from uninduced recombinant E. coli using the 
Qiagen Plasmid Kit. The maxi-prep protocol was used according to the manufacturers 
instructions. The final pellet of plasmid DNA was gently resuspended in 200).!l sterile 
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Table 2.3 Composition of SOC Broth 
Component 
Bacto tryptone 
Bacto yeast extract 
NaCI 
KCI 
Amount 
20g per litre 
5g per litre 
10mM 
2.5mM 
The above components were added to lL of Ultrapure water (Elgastat) and allowed to 
dissolve. The media was then autoclaved at 15psi for 15min. 
Prior to use, the following filter-sterilised solutions at pH7 were added to give a final 
concentration of: 
10mM MgC12.6H20 
10mM MgS04.7H20 
2mM glucose 
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dH20 and stored at -20°C until required. The plasmid preparation was examined by 
agarose gel electrophoresis for the presence of covalently closed circular plasmid DNA. 
2.4.3.1 Determination of DNA concentration in plasmid preparations 
The optical density of diluted DNA samples were measured at 280nm and 260nm using 
paired quartz cuvettes, typical dilutions were I :100 to I :500. To calculate the DNA 
concentration; for short single stranded oligos an OD260nm of 1.0 is equivalent to 20llg 
mr) and for double stranded chromosomal and plasmid DNA, an OD260nm of 1.0 is 
equivalent to 50llg mr) . The ratio of OD260 : OD280 is then determined, the optimal 
ratio of 1.8: 1 indicates DNA is relatively free of contaminating protein. 
2.4.4 Automated cycle sequencing of DNA 
2.4.4.1 Preparation of DNA template and primer 
Template and primer DNA were added to a screw-capped eppendorf in the following 
quantities: 0.2pmol plasmid template, IOpmol primer, 1111 dimethyl sulphoxide (DMSO), 
this was made up to 16Jll with dH20. Dyedeoxy terminator sequencing chemistry was 
performed at CBD, DERA, using an annealing temperature of 50°C in a Molecular 
Biology Lab. Station (Catalyst, Applied Biosystems). DNA sequencing samples were 
purified by phenol extraction to remove excess Dyedeoxy terminators section (2.4.4.2). 
2.4.4.2 Purification of DNA sequencing samples 
The volume of sample was made up to 100111 with dH20. A mixture of phenol, water and 
chloroform (ABI) (100111) was mixed thoroughly with the sample (vortexed 2-4mins), the 
upper aqueous layer was retained and this process was repeated. The sequencing ladder 
was then precipitated by adding 20ml 10M ammonium acetate and 300111 ethanol for 10-
15min at -20°e. The mixture was centrifuged for 15min at maximum speed in a 
refrigerated microfuge, the ethanol was then removed and the pellet washed with 300!!1 
ice-cold 70% ethanol. The solution was then centrifuged as before and all traces of 
ethanol removed and the pellet allowed to dry. Samples were then sequenced on a TAQ 
sequencer by dideoxy sequencing chemistry by CBD, DERA. 
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2.5 SDS-P AGE 
2.5.1 Polyacrylamide gels 
SDS-PAGE of proteins was essentially performed by the method of Laemmli (1970). 
Resolving gels contained 15% (w/v) acrylamide, 0.4% (w/v) bis-acrylamide in 0.375M 
Tris-HCI, 0.1 %(w/v) SDS, pH8.8, and were prepared by diluting a 30% (w/v) 
acrylamide/0.8% (w/v) bis-acrylamide stock solution (Protogel) 1: 1 in the appropriate 
buffer. Polymerisation of the gel was induced by the addition of 450J..lI of a 10% (w/v) 
ammonium persulphate solution and 45J..lI of N,N,N',N'-tetramethylethylenediamine 
(TEMED) to 60ml of the above solution prior to pouring into a gel casting chamber. 
Stacking gels contained 4% (w/v) acrylamide, 1 % (w/v) bis-acrylamide and 20% sucrose 
in 0.125M Tris-HCI, 0.1 % (w/v) SDS, pH6.8. Polymerisation was induced by the addition 
of ammonium persulphate and TEMED in the same proportions as for the resolving gel. 
Prior to pouring the stacking gel, a comb of the appropriate size was placed on top of the 
resolving gel in the casting chamber, loading wells were formed by pouring the stacking 
gel with the comb in place. 
2.5.2 Preparation of samples 
Samples were diluted to the appropriate concentration in PBS, then diluted 4: 1 in SDS-
PAGE sample buffer to give a final concentration of 1% (w/v) SDS, 0.1% (v/v) 
mercaptoethanol, 10% (v/v) glycerol and 1mg mr) bromophenol blue. Samples were then 
heated at 100°C for 5min and allowed to cool before loading onto the gel. Up to IOOIlI or 
40J..lI of sample were loaded onto 16cm or 6cm gels respectively. 
2.5.3 Electrophoresis 
Slab gels of either 16cm (Biorad, Protean II system) or 6cm (Hoeffer, Mighty Small II 
system) were used and electrophoresis carried out using a constant current of 50mA for 6h 
or 25mA for 90min respectively. The buffer used for electrophoresis contained 25mM 
Tris-HCI, 0.2M glycine and 0.1 %(w/v) SDS, pH8.3. 
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2.5.4 Molecular weight determination 
The molecular weight of proteins was determined using low range molecular weight 
markers (Pharmacia). The molecular weight of proteins was determined by comparing 
their electrophoretic mobilities with those of the molecular weight markers. Molecular 
weight was confirmed by image analysis (Millipore Bio Image System), the relative 
proportions of proteins in samples was also quantified in this manner. 
2.5.5 Coomassie blue staining 
Proteins were visualised by staining with 0.1 %(w/v) Coomassie brilliant blue R-250, 
prepared by dissolving in 10% (v/v) glacial acetic acid and 25% (v/v) isopropanol. Gels 
were incubated for 4-5h in the above solution and destained by incubating with shaking in 
40% (v/v) methanol, with several changes of destaining solution. 
2.5.6 Image analysis ofSDS-PAGE gels 
Image analysis was carried out using either a Millipore Bio Image system or Bio-Rad 
Imaging Densitometer (model GS-690) to quantify the relative proportions of proteins in 
samples after SDS-PAGE and Coomassie blue staining. 
2.5.7 Periodic acid Schiffs (PAS) stain for glycoproteins 
Polyacrylamide gels were stained using a PAS stain protocol developed from published 
protocols (Matthieu and Quarles, 1973; Segrest and Jackson, 1971). Purified native F1 
antigen was loaded onto a 15% polyacrylamide gel (30~g protein). After electrophoresis 
(2.5.3), proteins were fixed by immersing the gel in a mixture of ethanol, glacial acetic 
acid and distilled water in a ratio of 8: 1: 11 respectively, for Ih at room temperature. The 
gel was then incubated in 0.7%(v/v) periodic acid for 2-3h at room temperature with 
gentle agitation, followed by 2-3h incubation in O.2%(w/v) sodium metabisulphite. 
Finally, the gel was incubated in Schiffs reagent (Sigma) for 12-18h at room temperature, 
excluded from light. Glycosylated proteins were detected as intense pink bands. 
2.5.8 Determination of isoelectric point (pI) 
The Pharmacia Phast Gel system, designed for the rapid electrophoresis of proteins, was 
used to determine the (pI) of FI antigen. Pharmacia pre-packed IEF 4-6.5 gels, which 
contained carrier ampholytes to generate a stable linear pH gradient across the gel were 
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used. Purifed Fl antigen (section 2.3.1) was loaded onto gels and electrophoresed at 250V 
and lOrnA for approximately 20min. Proteins were visualised by Coomassie blue 
staining, carried out automatically in the Phast system, using a pre-programmed method. 
The gel was calibrated using Pharmacia low pI calibration kit containing human carbonic 
anhydrase B (PI 6.6), bovine carbonic anhydrase B (PI 5.9), ~-lactoglobulin A (pI 5.1), 
soyabean trypsin inhibitor (pI 4.6), glucose oxidase (pI 4.2) and amylglucosidase(pI 3.6). 
The pI point ofF! antigen was determined by comparing its electrophoretic mobility with 
those of the standards. 
2.6 Structural studies on the Fl antigen of Y. pestis 
2.6.1 N-terminal sequencing 
Edmans reagent (phenyl isothiocyanate) is coupled to the free N-terminus under basic 
conditions, for example, aqueous trimethylamine supplied as a vapour. This produces the 
phenylthiocarbamyl (PTC) protein. The derivatized N-terminal amino-acid is cleaved 
using a strong, usually volatile acid, for example, trifluoroacetic acid. This produces a free 
unit, the anilinothiozolinone (ATZ) amino-acid and leaves the protein with a fresh N-
terminus, which can be derivatized in turn. The ATZ amino-acid is unstable and needs to 
undergo a further reaction before analysis. The ATZ amino-acid is converted to the more 
stable PTH (phenylthiohydantoin) formed by reaction with aqueous acetonitrile is then 
injected onto the HPLC system for identification and quantitation. Identification of PTH 
amino-acids is by the retention time on the HPLC column. 
Purified FI antigen at varying concentrations was applied to SDS-PAGE gels (section 
2.5), typically 2-20J.lg of protein was loaded. Following SDS-PAGE, proteins were 
transferred to nitrocellulose membranes by Western blot (section 2.7.2). Membranes were 
then stained with Amido black stain containing 0.1 %(w/v) amido black, 25%(w/v) 
isopropanol and 10%(v/v) acetic acid to visualise the proteins. This was followed by 
destaining with a mixture of 25%(v/v) propanol and lO%(v/v) acetic acid. The FI band of 
the appropriate intensity was selected for N-terminal sequencing using the method 
detailed above. Native and recombinant FI were sequenced by the Protein and Nucleotide 
Chemistry section at CAMR. 
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2.6.2 Fast Atom Bombardment Mass Spectroscopy (FAB-MS) 
F AB-MS was used to detennine whether any post-translational modification, such as 
glycosylation, was detectable by comparing the actual and calculated mass of peptide 
fragments from Fl antigen by FAB-MS. 
In F AB-MS the sample is dissolved in a liquid of low vapour pressure, often glycerol, 
thioglycerol or diethrythrietol (this is referred to as the matrix), and is bombarded by a 
beam of energetic particles, such as xenon atoms, that sputter sample molecules from the 
surface layers of the matrix into the mass spectrometer vacuum. Proton or other cation 
attachment produces abundant positively charged ions characteristic of the molecular 
mass of the sample. Negatively charged ions are also generated and spectra may be 
recorded in either mode by selection of the polarity of the ion extraction voltages. 
At low mass F AB, spectra are generally dominated by signals attributable to ionisation of 
the matrix. The background of "chemical noise" extending to high mass, which gives 
FAB spectra their characteristic peak-at-every-mass appearance, is probably attributable 
to direct hits on sample and matrix molecules by the bombarding species. 
The technique is most effectively deployed in conjunction with conventional strategies for 
protein characterisation. There are, however, a number of considerations when using this 
technique. The purity and quality of the sample can detennine the success of an FAB-MS 
experiment. During preparation of the sample, detergent-solubilisation steps should be 
avoided. Ionic materials employed in sample preparation, such as, ammonium sulphate, 
denaturing reagents, like urea and guanidium Hel and ion-pairing reagents can also 
seriously interfere with F AB-MS and need to be removed. Similarly, sodium and 
potassium salts, common in samples of biological origin, cause problems (Wait, 1993). 
Figure 2.2 shows a typical F AB-MS experiment. A number of different approaches were 
investigated. 
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Figure 2.2 Schematic diagram of a typical FAB-MS experiment 
Atom 
-Gun 
Xenon Atom Beam 
·=·······"'··,······"',··,""·,,·,",,·,,·,"'·,·':";.,·'tt· • I M analyser 
", :\~f:~~:~.~~~~~1~J:);r~)~!~{~i~~·t~~:.::::·· ">:> \-- I ass-
Sample probe Sample ion beam. 
The sample, dissolved in a liquid oflow vapour pressure on the probe tip, is bombarded with a beam of energetic particles, such as, xenon atoms, which 
sputters ionised sample molecules into the mass spectrometer vacuum. The resulting ions are then mass-analysed. 
Wait (1993) 
2.6.2.1 Acetolysis 
Purifed native Fl antigen was examined by acetolysis (Naik et ai., 1985). The procedure 
is used as a preliminary to a more detailed structural study and is based on acetolysis of 
intact glycoconjugate generating peracetylated carbohydrate groups from oligosaccharides 
and proteins. Chloroform-extracted carbohydrate fragments are then analysed by F AB-
MS.Any peptide fragments generated by acetolysis in addition to any salt, remain in the 
water layer and do not interfere with the subsequent mass spectrometric analysis. In this 
way, the presence of hexoses, aminohexoses and sialic acid can be determined. The aim 
of this was to determine whether acetolysis and subsequent F AB-MS can confirm the 
presence of carbohydrate. 
Fl antigen (lmg) and ribonuclease A (positive control) were dissolved in a mixture of 
glacial acetic acid, acetic anhydride and sulphuric acid in a ratio of 10: 1 : 1 respectively. 
The mixtures were heated to 60°C, 0.2ml aliqouts were removed at 0.5, 2, 5, 8 and 24h 
and the reaction quenched by the addition of Iml of distilled water. An equal volume of 
chloroform was added to extract the peracetylated carbohydrate fragments. The 
chloroform was allowed to evaporate and the resulting material examined by FAB-MS. 
2.6.2.2 Tryptic digestion of Fl antigen 
This series of experiments aimed to digest Fl antigen with trypsin, followed by separation 
of the resulting peptide fragments by HPLC and subsequent analysis of the fragments by 
FAB-MS. 
Fl was digested using trypsin (bovine pancreas from Boehringer Manmheim) using a 
ratio of 50: 1 respectively, digestion took place at 37°C and samples were removed at 4, 6 
and 18h; digestion was terminated by freezing at -20°C. The resulting peptide fragments 
were examined by F AB-MS and compared with the calculated mass of fragments that 
should be produced by tryptic digestion. FI antigen in its native state proved to be 
resistant to digestion and to overcome this problem, two approaches were used: 
a) Fl in 10mM TrislHCl pH8 was denatured by heating at 100°C for 5min 
b) Native Fl antigen was diluted in 8M urea and subsequently digested in 2M urea (Allen, 
1983). 
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For both (a) and (b), tryptic digests were sampled at 4, 6 and 18h, digestion was 
terminated by freezing the samples at -20°C. Samples were thawed and desalted on a 
PDI0 G25 Sephadex column (Pharmacia) and the resulting protein solution was freeze-
dried to concentrate the protein prior to HPLC. 
In preparation for HPLC, samples were resuspended in 0.1 % trifluoroacetic acid (lOJlg 
mr\ HPLC was carried out using a Browning Spheri-5 RP8 column, 200Jlg of tryptic 
digest was injected onto the column for each run and peptide fragments eluted using an 
acetonitrile gradient. Alpha-melanocyte Stimulating Hormone (a.-MSH) was used as a 
positive control, this protein has two tryptic digest sites. 
2.6.3 Electrospray ionisation mass spectroscopy (ESI-MS) 
Electrospray ion production requires two steps; dispersal of highly charged droplets at 
near atmospheric pressure, followed by droplet evaporation. An electrospray is generally 
produced by application of a high electric field to a small flow of liquid (typically, 1 -
40Jlllmin) from a capillary tube. For effective ESI-MS, an appropriate liquid flow rate 
results in dispersion of the liquid as a fine mist, both thermally assisted or gas-
nebulisation assisted electro sprays allow higher flow rates to be used, but decrease the 
extent of droplet charging. 
The electric field results in charge accumulation on the surface of the liquid at the 
capillary terminus; therefore, the flow rate, resistance and surface tension are important 
factors in droplet production. The high electric field results in disruption of the liquid 
surface and formation of highly charged liquid droplets, positively or negatively charged 
droplets can be produced depending on capillary bias. The electrospray "source" is 
typically a metal or glass capillary incorporating a method for electrically biasing the 
liquid solution relative to a counter electrode. Solutions, typically water-methanol 
mixtures, containing analyte and often other additives, such as, acetic acid, flow to the 
capillary terminus. The principle requirement of an ESI-MS interface is to transport ions 
from the high-pressure region into the mass spectrometer as efficiently as possible 
(Geisow, 1991; Fenn et al., 1990). 
The components of ESI-MS instrumentation are; i)the electro spray source, or "tip", where 
electrostatic nebulisation of the liquid stream occurs, ii)the atmospheric/vacuum interface 
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where droplets and resulting ions are desolvated and transferred from near-atmospheric 
pressure to the vacuum environment of the mass spectrometer and iii) the mass 
spectrometer, typically of conventional design, where analysis occurs. In recent years 
ESI-MS has become an important tool in the analysis of peptides and proteins. Figure 2.3 
is a schematic of a typical ESI-MS experiment. 
Native Fl antigen in distilled water (lmg mr!) was examined by ESI-MS at CBD, DERA. 
The molecular weight obtained by ESI-MS was compared to the molecular weight as 
predicted from the nucleotide and deduced amino-acid sequence. 
2.7 Vaccine Delivery 
2.7.1 Preparation of PLG microspheres 
The Fl antigen was microencapsulated in PLG micro spheres by an emulsion-based 
process (O'Hagan et a/., 1994; Jones et at., 1996). 
2.7.1.1 8~m microspheres 
500mg of Poly (D,L-Iactide-co-glycolide 50:50) PLG (Resomer RG506, Alpha Chemicals 
Ltd) was dissolved in 3ml dichloromethane and mixed with 0.3ml Fl (20mg mr!). This 
suspension was emulsified using a Silverson homogeniser for 2.5min at half maximum 
speed. The emulsion was then added to 100ml 8%(v/v) polyvinylalcohol (PV A) and 
emulsification continued for a further 2.5min. This suspension was immediately added to 
lL distilled water, stirring continuously. The resulting micro spheres were washed and 
centrifuged at 5500 x g for 33min, followed by two washes at 5500 x g for 18min. The 
final pellet of micro spheres was resuspended in a small amount of distilled water and 
gently homogenised using a hand held homogeniser to ensure an even suspension. The 
PLG micro spheres were then freeze-dried and stored under vacuum over dessicant at 4°C 
until required. 
2.7.1.2 l~m microspheres 
1 ~m micro spheres were prepared in the same way as the 8~m spheres, except 1.54g PLO 
was dissolved in 14.2ml of dichloromethane; 4.6ml of this solution was mixed with O.4ml 
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Fig. 2.3 Schematic diagram of ESI-MS 
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protein solution (O.3ml Fl at 20mg mrl in O.lml distilled water). The emulsion was then 
added to SOml 8%(v/v) PYA and treated as described 2.7.1.1 
2.7.2 Sizing of microspheres 
2.7.2.1 Coulter counter 
After calibration with latex beads of the appropriate size, microspheres were sized using a 
Coulter counter ZM with a 30~M aperture orifice tube, the preset gain was set at 1.0, 
attenuation at 16.0 and a current of 1000mA was used. 
2.7.2.2 Preparation and examination of microspheres by SEM 
Lyophilised microsphere samples were dusted onto double-sided sticky carbon tabs 
mounted on 112 inch aluminium SEM specimen tabs. Specimens were then coated with 
approximately 10nm of gold-palladium (AulPd, 60:40) by ion-beam sputtering prior to 
examination in a Philips XL30 FEG scanning electron microscope operated at 4kV. 
Micrographs were recorded on Kodak T -max 100 film. 
2.7.3 Quantification of antigen in microspheres 
A Smg sample of microspheres were resuspended in SO~1 100mM NaOH containing 
1 %SDS. Samples were then heated at 100°C for 4min in a boiling waterbath to disrupt the 
microspheres. After cooling, samples were microfuged at 13000rpm for 10min and the 
supernatant retained. The protein concentration in each sample was estimated using the 
BCA protein assay. From this, the entrapment efficiency of the microspheres was 
calaculated: 
Ilg protein per mg micro spheres x 100% = entrapment efficiency 
J..lg protein per mg PLG polymer used 
2.7.4 In vitro release of antigen from microspheres 
A SOmg sample of micro spheres were resuspended in SOO~l PBS containing 0.05%(w/v) 
sodium azide. Microspheres were then incubated at 37°C on a Rotamix revolving 
eppendorf rack in eppendorfs sealed by "O-rings". Samples (SOJ..lI) were removed at 
intervals up to 42 days, then microfuged at 13000rpm for 10min and the supernatant 
stored at _20oe until required. 
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The amount of protein in each sample was estimated using the Pierce BCA protein assay 
by either the standard or enhanced protocol as appropriate according to manufacturers 
instructions. 
2.7.5 Preparation of liposomes 
Liposomes were prepared using the dehydration-rehydration method of Gregoriadis 
(1991, 1989). Liposomes encapsulating antigen were composed of 
dipalmitoylphosphatidylcholine (DPPC),CH and dicetyl phosphate (DCP) in the molar 
ratio 7:2:1 respectively. Lipids were dissolved in chloroform prior to evaporating the 
solvent under reduced pressure to leave a film of lipid which was then lyophilised. 
Liposomes surface-labeled with antigen were made up of distearoylphosphatidylcholine 
(DSPC), hydrogenated phosphatidylserine (DPPS), CH and the N-hydroxysuccinimide 
ester of palmitic acid (NHSP) in the molar ratio of 1: 1 :2:0.56 respectively. The lipids 
were dissolved in a mixture of chloroform and methanol (9:1, v/v). The lipid film was 
produced by evaporation as described above. 
For liposomes encapSUlating antigen, the lipid film was rehydrated in 4ml of solution 
containing 4mg mrl of antigen in PBS, pH7.2 and then incubated in at 5SoC for 15mins. 
However, for surface-labeled liposomes, the first step is to produce "ghost" liposomes by 
adding 2ml PBS, pH7.2 to the lipid film and incubating as above. 
The lipid mixture was then freeze-thawed several times at 5SoC to ensure that the lipid 
film was completely dissolved. The liposomes were formed by extrusion through O.4llm 
Nucleopore polycarbonate (PC) membranes (Costar) for 2 cycles followed by extrusion 
through a 0.21lm PC membranes for 8 cycles. 
The "ghost" liposomes produced in this way were then surface-labeled with the Fl 
antigen by adding 2ml of antigen solution (Smg mrl in PBS, pH7.2) to the empty 
liposome vesicles. This mixture was then incubated at 37°C for 18h sealed under nitrogen 
to allow the condensation reaction of antigen onto NHSP on the liposomal surface. 
The liposomes were separated from free antigen by centrifugation at 100000 x g for 
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60min, followed by two washes in PBS, pH7.2. The final liposome pellet was 
resuspended in the same buffer. 
2.7.6 Sizing of liposomes 
Two techniques were used, the first based on laser light-scattering by particles in solution 
and the second invoving direct observation of the liposomes by electron microscopy. 
2.7.6.1 Photocorrelation spectroscopy (peS) 
The size and size-distribution of liposomes was determined by pes using a BI-90 particle 
sizer (Brookhaven Instruments). PCS is the analysis of the time dependence of intensity 
fluctuations in scattered laser light due to Brownian motion of particles in solution or 
suspension. Since small particles diffuse more rapidly than large particles, the rate of 
fluctuation of scattered light intensity varies accordingly; the movement of large particles 
in a fluid medium is slower than for small particles, and the fluctuations in light intensity 
are therefore, correpondingly slower, large particles produce scattered light of a greater 
intensity than smaller particles (fig.2.4). Using the BI-90 it was possible to measure 
particles in the range of about Snm to SJlm. A laser light source (helium, neon or argon) is 
focused on the contents of a cuvette containing the sample. The cuvette is housed within a 
thermostatically controlled cell. The temperature of this compartment should preferably 
be within +/- O.loC of that required. This minimises any potential errors due to variation 
in fluid viscosity, but more importantly, will minimise random convection currents 
superimposed onto Brownian movement which could lead to substantial errors in particle 
size measurement. 
The temperature at which PCS was performed was 2SoC, the machine equilibrated to this 
temperature automatically before commencing measurments. Scattered laser light from 
the sample was detected by a photomultiplier assembly situated at an angle of 90° relative 
to the laser beam. Once the signal was recorded as a series of photomultiplier bursts over 
a period of time the mathematical process of correlation was carried out automatically. 
Data was obtained as mean particle size, these measurements were amplified and 
measurements at different time points were analysed to give a correlation function. 
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Fig. 2.4 Fluctuations in light intensity in relation to particle size. 
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Fluctuations in light intensity of a beam oflaser light passing through a suspension of 
particles occur because of movement of the particles in the beam as a result of 
Brownian motion. The movement of large particles in a fluid medium is slower than for 
small particles, and fluctuations in light intensity are therefore correspondingly slower. 
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All buffers used for suspension of liposomes were filtered through a 0.2~m minisart filter 
before PCS to eliminate problems caused by dust. The samples were diluted to give a 
suitable count rate of between 30000-150000, typically 15-25~1 sample was added to 3ml 
of filtered PBS and then measured. 
2.7.6.2 Preparation and examination of liposomes by transmission electron 
microscopy (TEM) 
Approximately 3~1 of liposome suspension (sufficient to form a shallow meniscus) was 
applied to a 400 mesh copper electron microscopy specimen grid coated with a 
formvar/carbon film. After approximately 30sec. the suspension was removed by 
touching the edge of the grid with a piece of moist filter paper. 
A similar volume of negative stain (1 % sodium silicotungstate, pH6.8) was then applied 
to the grid and after lOsec removed in a similar way. The grid was then allowed to air dry 
(approx. 5min) prior to examination in a Philips CMIOO transmission electron microscope 
operated at 80kV. Micrographs were recorded on Ilford EM technical film. Fig. 2.5 shows 
a schematic diagram of negative staining for TEM. 
2.7.7 Quantification of antigen in liposomes 
The enhanced BCA protein assay (Pierce) was used to estimate the amount of protein in 
liposome preparations. Fifty microlitres of liposome solution was mixed with an equal 
amount of PBS and to this 10~1 of 10%(v/v) Triton X-IOO was added to lyse the 
liposomes. The mixture was then assayed using the BCA enhanced protein assay protocol 
according to the manufacturers instructions. For surface-labeled liposomes, the above 
method was used but the addition of Triton X-IOO was omitted because the liposomes 
needed to be intact. 
2.8 Immunological techniques 
2.8.1 Enzyme linked immuno-absorbent assay (ELISA) 
ELISA was used for the detection of specific antibodies in murine and rabbit sera. The 
appropriate purified antigen was coated onto 96well plates (Nunc maxisorb immuno-
plate) by placing 100~1 of a lO~gml-l solution diluted in carbonate coating buffer (O.05M 
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Fig. 2.5 Negative staining of Iiposomes for electron microscopy 
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Liposomes are embedded in a thin film of negative stain, electron-transparent material shows up as bright areas and electron-dense material as dark 
areas on the electron micrograph. 
New (1994) 
sodium carbonate, pH 9.6) into each well. Following overnight incubation at 4°C, the 
plates were washed 3 times with PBS containing 0.01% (v/v) Tween 20, after which 
250J..lI of PBS containing 0.01% (v/v) Tween 20 and 4% normal horse serum (Gibco) 
were added to each well and incubated for Ih at room temperature to block any 
unoccupied sites in the wells. 
Serial dilutions of test sera were prepared in blocking buffer in the blocked ELISA plates 
to produce a final volume of 100J..ll per well, plates were then incubated at room 
temperature for 2h. After further washing 100J..lI of an appropriate dilution of anti-Ig class-
specific and species specific antibody conjugated to HRP was added to each well and 
incubated for a further Ih. Finally, the plates were washed and colour development 
carried out using N,N,N,N' - tetramethylbenzidene (TMB) substrate solution prepared 
using TMB tablets (Sigma) and prepared according to manufacturers instructions. To each 
well, 100J..lI ofTMB solution was added and incubated, with shaking, for IOmin at room 
temperature. The reaction was stopped by the addition of 25J..lI of 2M sulphuric acid to 
each well and absorbances measured at 450nm on a Titretek (MCC 340) ELISA reader. 
All plates contained wells from which the primary antibody had been omitted to allow 
non-specific background levels of absorbance due to conjugate binding to be determined. 
ELISA titres were expressed as the reciprocal of the serum dilution required to give 50% 
endpoint absorbance. 
2.8.2 Analysis of spleens and Peyer's patches (PPs) 
Spleens were removed from animals into RPMI tissue culture media (ICN Flow 
laboratories) and pooled according to treatment group. A crude suspension of spleen cells 
was prepared by sieving through a narrow gauge wire mesh. Lymphocyte suspensions 
were then prepared by density gradient separation using Hyacolin (Sigma). PPs were 
treated in the same way and in both cases lymphocytes were used in a modified ELISA 
for the detection of antibody-secreting cells (ASCs) (Czerinsky et al. 1988). 
2.8.2.1 Assay of ASCs in splcen and PPs in vitro 
A modifed ELISA was used in which sterile microtitre plates (Nunc maxi-sorp) were 
coated with Fl in PBS (lJ.1g mr)) overnight at 4°C under aseptic conditions. The plates 
were blocked with RPMI containing 10% (v/v) foetal calf serum (FCS) for Ih at 37°C. 
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Samples (200111) of lymphocytes from spleen or PP's (2 x lO7 cells) were added to the 
first well of the appropriate row on the assay plate, doubling dilutions were then prepared 
, ° for each sample. Plates were covered and incubated at 37 C, 5% CO2 for 20h. The plate 
were then gently washed (x3) in PBS containing 0.01% (v/v) Tween 20, prior to the 
addition of peroxidase-labeled anti-mouse immunoglobulin conjugate ( IgG, A or M from 
Jackson). Plates were incubated for 1h at 37°C and washed as before. Soluble TMB 
substrate (100111 per well) was added and the colour reaction allowed to develop for up to 
20min at 20°C, the reaction was stopped by the addition of 50111 per well of 2M sulphuric 
acid. Colour development was measured at 450nm (Titertek Multiscan MCC, ICN Flow). 
Lymphocytes from spleens and PP's from unimmunised mice were used as controls. 
2.8.3 Western blotting 
Proteins separated by SDS-PAGE were electrophoretically transferred onto nitrocellulose 
membrane (Schleicher and Schuell) with a pore size of 0.2Ilm. SDS-P AGE gels were 
soaked prior to blotting in renaturation buffer (appendix 1) as this enhanced the detection 
of F1 antigen by Western blot. Membranes were wetted with transfer buffer containing 
25mM TrisIHCI, 192mM glycine, pH8.3. Transfer was carried out in a Hoeffer TE-22 
Transphor unit (6cm gels) or a Bio-rad Transblot cell (16cm gels) containing transfer 
buffer at 30mA, 4°C overnight. 
After transfer, membranes were incubated for 2h in PBS containing 0.01 % (v/v) Tween 
20 and 1% (w/v) skimmed milk powder to block unoccupied sites on the membrane. 
Following this blocking step, the membrane was washed three times for lOmin periods in 
PBS containing 0.01 %(v/v) Tween 20 and then probed by incubation for 1-2h with an 
appropriate dilution of test antibody or sera in PBS containing 0.01 % (v/v) Tween 20. 
After further washing, the membrane was incubated for 1h with an appropriate dilution of 
an anti-Ig class-specific and species-specific antibody conjugated to horseradish 
peroxidase (HRP). After further washing the membrane, but this time in PBS alone, 
colour development was carried out using the substrate 4-chloro-1-napthol were dissolved 
in Iml methanol and 200111 of this solution was added dropwise, with stirring, to 20ml of 
PBS, followed by the addition of lOll1 of hydrogen peroxide. Membranes were incubated 
in this solution and colour development was stopped, when appropriate, by rinsing in 
water and allowing the membrane to air-dry. 
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2.8.3.1 Molecular weight determination 
Membranes were calibrated by loading biotinylated molecular weight markers 
(Pharmacia, low range) onto the gel to be transferred. Development was carried out as 
described in 2.6.2, with the addition of streptavidin (Amersham) diluted 1: I 000 in PBS 
for Ih as an additional incubation step. Prestained molecular weight markers (Bio-Rad, 
low range) were also loaded onto the gel to be transferred. These were used only to 
confirm the efficient transfer of proteins and the positions of relevant proteins on 
membranes and not for precise molecular weight determination. 
2.8.3.2 Detection of glycoprotein by enzyme immunoassay 
To confirm the PAS stain (2.5.6), Fl antigen was examined usin'g a dioxygenin (DIG) 
glycan detection kit (Boehringer Mannheim). In this assay, adjacent hydroxyl groups in 
sugars are oxidised to aldehyde groups by mild periodate treatment. The spacer-linked 
steroid hapten, dioxygenin (DIG), is then covalently attached to these aldehydes via a 
hydrazide group. DIG-labelled glycoconjugates are subsequently detected in enzyme 
immunoassay using a DIG-specific antibody conjugated to alkaline phosphatase. 
Purified Fl was electrophoresed on a 12% polyacrylamide gel, together with glycoprotein 
positive (transferrin) and negative (creatinase) controls and proteins transferred to a 2~m 
nitrocellulose membrane. The membrane was then stained with the Ponceau S stain 
supplied in the kit and the positions of the molecular weight markers, Fl and controls 
marked. The membrane was then probed using DIG glycan detection kit reagents to detect 
glycoproteins bound to the membrane, a positive result was recorded if a dark greylblack 
band developed. 
2.8.4 Immunisations 
2.8.4.1 Rabbit serum 
A New Zealand White rabbit was immunised with purified native Fl antigen for the 
production of anti-Fl polyc1onal serum. For the primary immunisation, the rabbit was 
given a total of 350~g of antigen, mixed with Alhydrogel as adjuvant, using both 
intramuscular and subcutaneous injections. Approximately 3weeks later the rabbit was 
boosted with the same dose of antigen mixed with Alhydrogel. The rabbit was then bled 
from a superficial vein and the serum antibody titre determined. On the basis of this assay, 
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a further booster immunisation of the same dose as above was administered. Two weeks 
later the rabbit was bled as before and, after overnight incubation at 4°C, the serum was 
separated from the whole clotted blood. The serum was centrifuged at 6000 x g for 5min 
to remove any remaining red blood cells, then aliquoted and stored at .. 20°C. 
2.8.3.2 Immunisation of mice 
For serological and m~cosal antibody response studies, groups of 5 mice were immunised 
with either antigen adsorbed to Alhydrogel, l/J.m or 8/J.m sized PLO microspheres or with 
liposome formulations. Single or multiple doses were given i.p., intranasally or by gavage 
and sera collected, separated and stored as above. 
Intraperitoneal immunisation 
Mice were immunised i.p with purified antigen mixed with Alhydrogel to give a final 
concentration of 50~g mr\ each animal received a 10~g dose Lp. Alternatively, the 
appropriate dose of PLO microspheres or liposomes was injected i.p. in PBS. Mice were 
immunised with one dose or three doses given at two week intervals. 
Oral immunisation 
Sufficient freeze-dried PLG microspheres were resuspended in O.IM sodium bicarbonate 
to give a solution of 50/J.g mr! . Aliquots (0.2ml) of this solution were given to individual 
mice by oral gavage. Control groups received 0.2ml of non-encapsulated antigen (50/J.g 
mr!) in PBS. Sufficient liposome suspension was given by oral gavage so that each 
animal received 6-1 O~g antigen as required. 
Intranasal immunisation 
For immunisations given Ln., mice were lightly anaethestised with diethyl ether, turned 
ventral side uppermost and the appropriate dose of non-encapsulated antigen, PLG 
micro spheres or liposomes was administered to the nostrils in PBS. The vaccine 
formulation was allowed to be completely inhaled by the mouse by slowly releasing it 
into the nostrils using an automatic displacement pipette (Finnpipette). 
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2.8.4 Collection and preparation of murine samples 
Sera 
Six to eight week old female Balb/c mice (Charles River Laboratories) were immunised 
with various antigen formulations for the production of polyclonal sera as described 
above. Serial bleeds were taken from the major tail vein and mice were terminally bled by 
cardiac puncture, whilst under anaesthesia, the sera were separated and stored as in 
section 2.8.3.1. 
Faecal pellets 
Freshly voided faecal pellets were collected from animals and stored at -70oC until 
required. Prior to assays, pellets were resuspended in PBS (50J-lfper pellet), vigorously 
vortexed and incubated at 20°C for 15min. Samples were again vortexed and centrifuged 
at 1000 x g for 5min. The supernatants were collected and used immediately for ELISA 
(section 2.8.1). 
Saliva 
Saliva samples (approximately 50JlI) were collected in capillary tubes following i.p. 
injection of mice with O.lml of a 1mg mrl aqueous solution of pilocarpine. Samples were 
transferred to Eppendorftubes and stored at -70°C until required for assay. 
2.8.5 Production of monoclonal antibody 
A hybridoma cell line secreting an IgA anti-Fl monoclonal antibody was obtained from 
NCTC. The hybridoma cell line was cultured by ECACC, CAMR and tissue culture 
supernatant collected. This tissue culture fluid was used in the immunological methods 
described above. 
2.9 Protection studies using a mouse sub-cutaneous challenge model 
2.9.1 Immunisation of mice 
In the protection experiments, a single 10Jlg dose or mUltiple doses of FI antigen 
encapsulated in 1 J-lm or 8Jlm PLGmicrospheres were given i.p., orally or i.n. to groups of 
8 to 10 mice on day O. The same doses of antigen in Alhydrogel was also administered to 
other groups. 
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Mice were immunised with single or multiple doses of liposome-antigen formulations, 
given either i.p., orally or Ln. All immunisations were given in doses of 6 to I O~g of 
antigen. 
Whole cell vaccine (Greer Laboratories) was given i.m. in two doses, on dayO and day16 
of the immunisation schedule. Each dose consisted ofO.1ml of vaccine (representing one 
fifth of the human dose) and contained approximately 2 x 108 formaldehyde-killed plague 
bacilli. 
2.9.2 Sub-cutaneous challenge 
Challenge inocula were prepared and infection carried out at CBD, DERA. Mice were 
challenged with 103, 105 or 107 colony forming units (cfu) of Y. pestis GB strain. This 
strain was isolated from a fatal case of plague and has an LDso of <1 cfu in Balb/c mice 
by the sub-cutaneous route (Russell et al., 1995). Survivors were monitored up to 14 days 
after challenge for development of symptoms. Animals which succumbed to challenge 
were autopsied, livers and spleens were scored for enlargement and any evidence of 
abnormality was noted. Samples of blood, sections of liver and spleen and swabs from the 
challenge site were smeared onto Congo Red agar or Yersinia selective agar (YSA, 
Oxoid). The plates were incubated at 28°C and observed for growth after 48h. At the end 
of the 14day observation period, survivors were killed and tissues removed for 
bacteriological and gross morphological analysis as above. 
91 
Chapter 3 
Purification of Fl antigen 
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3.1 Introduction 
The aim of this study was to purify and characterise the native FI antigen from Y. pestis as 
well as a recombinant FI protein, to detennine the contribution of these antigens to the 
protective immune response and to assess their suitability as component antigens in an 
acellular vaccine. In order to do this, an earlier extraction method (Baker et al., 1952) was 
modified and used to optimise the conditions for the production of large quantities of 
highly purified FI antigen. 
The FI antigen of Y. pestis was first extracted by Baker et a1. (1952) from acetone-dried 
cells grown on agar plates using a solution of toluene-saturated' sodium chloride. The 
antigen was partially purified by differential ammonium sulphate precipitations, which 
yielded two FI-containing fractions, IA and IB. Fraction IA consisted of protein and 
carbohydrate, whereas fraction IB was composed of protein only. In Baker's extraction 
method, Fl was the primary component of both fraction lA and fraction IB, however, 
other Y. pestis-specific antigens were most likely present in these early preparations and 
these were used for the early plague protection studies in animal models (Burrows and 
Bacon, 1956). Early purification studies suggested that Fl is released from the bacterial 
cell and is present in the culture supernatant (Englesberg and Levy, 1954; Baker et al., 
1952). 
The rFI antigen in this study was produced as a GST-fusion protein in E. coli. Gene fusion 
systems have been successfully used to facilitate the expression of proteins and peptides. A 
number of systems have been developed for this purpose. Most commonly, peptides have 
been fused to ~-galactosidase and expressed in E. coli using the ribosome binding site and 
translation start of the lac Z gene (Casadaban et al., 1980; Koenen et a1., 1982). Such 
hybrid proteins can be purified by affinity chromatography (Ullman, 1984). Other vectors 
direct the synthesis of peptides as fusions with staphylococcal protein A (Nakajima et al., 
1995), which can be purified by affinity chromatography on IgG Sepharose (Uhlen et al., 
1983; Lowenadler et al., 1986). Disadvantages of such methods include the possibility that 
denaturing reagents used during purification may alter the antigenic and functional 
properties of the purified product. An additional problem with the protein A system is that 
the binding of fusion proteins to IgG complicates the immunological analysis. Other 
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expression strategies involve the synthesis of polypeptides containing polyarginine at their 
C-terminus which can be purified by cation-exchange chromatography (Sassenfeld and 
Brewer, 1984) or the production of peptides or proteins from recombinant bacterial strains 
that secrete the peptide or protein into the culture medium (Andrews et al., 1996). An 
alternative approach, which may avoid several of the difficulties described, is to fuse the 
protein of interest to a specific binding protein, such as GST or maltose binding protein. 
Maltose binding protein (MBP) is the product of the mal E gene from E. coli K12 (Maina 
et at., 1988). A MBP fusion protein can be affinity purified by binding to amylose resin. 
The fusion protein is then eluted with free maltose and the protein of interest is then 
cleaved using factor Xa protease. The MBP is then separated from the free protein of 
interest by repeating the affinity chromatography with amylose resin. GST is a protein 
purified from Schistosoma japonicum and binds glutathione. The GST fused to the protein 
of interest can be purified by affinity chromatography on Glutathione B sepharose. The 
protein can then be cleaved from the GST using factor Xa, which can be done while the 
fusion protein is bound to the column or after eluting the fusion protein with free 
glutathione, followed by further affinity chromatography. The GST method has been used 
to produce a recombinant V antigen (Leary et ai., 1995) and was the method employed 
here for the production of a recombinant Fl. 
3.2 Purification of Native Fl Antigen 
3.2.1 Detection and identification of the F1 antigen 
Two Fl + strains of Y. pestis were examined, MRE 1176 and MRE 1447.The Fl- strain 
MRE 2486 was also examined as a negative control. The strains were grown at 37°C in 
chemically defined medium (Straley and Bowmer, 1986). Cells were harvested and then 
homogenised using glass beads in a bead beater (Stratech Ltd). Proteins in the culture 
supernatant were precipitated by the addition of acetone cooled to -20°C (Glosnicka and 
Gruszkiewicz, 1980). Proteins were similarly precipitated from homogenised whole cells 
and from the cell homogenate supernatant. 
A sample of whole cells from the cell pellet was washed with a solution of 1M NaC!. The 
supernatant from this salt wash was retained and the proteins precipitated using cold 
acetone as above. The acetone precipitates were examined by SDS-PAGE (fig. 3.1). A 
17 .5kDa band was seen in the F 1 + strains but not in the F 1- strain. This band was especially 
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Fig. 3.1 Detection of the Fraction 1 (Ft) antigen from 
Y. pestis by SDS PAGE 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
,--~I L-I ___ ---' I----~II-I -----I 
CHP CHS CSP HSWP 
Lane 1,8 and 15, molecular weight markers; Lane 2,5,9 and 12, MRE 2486 (Fl-); 
Lane 3, 6, 10 and 13, MRE 1176 (F1+); Lane 4, 7,11 and 14, MRE 1447 (F1+) 
CHP: 
CHS: 
CSP: 
HSWP: 
Pellet from homogenised cells 
Supernatant from homogenised cells 
Proteins in precipitate of culture supernatant 
Proteins in precipitate of 1 M NaCI wash 
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evident in MRE1447 and was tentatively identified as the Fl antigen. The Fl antigen band 
was evident in the salt wash, culture supernatant and the supernatant from homogenised 
cells; however, it was not clear in the pellet fraction ofhomogenised cells. 
Protein precipitated from the cytoplasm, cell homogenate, culture supernatant and 1M 
NaCI wash were tested by ELISA using monoclonal antibody, MAb F13G8, an IgA 
monoclonal antibody from the NCTC which is specific for the Fl antigen. The results 
showed that F1 antigen could only be detected in the Fl + strains in the culture supernatant, 
the 1M NaCl wash and the cell homogenate supernatant (fig. 3.2). These findings agreed 
with the SDS-PAGE results and confirmed that MRE 1447 produced more Fl in these 
fractions than MRE 1176. Therefore, future experimental work concentrated on purifying 
and characterising the F 1 antigen from MRE 1447. 
ELISA of culture supernatants prepared from F1 + and F1- strains grown at 26°C and 37°C 
showed that samples from the F1- strain grown at 26°C or 37°C and samples from Fl + 
strains grown at 26°C were not recognised by the anti-Fl monoclonal antibody (Mab) 
F13GS (NCTC). The samples prepared from the F1+ strain grown at 37°C were recognised 
by the Mab (fig. 3.3). These assays further identified the protein as the F1 antigen because 
the F1 antigen is produced at 37°C but not at 26°C (Bennet and Tornabene, 1974). 
The identification of the F 1 antigen was confirmed by Western blot. Proteins separated by 
SDS-PAGE were transferred to nitro-cellulose membranes and probed using the anti-F1 
MAb F13GS. Fig. 3.4 shows that the Mab reacted only with the 17.5kDa protein in the F1+ 
samples. The Western blot procedure included a renaturation step prior to blotting (section 
2.S.2) which enhanced the detection of the 17.5kDa protein (Dun..Tl, 1986). 
3.2.2 Growth of Y. pestis to determine the most suitable starting material for 
purification. 
The F1+ strain of Y. pestis, MRE1447, was examined in addition to the Fl" strain, 
MRE2486, under different culture conditions and extraction methods to determine the most 
appropriate initial source of the Fl antigen (refer to fig 3.1). As a result of these 
investigations, Y.pestis MRE1447 grown in YPMH medium at 37°C for 48h, was found to 
produce substantial amounts of the Fl antigen in the culture supernatant. Washing the 
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Fig. 3.3 ELISA to demonstrate the effect of temperature on Fl 
antigen in culture supernatant 
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The graph shows F 1 precipitated from culture supernatant after growing the F 1 + strain, 
MRE 1447, at 26°C and 37°C and similar precipitates from the Fl" strain, MRE 2486. 
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Fig. 3.4 Identification of the Fraction 1 antigen of Y. pestis 
by Western Blotting using MAb F13G8 
Total protein stained with 
Amido Black 
123 
Immunobiot with F I-specific 
MAbF13G8 
1 2 3 4 
Lane: 
1. 1M NaCI wash of Y pestis MRE 1447 (Fl+) 
2. Culture supernatant from Y pestis MRE 1447 
3. Culture supernatant from Y pestis MRE 2486 (F 1-) 
4. Biotinylated molecular weight markers 
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33 
20 
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whole cells with 1M NaCI removed the Fl antigen from the cell surface, but the resulting 
sample was more heavily contaminated with other proteins than YPMH culture 
supernatant. Culture supernatants were therefore selected as the most appropriate starting 
material. 
The effect of pH on the amount of Fl produced in culture supernatant was also examined. 
ELISA performed on precipitates of supernatants from cultures grown at different pH, 
showed that there was correlation between pH and the amount of Fl antigen present in 
culture supernatant (fig. 3.5, table3.1). A pH of 7.4 was found to produce consistently 
higher yields ofFI antigen in culture supernatant than lower culture pH of 5.5 and 6.4. 
Therefore, Y. pestis MRE1447 (Fl+) was grown in YPMH liquid media and the pH 
maintained at pH7.4. The culture supernatant was retained as starting material for the 
purification ofthe Fl antigen. 
3.2.3 Purification of the Fl antigen by ammonium sulphate precipitation 
Different ammonium SUlphate concentrations were examined to determine the optimum 
concentration for the extraction and purification of the Fl antigen from culture supernatant. 
Aliquots of supernatants and pellets from the precipitates were analysed by SDS-P AGE 
(fig.3.6) which showed that 40% ammonium sulphate precipitated most of the Fl antigen 
at greater than 90% purity as determined by image analysis (section 2.5.6), and little of the 
protein was precipitated by 30% ammonium sulphate. Forty percent ammonium sulphate 
was therefore used for purification of the Fl antigen from culture supernatants. 
3.2.4 Gel filtration chromatography to further purify Fl antigen 
Sephacryl S200 chromatography was carried out to determine whether the Fl antigen could 
be further purified according to the molecular weight of the protein. 
A Sephacryl S200 HR column (Pharmacia), with a protein fractionation range of 5-250kDa 
and a bed height ofSOcm was set up and washed with O.IM Tris HCI, O.IM NaCI, pH S.O. 
The void volume was calculated by the elution of a blue dextran solution and the column 
was calibrated using standard proteins, bovine serum albumin, carbonic anhydrase and 
cytochrome c. Twenty milligrams of F 1 precipitated from culture supernatant was 
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Fig. 3.5 
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Table 3.1 
ELISA showing the effect of pH on Fl antigen in 
culture supernatant. 
o - pH7.4 
• - pH6.4 
• - F1 standard [J 
-
H5.5 
2.0 2.5 3.0 3.5 4.0 4.5 5.0 
Log Dilution 
pH of culture 
5.5 
6.4 
7.4 
FI standard 
Concentration of purified Fl 
(J.lg mrl) 
6.5 
22.5 
42.5 
20.0 
The graph shows F 1 precipitated from culture supernatant after growing the F 1 + strain, 
MRE 1447 at 37°C at culture pH of 5.5,6.0 and 7.4. An Fl standard was also included so 
that the amount of F 1 produced at each pH could be quantified, table 3.1. 
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Fig. 3.6 SDS PAGE showing purification of the Fl antigen using 
different concentrations of ammonium sulphate 
1 2 3 4 5 6 7 8 9 10 
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Lane: 
1. Molecular weight markers 
2. Y. pestis MRE 1447 cu lture supernatant (starting material) 
3. Proteins precipitated by 40% ammonium sulphate 
4. Proteins precipitated by 60% ammonium sulphate after 40% precipitation 
5. As lane 2 
6. Proteins precipitated by 50% ammonium sulphate after 30% precipitation 
7. Proteins precipitated by 60% ammonium sulphate after 50% precipitation 
8. Proteins precipitated by 30% ammonium sulphate 
9. As lane 2 
10.As lane 1 
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applied to the surface of the column, eluted at a flow rate of 0.3mllmin and fractions (3ml) 
were collected and tested for the presence ofFl by SDS PAGE; only the fractions eluted at 
the void volume (1 to 6) contained Fl. The Fl peak was found to elute very close to the 
void volume giving an estimated molecular weight of 60-300kDa (fig. 3.7). This result 
indicates that the small 17.5kDa Fl subunit forms high molecular weight aggregates. This 
was confirmed by running supernatant precipitates from Fl + and Fr strains on a non-
denaturing polyacrylamide gel and observation of a protein present in the stacking gel in 
the Fl + samples only (figure not shown). 
3.2.5 Ion exchange chromatography (lEe) to further purify Fl antigen 
In preparation for lEe, the pI of the F 1 antigen was determined by isoelectrofocusing (IEF) 
to be 4.5, which agrees approximately with the published pI of 4.8 (Bennet and Tornabene, 
1974) (fig.3.8). 
An MA7Q anionic exchange column (Biorad Laboratories) was used in an attempt to 
further purify the ammonium sulphate precipitated Fl antigen. Protein in 10mM Tris He} 
pH 8.0 was bound to the column and eluted using a 0 to 1M NaCI gradient. Fl in the eluted 
fractions was detected by immunoblotting with MAb F13G8. The Fl fractions were 
examined by SDS-P AGE, which showed that the majority of Fl was present in fraction 21 
and in agreement with the HPLC trace (fig. 3.9). There was no observed increase in purity 
of the fraction compared to the starting material; however, this proved to be an effective 
method for concentrating the F 1 antigen. 
3.2.6 Larger-scale production and purification of the Fl antigen 
Large-scale purification of the Fl antigen was achieved by growing Y. pestis MRE 1447 in 
a 25litre fermenter in the chemically defined medium YPMH (Straley and Bowmer, 1986) 
with the pH maintained at 7.4. The Fl antigen was precipitated from the culture 
supernatant by the addition of 40% ammonium sulphate. 
Repeated resuspension and centrifugation of the precipitated pellet in a low salt buffer 
produced a solution of the antigen. This process yielded up to 45mg of soluble purified Fl 
antigen per litre of culture supernatant and with consistent purity of>90%. Fig. 3.10 shows 
a purification scheme for Y. pestis F 1 antigen. 
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Fig.3.7 Sephacryl S200 gel filtration chromatography of 
Fl antigen. 
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kDa 
94 
67 
43 
30 
20 
14 
1 2 3 4 5 
Fraction SM 2 4 6 
Lane: 
1. Molecular weight markers 
2. Starting material (SM) 
3 - 8. Fractions 2 - 12 
6 
8 
105 
200 2S0 
7 8 9 10 
10 12 
~ Fl 
Fig. 3.8 Isoelectrofocusing to determine the isoelectric 
point (pI) of the Fl antigen 
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Fig. 3.8 continued. 
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Fig. 3.9 Ion Exchange Chromatography of Fl antigen of Y. pestis 
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3.9b. SDS PAGE of fractions from major peak of elution profile 
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A, shows the elution profile of the Fl antigen and B, SOS PAGE of the 
eluted fractions 
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Fig. 3.10 Schematic representation of the purification of the 
y. pestis Fl antigen 
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3.2.7 Endotoxin levels in purified native Fl 
Endotoxin levels in the purified F 1 antigen were tested using the Limulus Amebocyte 
Lysate (LAL) assay, according to manufacturers instructions. Samples typically contained 
SOOng endotoxin per mg of F 1; therefore, mice upon immunisation would receive 2ng 
endotoxin per IOf.lg dose Fl. No attempt was made to remove the endotoxin for the 
purposes of this study. 
3.3 Recombinant Fl antigen (rFl) 
3.3.1 Cloning of the cajl sequence into pGEX-5x-2 expression vector 
The approach used for the production of rF 1 antigen was as a fusion protein, using a 
method similar to that described by Leary et aI, 1995. The vector used was the pGEX-5x-2 
expression vector, which codes for the GST carrier protein (fig. 3.11). 
DNA from Y. pestis GB strain was extracted using Marmur's modified method (1961) 
which extracts mainly chromosomal DNA but enough plasmid DNA is also extracted to 
enable cloning of the cafl gene. The cafl gene was amplified by means of the polymerase 
chain reaction (PCR) using FlIS'D and FI/3'C primers. The PCR reaction was analysed by 
electrophoresis on a 1 % agarose gel and a PCR product of the predicted size (4S0bp) was 
observed (fig 3.12), this was used to proceed with the cloning strategy. 
The next stage of the cloning strategy was to prepare restriction digests of the amplified 
cajl gene and the pGEX-5x-2 vector using the restriction enzymes EcoRl and BamHl, in 
order to obtain a double digest which produces cohesive ends on the cafl PCR product and 
the pGEX vector. The resulting restriction digests were purified and the DNA extracted by 
ethanol precipitation. The concentration of DNA in the pGEX and cafl restriction digests 
was estimated and a ligation reaction was set up using a 1:3 vector:insert ratio. The ligation 
reaction was examined on a 0.7% agarose gel which showed that the molecular weight of 
the DNA had increased indicating that the ligation reaction was successful (fig. 3.13). 
Purified, ligated DNA was electroporated into E. coli JM 1 09 and the transfonned cells 
were grown up on L-ampicillin (L-amp) plates overnight at 37°C. Thirty recombinant 
colonies were picked across onto L-amp plates marked with a grid and were again 
incubated overnight at 37°C. The remaining cells were used to inoculate 50111 of sterile 
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Fig. 3.11 Diagrammatic representation of the pGEX-Sx-2 cloning vector. 
3.lla Structural elements on pGEX-5x-2 
Glutathione S-transferase gene region: lac promoter: -10: 205 - 211; -35: 183 - 188; 
lac operator: 217 - 237; Ribosome binding site for GST: 244; Start codon (ATG) for 
GST: 258; Coding region for factor Xa cleavage: 921 - 932; Primer region for double-
stranded sequencing: 874 - 890. 
Main cloning site (MCS): 934 - 970. 
J3-1actamase gene region: Promoter: -10: 1334 - 1339; -35: 1311 - 1316; Start codon 
(ATG): 1381; Stop codon (TAA): 2239. 
lac f1 gene region: Start codon (GTG): 3322; Stop codon (TGA): 4402. 
Plasmid replication region: Site of replication initiation: 2999; Region n~ssary for 
replication: 2306 - 3002. 
3.11b Restriction map of pGEX-5x-2 
BspM 1(63) 
pGEX-5X·2 
(973 bp 
III 
Fig.3.12 Agarose gel electrophoresis of PCR reaction of 
cafl DNA using Fl/5'D and Fl/3'C primers. 
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Fig. 3.13 Agarose gel electrophoresis of ligated 
cajl DNA and pGEX vector. 
1 2 3 4 
Lane: 
1. DNA base pair markers 
2. pGEX vector restriction digest 
3. As lane 2. 
4. Ligation reaction product 
The DNA had increased in size after ligation when compared with the restriction 
digests. Therefore, the ligation reaction was successful and the cajl had been 
inserted into the pGEX expression vector. 
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Fig. 3.14 Agarose gel electrophoresis of recombinant E. coli JMI09 
colony lysate polymerase chain reaction (peR) products. 
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On the double gel six clones showed to be positive, indicated by a cafl peR 
product of 450bp. The positve control used DNA of approximately 450bp from 
Y pestis GB strain. 
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distilled water per colony and these suspensions were used to prepare colony lysates 
followed by peR reactions to screen for positive clones. peR reactions of colony lysates 
were prepared using the same FI 5' and 3' primers as before, a cajl peR product of 450bp 
would indicate a positive clone; examination of the colony lysate peR reactions on 1 % 
agarose gel showed six positive clones (fig. 3.14). Two of these clones were randomly 
selected and referred to as JMI09 + pKR4 and JMI09 + pKRIO. L-amp broth cultures 
(lOOml) were set up to test these positive clones for expression of the FI-GST fusion 
protein and a culture of JMI09 + pGEX-5x-2 (i.e. no insert) was included as a negative 
control. After cultures reached an appropriate optical density at 600nm, expression was 
induced by the addition of IPTG and culture lysates were prepared and examined by SDS-
PAGE for expression of the FI-GST fusion protein (figure 3.15). The gel shows that 
JMI09 + pKR4 expressed the FI-GST fusion protein but JMI09 '+ pKRI0 did not; the 
uninduced culture and the negative control did not express the fusion protein. The 
molecular weight of the fusion protein, 43kDa, agreed with the predicted molecular weight 
of a fusion protein between Fl (17.5kDa) and GST (26kDa) (fig. 3.15). 
Immunoblotting of the culture lysates with an anti-Fl monoclonal antibody, Mab F13G8, 
and mouse polyclonal anti-Fl antibody, showed that JMI09 + pKR4 expressed a fusion 
protein that reacted with both antibodies. Fig. 3.16 shows a Western blot probed with 
mouse polyclonal anti-Fl antibody, an identical blot was obtained using Mab F13G8. On 
both blots there were smaller proteins beneath the fusion protein that had reacted with the 
Mab, these may be breakdown products of the fusion protein. 
The pKR4 plasmid DNA was purified with the Qiagen Plasmid Kit, using the maxi-prep 
protocol. The DNA was sequenced on a T AQ sequencer and the resulting sequence 
confirmed the cloning site (results not shown). 
The strain expressing the fusion protein was used to evaluate the amount of fusion protein 
produced during the time course of induction with IPTG. The strain was grown as 
described in section 2.1.2 and 500)l1 samples were taken and prepared for SDS-P AGE, 
immediately prior to induction and at 30min or 1 h intervals after induction. The cultures 
were induced during the exponential phase of growth and the production of fusion protein 
did not appear to affect subsequent growth. Increasing amounts of fusion protein were 
observed up to 5h after induction (figure 3.17) indicating that the lac I repressor protein 
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Fig. 3.15 Expression of FI-GST fusion protein in culture lysates 
in selected strains of recombinant E. coli JMI09. 
Lane: 
1. Molecular weight markers 
2. Purified GST 
3. IPTG induced strain JMI09 + pKR4 
4. Strain JM109 + pKR4, no induction 
5. IPTG induced strain JM109 + pKR10 
6. Strain JM109 + pKR10, no induction 
7. IPTG induced pGEX 
8. pGEX, no induction 
9. Purified F 1 antigen 
10. As lane 1. 
Only the culture lysate from JMI09 + pKR4 induced with IPTG expressed the 
FI-GST fusion protein. The JMI09 + pGEX induced and non-induced cultures 
were included as controls, the induced culture expressed only GST. 
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FI-GST 
GST 
FI 
Fig. 3.16 Western blot of culture Iysates from recombinant 
E. coli JMI09 strains. 
1 2 3 4 
kDa 
, 
94 
---
66 ~ 
44 
33 
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Lane: 
1. Biotinylated molecular weight markers 
2. Purified Flantigen 
3. IPTG induced strain JM109 + pKR4 
4. Strain JM109 + pKR4. no induction 
5. IPTG induced strain JMI09 + pKRIO 
6. Strain JM109 + pKRlO. no induction 
7. IPTG induced strain JM109 + pGEX 
8. Strain JM109 + pGEX, no induction 
9. Prestained molecular weight markers 
The Western blot was probed with murine anti-F l polyclonal antibody 
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FI-GST 
FI 
Fig.3.17 Time course of appearance of FI-GST fusion protein 
in culture lysate of E. coli JMI09 + pKR4 after induction 
with IPTG 
kDa 
94 
67 
43 
30 
20 
14 
1 2 3 4 5 6 7 8 
~l-GST 
Time: 1h 2h 2.5h 3h 3.5h 4h 5h 
% fusion 21% 24% 36% 34% 35% 37% 43% 
protein: 
The induced culture was sampled at timed intervals and culture lysates were 
examined by SDS PAGE. The amount of fusion protein increased with time 
and after 5h incubation with IPTG the cultures lysate contained 43% F1-GST 
fusion protein when examined by image analysis. 
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prevented expression in the absence of IPTG, as confirmed by the results shown in figures 
3.15 and 3.16. After 5h induction time, the FI-GST fusion protein constituted 
approximately 43% of the total cellular protein as determined by image analysis (fig. 3.17). 
3.3.2 Purification of rFl 
3.3.2.1 Preparation of cell extracts of strain JMI09 + pKR4 
Strain JMI09 + pKR4 was grown and induced as described in section 2.1.2 and 2.2.2. Cells 
were harvested by centrifugation (section 2.2.2); the wet weight of the cells was 
determined and found to be approximately 4g per litre of culture. After the addition of 
lysozyme and Triton X-I00, a freeze-thaw sonication method was used to lyse cells 
(section 2.3.2) with lOx 30sec bursts of sonication, according to a predetermined protocol. 
The cell sonicate was centrifuged and both the supernatant and pellet were retained. It was 
anticipated that the fusion protein would be expressed in the periplasm and therefore 
present in the sonicate supernatant (Leary et al., 1995). 
3.3.2.2 Affinity chromatography on glutatione Sepbarose 
rFI was purified using the affinity of the GST part of the fusion protein to bind to the 
glutathione on the Sepharose in the affinity column. Supernatant from the centrifuged 
sonicate was passed three times down the glutathione Sepharose affinity column to ensure 
maximum binding of the fusion protein. The rFI was cleaved from the GST bound to the 
matrix using overnight incubation at 4°C with 60 units of factor Xa. The rFI was then 
eluted in 4ml PBS and the concentration of protein was estimated and found to be 
approximately O.35mg mr) from 20ml sonicate. 
The recombinant protein was examined by SDS-PAGE and compared with the purified 
native Fl (fig. 3.18). The rFI was not as pure as native Fl and was contaminated with 
some high molecular weight proteins. However, no GST had leached from the column 
indicating that cleavage was successful. 
3.3.2.3 Yield of rFI obtained from strain JMI09 + pKR4 
In a typical growth experiment, approximately 4g (wet weight) of cells were obtained from 
1 L of Terrific Broth culture of strain JM I 09 + pKR4 reSUlting in 20ml of cell sonicate. 
From this sonicate, approximately 1.4mg of cleaved protein was obtained from lL of the 
original JMI09 + pKR4 culture. This, however, was a low yield when compared to native 
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Fig. 3.18 SDS PAGE of recombinant Fl after affinity 
chromatography and cleavage from GST 
with factor Xa 
kDa 
94 
67 
43 
30 
20 
14 
1 2 3 
.. 
• 
Lane: 
I: Molecular weight markers 
2: Purified FI from Y. pestis 
4 5 
... 
n: 
3. Purified recombinant F 1 after cleavage with factor Xa 
4. As lane 3. 
5. Purified GST 
6. Prestained molecular weight markers 
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F1, and this low yield ofrFl was consistent from batch-to-batch. 
A BCA protein assay was carried out on the different fractions, including the sonicate 
before and after centrifugation, and the post-column eluate to determine the potential loss 
of fusion protein. These sonicate and eluate fractions were analysed by SDS-PAGE (fig. 
3.19) which indicated that most of the fusion protein remained in the sonicate pellet. Table 
3.3 shows that only a small amount of the protein in the sonicate supernatant bound to the 
affinity column (32.7%). Of this bound protein, the cleaved rFl product accounted for only 
6.19%. These two factors may have accounted for the low yields of rFl. 
3.3.2.4 Solubilisation of FI-GST fusion protein using Sarkosyl and size exclusion 
chromatography 
An attempt was made to solubilise the F1-GST fusion protein from strain JMI09 + pKR4 
prior to affinity chromatography in order to increase the yield of rFl. Briefly, lysozyme, 
followed by 2% w/v Sarkosyl was added to the bacterial cell paste. The solution was 
sonicated at full power for 7 x 30sec, with 15sec intervals to allow cooling, and the 
sonicate centrifuged at 27000 x g for 30min. The supernatant was retained and passed 
through a G25 Sephadex column to remove the Sarkosyl and exchange the buffer to PBS 
ready for affinity chromatography on a glutathione 4B Sepharose column (section 2.3.2). 
The elution profile from the G25 Sephadex column (fig 3.20) shows that most of the 
protein was present in fractions 15 to 23. Fractions were collected from the peak and 
examined by SDS-PAGE (fig 3.20). 
The sonicate supernatant starting material (100ml) contained approximately 200mg of 
protein, estimated by BCA assay. After 10 runs (10ml of sample per run) on the Sephadex 
G25 column, approximately 157mg protein was obtained. Therefore, 78.5% of the total 
protein was recovered. 
This material was then applied to an affinity chromatography column of Glutathione 
Sepharose 4B and cleavage was carried out using 60 units of factor Xa in 4ml PBS. 
Fractions from the affinity column were examined by SDS-PAGE (fig. 3.21) and this 
showed that the unbound fraction contained a large amount of fusion protein (43kDa). 
These are similar to the results observed before solubilisation of the F1-GST fusion protein 
(section 3.3.2.3). Although factor Xa cleavage was successful, fusion protein was eluted 
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Fig. 3.19 SDS PAGE of sonicate fractions from 
E. coli JMI09 + pKR4 
Lane: 
1. Molecular weight markers 
2. Culture lysate 
3. Total sonicate before centrifugation 
4. Sonicate pellet 
5. Sonicate supernatant 
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Table 3.3 Amount ofFl-GST bound to glutathione 
affinity column 
Protein estimation in fractions: mg ml-l 
Total sonicate (before centrifugation) lS.76mglml 
Sonicate supernatant (starting material before 
affmity column) 3.46mglml 
Column eluent (post affmity column) 2.33mglml 
rFl product after cleavage from GST O.3Smglml 
% protein bound to affinity column = 32.7% 
rFI product as a percentage of bound protein = 6.19% 
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in total 
volume 
3lS.2mg 
69.2mg 
46.6mg 
l.4mg 
Fig. 3.20 G25 Sepharose size exclusion chromatography 
of rFl antigen after solubilisation with Sarkosyl 
3.20a Typical elution profile 
0.6 
§ 0.5 
0 
00 0.4 <'I 
(1) 
0 § 0.3 of 
0 
fIl 
.0 0.2 < 
0.1 
0.0 
0 
~ P1 
50 100 
Rt(min) 
150 200 
Chromatography was carried out as described in section2.3.3. The column was 
eluted with column buffer and 2ml fractions collected. 
3.20b SDS PAGE analysis of fractions from major peak of the elution profile 
kDa 
94 
67 
43 
30 
20 
14 
1 
Fraction 
2 3 4 5 
Number: SM 13 15 17 
6 7 8 9 10 
19 21 23 24 25 
, ~ F1-GST 
fusion 
protein 
Virtually all of the protein was eluted in peak I(Pl). Fractions 15 - 23 corresponding 
to PI were pooled for further purification. 
SM : starting material; Rt : retention time 
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Fig.3.21 SDS PAGE of fractions after solubilisation of FI-GST 
fusion protein followed by affinity chromatography 
and cleavage with factor Xa. 
kDa 
94 
67 
43 
30 
20 
14 
1 2 3 4 5 6 7 8 9 10 
Lane: 1. Molecular weight markers 
2. Sonicate pellet 
3. Sonicate supernatant before gel filtration on G25 sepharose 
4. Sonicate supernatant after gel filtration on G25 sepharose 
5. Unbound protein from affinity chromatography 
6. Cleaved rF1 first fraction from affinity column 
7. Cleaved rF1 second fraction from affmity column 
8. Cleaved rF1 third fraction from affinity column 
9. Eluted GST fraction 
10. Molecular weight markers 
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rFl 
17.5kDa 
and only a small amount of cleaved rFl was obtained. Therefore, solubilisation of the 
fusion protein in Sarkosyl prior to affinity chromatography did not increase yields of 
cleaved rFI. There may have been problems with the binding of the GST moiety of the 
fusion protein to the glutathione affinity column and this may have been why no GST was 
observed in the eluted GST fraction after affinity chromatography. 
3.4 Discussion 
The Baker extraction method for Fl from Y. pestis cells grown on solid media (Baker et 
ai., 1952) has been used extensively over the years. In this study large yields of Fl, 
typically, up to 45mg per litre were obtained from culture precipitates of Y. pestis grown in 
a chemically defined liquid medium by precipitation with 40% ammonium sulphate 
followed by resuspension and centrifugation in a low salt buffer (fig. 3.10). The protein 
was found to be >90% pure using this method and because a chemically defined medium 
was used there were no contaminating proteins from the culture medium. Although large 
quantities of cell-bound Fl were released by washing whole cells withlM NaCI (figs. 3.1 
and 3.2), these extracts were more heavily contaminated with other cell-surface proteins 
than was culture supernatant-derived Fl. Therefore, growth of Y. pestis in liquid culture is 
a practical approach to scaling-up the production of Fl antigen. In addition, supernatant-
derived Fl was not exposed to organic solvents or high concentrations of sodium chloride 
necessary when extracting cell-bound Fl, which may alter the immunogenicity of the 
protein. 
The findings that Fl was released from the cell surface and could be purified from culture 
supernatant agree with previous reports (Andrews et ai., 1996; Englesberg and Levy, 
1954). This phenomenon was exploited for the development of this extraction and 
purification scheme, cell-free Fl was isolated and purified more easily than cell-bound 
antigen and simplified the procedure when scaled-up. 
Endotoxin levels in the purified antigen were tested using the LAL assay. The levels 
present were thought to be acceptable and no attempt was made to remove it. However, it 
is unclear as to how endotoxin might interact with protective antigens and how their 
immunogenicity and protective potency might be affected by the presence of this 
immunomodulatory outer membrane component. This question could be addressed in any 
future studies. For example, LPS could be removed using Polymyxin B as described by 
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Andrews et aZ., 1996. 
The rFl, however, was more difficult to purify than native Fl. The cajl sequence was 
cloned successfully into the pGEX vector and the GST-FI fusion protein expressed in 
adequate quantities. However, the fusion protein was found to be insoluble and the 
majority remained in the sonicate peIIet. Attempts were made to solubilise the fusion 
protein in the sonicate using sarkosyl and purification of the fusion protein by gel-filtration 
chromatography (fig. 3.20). This was successful but problems were then encountered with 
the fusion protein not binding efficiently with the glutathione S sepharose column. This 
may have been caused by conformational changes in the GST part of the fusion protein 
because of the cajl insert and, therefore, only low yields of recombinant Fl were obtained. 
However, sufficient rFI was obtained to carry out some characterisation studies and to 
examine the protective efficacy of the antigen to a limited extent. 
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Chapter 4 
Characterisation of Fl antigen 
4.1 Introduction 
The extracellular material surrounding Y. pestis has been described by terms such as, 
"capsule", "envelope" and "slime layer". Englesberg and Levy (1954) found that FI 
antigen, the main component of this layer, went into solution prior to extraction, 
suggesting that the antigenic material was derived from the envelope layer. This material 
was shed into the culture medium and could be extracted from cell-free culture supernatant 
(Englesberg and Levy, 1954; Baker et al., 1952), suggesting that it is a soluble envelope or 
slime layer, rather than a distinct capsule. 
Crocker et al. (1956) compared the extracellular substance of virulent and avirulent 
strains, using electron and light microscopy and found that the extracellular substance was 
more abundant in virulent strains and was easily removed by washing in distilled water. 
The ability to synthesise this capsule is characteristic of all fully virulent strains (Burrows 
and Bacon, 1956); there has been only one recorded human case of plague caused by an 
F 1- strain and very few naturally occurring virulent strains without the capsule have been 
isolated from non-human sources (Friedlander et al., 1995; Winter et al. 1960). Therefore, 
FI is an important virulence determinant and more detailed characterisation of the 
chemical and physical properties of this antigen might explain why this is so. 
The F 1 antigen has been reported to be glycosylated, bearing galactose and fucose residues 
as determined by gas-liquid chromatographic analyses performed on acid hydrolysates of 
the antigen. Protein and peptide fragments were removed from the hydrolysates with 
Dowex I-X8 ion exchange resin. Sugar derivatives were analysed by gas liquid 
chromatography (GLC) and the main carbohydrate component was identified as galactose 
(Bennet, and Tornabene 1974; Glosnicka and Gruszkiwicz, 1980). It was also found that 
F I formed large aggregates and eluted close to the void volume of a gel filtration column 
and this was also observed in the present study (section 3.2.4). Aggregated FI has low 
mobility when applied to a native polyacrylamide gel, but may be disaggregated by boiling 
in SDS/mercaptoethanol for 5 to 10min, as demonstrated by increased mobility in 
polyacrylamide gels under denaturing conditions (section 3.2.3). Disaggregated Fl will 
reaggregate if the denaturing reagent is removed (Bennet, and Tornabene 1974). FI 
aggregates of large molecular weight dissociate into sub-units of between 15-17kDa under 
denaturing conditions (Glosnicka and Gruskiwicz, 1980). 
The size of the Fl monomer, predicted by the coding sequence of the structural gene, 
agreed with previous studies which reported it to be 15.0-17.5kDa polypeptide with an 
isoelectric point of 4.5 in denaturing and IEF gels (section 3.2.5, 3.2.1). The amino acid 
sequence predicts a hydrophobic protein p-sheet secondary structure (Galyov et a/., 1990), 
and this hydrophobicity may account for the aggregation observed under physiological 
conditions. 
4.2 N-terminal sequencing of the Fl antigen 
The primary structure of Fl antigen has been deduced from the nucleotide sequence 
(Galyov et al., 1990). The amino acid sequences of the native and recombinant Fl were 
determined in order to make a comparison with the deduced sequence. In these 
experiments, the Pehr Edman reaction process was used (Tschesche and Dietl, 1975), 
involving the sequential degradation of proteins and peptides to determine the sequence of 
the constituent amino acids. The process allows repeated cycles of degradation of the N-
tenninal amino acid and subsequent identification. 
Samples of purified native FI or recombinant FI were applied to a polyacrylamide gel 
using 2~g, 6~g, 12~g, 14~g and 20~g of protein. The proteins were then transferred to 
nitro-cellulose membrane (0.2~m pore size) by Western blot. The proteins were stained 
using Arnido Black total protein stain and the FI band of an appropriate intensity was 
selected for sequencing. The first ten amino acids were successfully sequenced (fig. 4.1) 
and agreed with the published sequence (Galyov et a/., 1990). The only exception is that in 
the rF 1, the first three amino acids are from the pGEX plasmid, indicating that the 
cleavage site is a few amino acids before the cafl sequence begins. In addition, less rF I 
was loaded onto gels and hence fewer amino acids were sequenced. 
4.3 Investigation of the glycosylation of the Fl antigen 
Attempts were made during the course of this study to confirm the report that the native 
FI is glycosylated (Bennet and Tornabene, 1974; Glosnicka and Gruszkiwicz, 1980). 
IH) 
Fig. 4.1 N-terminal amino-acid sequence of Fl antigen determined 
by Edman degradation 
4.1a Native Fl 
Residue 1 5 10 15 
A - D - L - T -X -X -T -T -A - - - - - - -
4.1h Recombinant Fl 
Residue 1 5 10 15 
G-I-P-A-D-L-T-A- - - - - - --
Key: G = glycine 
I = isoleucine 
P = proline 
A = alanine 
D = aspartic acid 
L = leucine 
T = threonine 
X = undetermined 
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4.3.1 PAS stain for glycoproteins 
Polyacrylamide gels were stained using a PAS stain procedure (section 2.5.6) developed 
from published methods (Matthieu and Quarles, 1973: Segrest and Jackson, 1971). 
Purified Fl antigen was run on polyacrylamide gels together with a glycosylated (a.-
glycoprotein) and a non-glycosylated protein (lysozyme) as positive and negative controls 
respectively. The glycosylated a.-glycoprotein stained as a pink band, whereas the Fl and 
the non-glycosylated lysozyme did not stain, indicating that Fl is not sufficiently 
glycosylated to be detected by this method (fig 4.2). This procedure was repeated several 
times using increasing concentrations of protein, but staining of the F 1 antigen was not 
observed. 
4.3.2 Detection of glycosylation by enzyme immunoassay 
To confirm the PAS stain results, the FI antigen was tested using a DIG glycan detection 
kit (Boehringer Manheim). In this assay, adjacent hydroxyl groups in sugars are oxidised 
to aldehyde groups by mild periodate treatment. The spacer-linked steroid hapten, DIG, is 
then covalently attached to these aldehydes via a hydrazide group. DIG-labelled 
glycoconjugates are subsequently detectoo in enzyme immunoassay using a DIG-specific 
antibody conjugated to alkaline phosphatase. Purified F 1 was run on polyacrylamide gels 
together with glycoprotein positive and negative controls. Proteins were then transferred 
onto a 211m nitro-cellulose membrane, and stained with Ponceau S stain supplied in the kit. 
The position of the molecular weight markers, Fl and controls were marked (this is 
demonstrated in fig. 4.4b). The membrane was then probed using DIG glycan detection kit 
reagents to detect glycoproteins bound to the membrane, a positive result being indicated 
by development of a dark band. In figure 4.3, only the positive control glycoprotein 
produced a dark band, again suggesting that Fl is not glycosylated to a level detectable by 
this method. The positive and negative controls were transferrin and creatinase 
respectively and were supplied in the glycan detection kit. 
Since the previous experiments suggested that the purified material was not glycosylated, a 
further study was carried out using F 1 samples extracted from Y. pestis culture 
supernatants derived from cells grown in YPMH and a complex medium (blood agar base 
broth). Cultures (1 OOml) in both media were grown at 37()C for 48h. F I antigen was 
Fig. 4.2 Periodic Acid Schiffs (PAS) Stain for glycoproteins 
1 2 3 4 5 
;.... a-glycoprotein 
positive control 
) 
Lane: 1. Molecular weight markers 
2. Lysozyme (negative control) 
3. F 1 antigen 
4. F1 antigen 
5. a-glycoprotein (positive control) 
Only the positive control glycoprotein has stained with PAS stain. 
Glycoproteins show up as an intense pink band when stained using this method. 
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Fig. 4.3 Detection of glycoproteins using dioxygenin (DIG) 
glycan detection system 
1 2 3 4 5 6 
.... --
'-
Lane: 1. Transferrin (positive control glycoprotein) 
2. no sample 
3 - 6. F1 antigen 
7. Creatinase (negative control) 
8. Molecular weight markers 
7 8 
The dioxygenin probe reacts with glycosylated proteins producing an intense, 
dark band. The transferrin positive control was detected in this way, there was 
some reaction with the negative control but the band was not as intense.There 
was some reaction with material at the top ofthe gel where the material had 
not run into the SDS-page gel used for this Western blot, also some of the 
material from lane I had leaked into lane2. Fl antigen was not detected. 
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purified from the culture supernatant directly or from a 1M NaCI wash of the cells in an 
attempt to determine whether the F 1 antigen requires a more complex media in order to be 
glycosylated or that the FI more closely associated with the cell is glycosylated. Proteins 
bound to a nitro-cellulose membrane were again stained with Ponceau S and marked 
(fig.4.4b), the membrane was then probed using the DIG glycan detection kit. The results 
showed that only the positive control glycoprotein produced a dark band, all F 1 samples 
tested were negative. Figure 4.4a shows a Coomassie Blue stained polyacrylamide gel and 
the equivalent Western blot probed using the glycan detection kit (fig 4.4b). 
4.3.3. Detection of glycosylation using FAB-MS 
Following these experiments, the problem of determining glycosylation was approached in 
a different way using F AB-MS. 
F AB-MS has a number of advantages over conventional methods, for example, unusual 
and modified amino-acid residues can be easily identified, mixtures of peptides are 
amenable to analysis and because there is no requirement for a free N-terminus, cyclic and 
N-terminally blocked materials can be characterised. 
The technique is particularly useful in the identification of post-translational modifications 
including glycosylation. FAB-MS can also be used to check the correctness of 
chromosomal DNA-derived protein sequences. 
4.3.3.1 Acetolysis 
Purified FI was examined by FAB-MS after acetolysis of the native protein (Naik et al., 
1985). The procedure is a useful preliminary to a more detailed structural study. The 
method is based on acetolysis of an intact glycoconjugate generating a mixture of 
peracetylated carbohydrate groups from oligosaccharides and glycoproteins which are then 
extracted with chloroform and analysed by F AB-MS. Contaminating salt and peptide 
fragments generated by acetolysis remain in the water layer and do not interfere with the 
subsequent mass spectrometric analysis. In this way, the presence of hexoses, 
aminohexoses and sialic acid can be determined. The aim of these experiments was to 
determine whether acetolysis and subsequent F AB-MS of F 1 could detect the presence of 
carbohydrate~ the time course used, in principle, would permit the detection of fragments 
from labile and resistant glycosidic bonds. 
Fig. 4.4 Comparison of Fl antigen grown in different culture 
media for detection of glycosylation using DIG kit 
4.4aSDSPAGE 
kDa 
97 
66 
45 
31 
21 
14 
1 2 3 4 5 6 7 8 9 10 
-:--~ transferrin 
-
- + control 
-
....... 1- Fl 
4.4b Western blot and detection of glycosylation by dioxygenin conjugate 
10 9 8 7 6 5 4 3 2 1 
kDa 
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For both gels: 
Lane: 1. Molecular weight markers 
2. Transferrin (+ control) 
3. F1 in YPMH culture supernatant 
4. F 1 purifed from YPMH culture supernatant 
5. FI in 1M NaCI wash of cells grown in YPMH 
6 -8. As lanes 3 to 4 except the samples are from ce1Js grown in Blood Agar 
Base Broth 
7. Creati nase (- contro I) 
8. Molecular weight markers 
136 
One milligram of purified Fl antigen was used and samples taken at O.Sh, 2h, Sh, 8h and 
24h. A ribonuclease A positive control was treated in the same way. After extraction with 
chlorofonn, the samples were dried by evaporation in a fume cupboard for 48h and then 
analysed by F AB-MS. After 5h, the ribonuclease A control had broken down into mono-
hexose, di-hexose and tri-hexose sugars, detected as B-type carbenium ions which showed 
as peaks in the spectra at 331, 619.2 and 907.41m1z (mass-to-charge) respectively (fig. 
4.5a). 
With acetolysis, the dominant pattern of cleavage of the peracetylated neutral 
polysaccharides is on the non-reducing side of the glycosidic oxygen, With charge retention 
on the non-reducing fragment, giving B-type carbenium ions: 
331~ 619~ 907~ 
Hexose - 0 - Hexose - 0 - Hexose - 0 - Hexose - 0 - ......... . 
Such fragments would however, also anse from peracetylated monosaccharides, 
disaccharides and trisaccharides generated by acetolysis. The presence of free 
monosaccharide cannot be inferred from the presence of the ion at 331m1z, it could equally 
have originated from (gas-phase) fragmentation of a longer oligosaccharide and this also 
applies for ions generated at 619 and 907m1z. 
The F 1 samples collected at different time points during acetolysis were also analysed by 
FAll-MS, and peaks corresponding to hexoses are shown in fig. 4.5b. The peaks produced 
by the F 1 samples were similar to those obtained from the positive control, indicating the 
presence of carbohydrate in the purified antigen. However, this technique was only an 
indication of glycosylation and does not establish that a protein is a glycoprotein~ a sample 
contaminated with polysaccharide would give similar results to a bonafide glycoprotein. 
4.3.3.2 Tryptic digestion of the Fl antigen 
This series of experiments aimed to digest the Fl with trypsin, followed by separation of 
the resulting peptide fragments by Reverse Phase HPLC (Mant and Hodges, 1991) and 
subsequent analysis of the fragments by FAB-MS. The predicted fragments produced by 
In 
Fig. 4.5 FAB-MS of positive control glycoprotein (ribonuclease A) 
after Sh of acetolysis showing the signals corresponding to 
hexose polymers and comparison with the Fl antigen. 
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digestion with trypsin for both F 1 and the control protein, and the calculated masses of 
these fragments, are shown in tables 4.1 and 4.2 and fig.4.6. If actual mass of fragments 
does not agree with the calculated mass, post-translational modification of the protein, 
such as, glycosylation, might have occurre~. a- melanocyte stimulating hormone (a-
MSH), which has one tryptic digest site, was used as a positive control for these 
experiments (table 4.1). 
In the first experiment, Fl was digested with trypsin (section 2.6.2.2) and the digest 
examined by FAB-MS before HPLC. The results of this experiment are shown in fig. 4.7 
and none of the predicted mass peaks were evident; in addition, a poor HPLC profile was 
observed indicating that F 1 is resistant to proteolysis. This was a pre1iininary experiment to 
analyse a crude tryptic digest of F 1 antigen and to overcome these problems two 
approaches were used: 
a) Denaturation ofFI antigen by heating at 100°C for 5min, followed by tryptic digestion 
ofFl in lOmM Tris/HCI, pH8.0. 
b) Tryptic digestion of F 1 under denaturing conditions; the F 1 was denatured in 8M urea 
and digested with trypsin in 2M urea (Allen, 1983). 
For both a) and b), tryptic digests were sampled at 4h, 6h and 16h and freezing the 
samples at -20°C terminated digestion. The samples were desalted using a PDIO G25 
sephadex column (Pharmacia) and freeze-dried prior to HPLC. 
In preparation for HPLC, the samples were resuspended in 0.1 % trifluoroacetic acid to a 
concentration of 1O~g/~1. Reverse phase HPLC was carried out using a Browning Spheri-
5 RP8 column, 200~g of tryptic digest was injected onto the column for each run and 
peptide fragments were eluted using an acetonitrile gradient. The a-MSH positive control 
had one digest site and therefore two major peaks should have been observed on HPLC 
(fig. 4.8a). 
A satisfactory HPLC profile was not produced by the urea-denatured F I; no peaks were 
observed and this may have been due to insufficient denaturation taking place to allow 
tryptic digestion of the protein. Alternatively, F 1 may have unfolded in 8M urea but some 
renaturation had taken place when it was diluted into 2M urea for tryptic digestion. 
I ) <) 
Table 4.1 Amino acid sequence of a-MSH showing the tryptic digest 
site, predicted mass of intact peptide and peptide fragments 
after tryptic cleavage are also shown. 
Peptide 
Intact 
T1 
T2 
Sequence 
SYSMEHFRrWGKPV 
SYSMEHFR 
WGKPV 
Arrow indicates tryptic digest site. 
Calculated Mass[ M+H]++ 
1664.8 
1098.483 
585.3274 
Peaks on the F AB-MS spectra should be obtained at the predicted mass values 
J.1f ) 
Table 4.2 Predicted peptide fragments from the tryptic cleavage of the 
product of 1'. pestis cajl gene. 
Peptide Sequence Calculated Mass[ M+Ht 
TI 13 - R39 3504.9 
T2 40-~5 738.87 
T3 E46 - K73 2907.282 
T4 T74 - K108 3757.95 
T5 V I09 - KIl2 416.5 
T6 D1l3 - R1l5 377.35 
T7 DI16 - Kl22 821.88 
T8 V123 - RI45 2452.65 
T9 SI46 - K I50 491.54 
T10 GI51 - KI53 261.277 
TIl LI54 - KI5s 459.54 
T12 KI59 - Q170 1498.606 
Peaks on the F AB-MS spectra should be obtained at the predicted mass values. However, 
some of the low mass fragments may not be detected. 
1·11 
Fig. 4.6 
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51 
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82 
548 
96 
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139 
723 
154 
767 
169 
Predicted peptides produced by the tryptic cleavage of the 
product of Y. pestis caJl gene 
GCAGATTTAACTGCAAGCACCACTGCAACGGCAACTCTTGTTGA 
A DL T AS T TAT A T LV E 
ACCAGCCCGCATCACTCTTACATATAAGGAAGGCGCTCCAATTA 
P A RII T L T Y KIE GAP I 
CATTATGGACAATGGAAACATCGATACAGAATTACTTGTTGGTA 
TIM D N G N I D TEL· L V G 
CGCTTACTCTTGGCGGCTATAAAACAGGAACCACTAGCACATCT 
T L T L G G Y Kf T G T T S T S 
GTTAACTTTACAGATGCCGCGGGTGATCCCATGTACTTAACATT 
VNFTDAA GDPMY LTF 
TACTTCTCAGGATGGAAATAACCACCAATTCACTACAAAAGTGA 
TS Q DG N NIl Q F T TKIV 
TTGGCAAGGATTCTAGAGATTTTGATATCTCTCCTAAGGTAAAC 
I G KiD S RiD F DIS P K r N 
GGTGAGAACCTTGTGGGGGATGACGTCGTCTTGGCTACGGGCA 
GENLVGDDVVLATG 
GCCAGGATTTCTTTGTTCGCTCAATTGGTTCCAAAGGCGGTAAA 
S Q D F F V R is I G S K lG G K 1 
CTTGCAGCAGGTAAATACACTGATGCTGTAACCGTAACCGTATC 
L A A G K IY T D A V T V T V S 
TAACCAATAATCCATATAGATAATAGATAAAGGAGGGCTATTAT 
N Q End 
Nucleotide and deduced amino acid sequence of the Y. pestis caj1 gene (Galyov et al., 
1990). Arrows indicate tryptic digestion sites. 
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Fig. 4.7 FAB-MS of tryptic digest of Fl antigen 
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Fig. 4.8 HPLC of tryptic digests of a-MSH and Fl antigen using a 
Spheri-5 RP8 column 
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Fig. 4.8b Tryptic digest of heat - denatured Fl after 6h incubation with Trypsin 
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thereby masking the tryptic digest sites. Tryptic digestion takes place in 2M urea because 
above this concentration trypsin is inactive. 
The HPLC profiles of peptide fragments produced from the positive control and the heat-
denatured Fl sample at 6h digestion are shown in fig. 4.8, one major (PI) and 8 minor 
peaks from F 1 were detected. The fragments were examined by F AB-MS and their size 
compared with predicted mass (tables 4.1 and 4.2). Two signals were observed at mlz 
585.2 and 1098.4 in the a-MSH fraction, corresponding to peak 1 (PI) (fig. 4.8a) and 
their masses agreed with the predicted masses of these fragments (fig4.9 and table 4.1). No 
mass-to-charge peaks were observed in fractions from P2, fig. 4.8a. In the case of the Fl 
antigen, however, none of the predicted mass-to-charge peaks were observed in any of the 
fractions analysed and very few actual mass-to-charge peaks were detected, making it 
impossible to determine whether any post-translational modification of the protein had 
occurred (figure not shown). 
4.3.4 ESI-MS of the Fl antigen. 
The data presented here were obtained from CBD sector, DERA, Porton Down, Salisbury 
and ESI-MS was carried out using the method described in section 2.6.3. 
ESI-MS enables an accurate determination of molecular weight and is therefore a useful 
tool for determining differences between apparent molecular weight on SDS-P AGE gels 
and actual molecular weight (Ashford, 1992). If the actual molecular weight differed 
greatly from the predicted molecular weight, post-translational modifications, such as 
glycosylation might have occurred. Galyov et al. (1990) predicted Fl to have a molecular 
weight of approximately 15kDa using the amino-acid sequence deduced from the sequence 
of the cafl gene. 
The native Fl analysed by ESI-MS was in solution in distilled water at a concentration of 
lmg mrl. Fig. 4.10 shows the ESI-MS data, giving a molecular weight for the Fl antigen 
of 15563.4 Da. This agrees with the molecular weight of 15kDa deduced from the gene 
sequence, indicating that there is no post-translational modification of the protein and 
therefore, culture-derived native FI antigen is not glycosylated. 
Fig. 4.9 FAB-MS of tryptic digest of a-MSH 
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This mass spectra was obtained from the fraction corresponding to PI (fig 4.8a), two 
major mass peaks were detected corresponding to the expected mass of the predicted 
peptide fragments (table 4.1). 
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Electrospray-ionisation mass spectroscopy (ESI-MS) of culture-derived Fl antigen determining the molecular 
weight of the protein. 
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4.4 Discussion 
This series of experiments were designed to further characterise the FI antigen, especially 
with respect to the glycosylation of the antigen. A number of techniques were used to 
explore the glycosylated state of the antigen. The classic stain for carbohydrates, PAS 
stain, only showed the presence of carbohydrate in the glycosylated control protein. 
Similar results were obtained when proteins were analysed using an enzyme immunoassay 
(DIG glycan detection kit, Boehringer Mannheim). 
F AB-MS techniques were used to investigate post-translational modification of the 
antigen. Acetolysis suggested that carbohydrate was present in samples of the FI antigen 
because F 1 had a similar mass signal profile to the ribonuclease A positive control 
glycoprotein. However, subsequent F AB-MS analysis of tryptic digests of F 1 did not 
confirm this. Acetolysis is a fairly crude technique and the hexose residues detected could 
have been present in LPS or other bacterial polysaccharides contaminating the FI sample. 
In section 3.3.2.5 the LAL assay for endotoxin showed that low levels of endotoxin were 
present in samples of Fl. Previous studies (Bennet and Tornabene, 1974; Glosnicka and 
Gruszkiwicz, 1980) detected galactose in samples of F 1; however, this hexose sugar may 
have been present because of endotoxin in the samples of F 1 analysed. In addition, their 
research may have employed different culturing and extraction conditions. 
The most conclusive evidence indicating that the F 1 antigen is not glycosylated came from 
the ESI-MS data. ESI-MS enables accurate molecular weight determinations and 
therefore, it is possible to use this technique as an aid to detecting post-translational 
modification of peptides and proteins of known amino-acid sequence. The gene sequence 
of cafl (Galyov et at. 1990) encodes a protein with a molecular weight of 15kDa. The 
ESI-MS data agreed with this and determined that the average molecular weight of 
culture-derived FI was 15.563kDa. Therefore, these results indicate that no post-
translational modification of the Fl antigen had occurred. On SDS-PAGE gels under 
denaturing conditions, the FI gives a molecular weight of 17.5kDa. However, SOS-PAGE 
gives only apparent molecular weights of proteins and protein sub-units (+/- 15%) and can 
therefore only give an estimation of molecular weight. 
1'1 X 
Chapter 5 
Encapsulation of Fl antigen 
5.1 Introduction 
A licensed fonnaldehyde-killed whole cell Y. pestis vaccine developed in the 1930's is 
still in use today despite its known limitations. One major limitation is that cases· of 
pneumonic plague have been reported in vaccinees and the vaccine can induce adverse 
clinical side effects. Subunit vaccines using protective components from Y. pestis may 
avoid adverse side effects, but will require adjuvants or delivery vehicles to boost 
immunity. Appropriate delivery fonnulations may induce both systemic and mucosal 
immunity thereby increasing the protection against both bubonic and pneumonic plague. 
Currently, the only adjuvant licensed for clinical use in humans is Alhydrogel. The 
sustained release of antigens from depots by fonnulation of vaccines with adjuvants, such 
as, Alhydrogel and oil-based adjuvants, is a prerequisite for the generation of potent 
immune responses. However, the release of antigens from these systems is short-lived 
compared with the escape of some slow release drugs used for contraception or cancer 
therapy, which are microencapsulated in biodegradable matrices (Beck et al., 1983; 
Verrijk et al., 1992). The use of a biodegradable matrix for the encapsulation of antigens 
may give an extra degree of control in the delivery of vaccines (Kohn et al., 1986; Morris 
et al., 1994; Walker, 1994), with particular emphasis on mucosal immunisation. Orally 
administered particulate materials of diameter <10j.tm are selectively taken up by the 
specialised M-cells in the gastrointestinal tract (GIT) and accumulate in the immune 
inductive tissues in the GIT, the Peyer's patches (PPs) (Bockman and Cooper, 1973; 
O'Hagan et al., 1990). Thus, the fonnulations of antigens into microparticles within this 
size range should facilitate their uptake into the PPs and initiate a mucosal immune 
response. Subsequently, microparticles may pass into the mesenteric lymph nodes and 
spleen, to generate a systemic immune response. 
The use of artificial lipid bilayers in the fonn of vesicles is another efficient means of 
presenting antigens to stimulate a potent immune response (Gregoriadis, 1988; Rooijen 
and Su, 1989). A large variety of phospholipids can be used in an aqueous solution of 
antigen to [onn either unilamellar or multilamellar vesicles. Antigens may be lipid soluble 
and insert into the artificial lipid bilayer, bind to the bilayer or become entrapped inside 
the tirosome vesicle. In multi lamellar vesicles, antigen may also become entrapped in the 
aqueous compartments between the bilayers. The surface may also have a net positive or 
ISO 
negative charge, a feature that can modulate the immune response (Stewart-Tull et ai., 
1978; Davies and Gregoriadis, 1987). By using phospholipids with a high transition 
temperature (Tc), or with an excess of cholesterol (CH), the lipid bilayers become rigid at 
37°C and this results in a slower release of antigen. 
In this study the Fl antigen was entrapped in PLG micro spheres and in Ii po somes. 
Additionally, Fl was used to label the surface of liposomes. The aim was to produce PLG 
microspheres of different sizes {lllm and 81lm} and characterise these biochemically and 
immunologically. The intended size of liposomes was 200nm; phospholipids with high Tc 
values were used in addition to CH so that the liposomes would release antigen more 
slowly and as for PLG micro spheres, the liposomes were characterised biochemically and 
immunologically. 
5.2 Biochemical characterisation of PLG microspheres containing Fl 
antigen 
5.2.1 Entrapment efficiency 
PLG microspheres encapsulating Fl antigen were produced under various conditions. The 
F 1 antigen was dialysed into different buffers in order to determine whether one type of 
buffer might have an advantage over another with respect to encapsulation efficiency and 
the amount of FI entrapped. The solvents used were distilled water, IOmM phosphate 
buffer, pH7.2 and a pI buffer with a pH at the isoelectric point of the antigen. In this study 
the pI buffer used was citrate buffer, pH 4.8. 
Using the three different buffer systems described above, Fl antigen was 
microencapsulated into lllm and 81lm micro spheres (Morris et al. 1994; Jones et al., 
1995). Varying the ratio of polymer used during the encapsulation process (section 2.7.1) 
controlled the size of the microspheres. 
The method for determining the amount of protein encapsulated is described in detail in 
section 2.7.3. Briefly, microspheres were resuspended in 50111 of 100mM NaOH 
containing 1% (w/v) SDS and then heated at 100°C for 4min to disrupt the microspheres 
and release the entrapped antigen. Samples were then allowed to cool and then centrifuged 
at 13000rpl11 for 10min. A BCA reagent protein assay was performed on the supernatant 
I') I 
from each sample; a bovine serum albumin (BSA) protein standard was included in the 
assay. The BSA standard (2mg ml-l) was treated in the same manner as the microsphere 
samples, after which it was diluted to a working solution of 1 mg mrl. 
The efficiency of entrapment and percent entrapment was calculated for each formulation 
(Fig. 5.1). The efficiency of entrapment showed that the protein present in distilled water 
gave the lowest levels of entrapment (approx. 40%), while antigen in phosphate and pI 
buffers overall had higher entrapment efficiencies (60-80%). 
5.2.2 Determination of the size of PLG microspheres encapsulating Fl antigen 
The size of the microparticles produced for each fonnulation was checked using a Coulter 
counter after calibration with latex beads. For the target size of 8~rn PLG micro spheres, 
the average particle size was found to be 7.35J.1.rn for all three formulations. However, for 
the target size of 1 J.lm micro spheres the average size was different for each formulation. 
Microparticles encapsulating FI antigen in distilled water were found to have an average 
particle size of 1.72~m; in phosphate buffer, the average was 1.65~m and in pI buffer the 
average size of the micro spheres was 1.99~m. Due to the limitations of the probe used it 
was not possible to measure the spread of particle size and to overcome this scanning 
electron microscopy was performed on samples ofPLG micro spheres (section 5.2.4). 
5.2.3 Electron microscopy of PLG microspheres 
Microspheres were examined using scanning electron Inlcroscopy to determine the 
spherical nature of the particles, confirm their size and the homogeneity of the PLG 
preparation (fig. 5.3 and 5.4). 
5.2.4 In vitro release of the Fl antigen from PLG microspheres 
An in vitro release study was carried out for each formulation to determine the amount of 
antigen released over a period of several weeks. Examination of the release profiles of the 
antigen also enables determination of whether the F I is internalised or coating the 
microparticles; if the antigen is coating the microspheres a much more rapid release profile 
would be expected. Freeze-dried micro spheres (50l1g) were resuspended in 50~tl PBS 
containing 0.05%(w/v) sodium azide and incubated at 37°C on a Rotamix eppendorf rack. 
Samples (50~L1) were removed at timed intervals over a period of six weeks. The 
1')2 
Fig. 5.1 Entrapment efficiencies and percent entrapment in different 
formulations of microencapsulated Fl antigen 
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Table 5.1 
Microsphere size 
(~m) 
8 
8 
8 
8um 1um 
Microsphere size 
Buffer used 
10mM 
phosphate 
10mM citrate 
(pI) 
10mM 
phosphate 
I OmM citrate 
(pI) 
Protein conc 
In 
micro spheres 
(~g mI-l ) 
12 
9.3 
8.3 
5.2 
3.7 
8.4 
l 'i, 
% Protein 
entrapped 
42 
77.5 
69.2 
43 
31 
70 
o Distilled water 
fil Phosphate buffer 
.pI buffer 
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In vitro release profiles of microencapsulated Fl antigen 
in 111m and BJ.lm microspheres using three different 
buffer systems. 
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supernatant from these samples was assayed using BCA reagent to determine the protein 
concentration and the percent protein released was plotted against time. 
Fig. 5.2 shows the in vitro release profile for each formulation. IJ.lm and 8J.lm 
microspheres with FI microencapsulated in phosphate and citrate buffers released the 
antigen much more rapidly than the distilled water formulation. The time taken to release 
50% of the total protein (half-life) for phosphate and citrate buffer was less than 10 days; 
for the distilled water formulation, however, the palf-life was approximately 42days, which 
equates to approximately Illg protein released per day. These results suggest that the FI 
was internalised in the micro spheres encapsulated in distilled water but surface bound on 
the microspheres produced using phosphate and pI buffers. However, for all formulations 
the release of antigen was sustained over the 42 day time period. 
5.3 Biochemical characterisation of Iiposomes containing Fl antigen 
The liposomes manufactured for the purposes of this study were used for oral and 
intranasal delivery in addition to parenteral delivery of Fl. Delivery route is an important 
consideration in liposome design (Clarke and Stokes, 1995). In this study, the lipid 
composition of both types of liposome was based on previously published methods and 
formulated for oral delivery (Childers et al., 1987), achieving as high a value as possible 
for entrapped volume:lipid ratio. The aim was to produce unilamellar vesicles of 
approximately 200nm in diameter consisting of DPPC, DCP and CH for liposomes 
encapsulating antigen; for liposomes surface-labeled with antigen. DSPC, DPPS, CH and 
the NHSP were used. In both cases the addition of CH serves to make the liposomes more 
robust and release antigen more slowly. In surface-labelled liposomes, the NHSP has a 
head and a tail region; the tail region embeds in the lipid membrane and groups on the head 
region react with lysine residues in the antigen, thereby labelling the surface of the 
liposomal membrane with antigen. The number of potential sites on a protein for binding to 
the liposome surface can be calculated by multiplying the combined molar ratios of the 
protein by the number of lysine residues in the protein. For FI surface-labelled liposomes, 
the molar ratios were; DSPC:DPPS:CH:NHSP:FI = 1: I :2:0.56:8, and as Fl contains 48 
lysine residues, there were 384 potential binding sites. 
Fig. 5.3 
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Fig. 5.4 Scanning electron microscopy of 8J..1m PLG microspheres 
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Surface-labeled liposomes were produced for comparison with liposomes encapsulating 
antigen to determine whether any advantage might be gained from F I being presented on 
the external surface. The hypothesis was that surface-labeled liposomes might mimic the in 
vivo situation where Fl is presented on the surface of Y. pestis. 
The liposomes encapsulating the Fl antigen had a net negative charge because DCP was 
included in their formulation, whereas for surface bound FI, the net charge of the 
liposomes was dependent on the net charge on the protein. 
5.3.1 Sizing of Iiposomes 
Liposomes were sized using PCS; a description of this method is given in section 2.7.6.1. 
The size of liposomes encapsulating F 1 antigen was consistent from batch-to-batch, 
ranging from 181nm to 220nm; for surface-labeled liposomes the average diameter was 
approximately 200nm with polydispersity values of approximately 0.1, which indicated that 
the samples were homogenous suspensions ofliposomes of uniform size. Fig. 5.5 shows a 
typical PCS profile for both encapsulating and surface-labeled liposomes. 
In one study, the size of the liposomes was monitored throughout the extrusion process 
(fig. 5.6). Extrusion of liposomes was carried out using Nucleopore PC membrane filters, 
O.4~m and 0.2~m in size (section 2.7.5). The pores in this type of membrane go straight 
through from one side to the other and so offer minimal resistance to material passing 
through it. The inherent flexibility of phosphlipid lamellae enables liposomes to change 
their conformation so that they can squeeze through the pores. However, liposomes which 
are much larger than the pore size are broken up in the process, and emerge from the 
membrane pore smaller than before. After several extrusion cycles through the membrane, 
a population of liposomes will be reduced in size to an average diameter somewhat smaner 
than the diameter of the membrane pore, with a small proportion still larger than the pore-
size, having squeezed through without breaking up. This was evident from the size 
distribution analysis (fig. 5.S). 
After extruding through two O.4~tm membranes, the liposomes had an effective diameter of 
250nl11. As the liposol11cs wcrc extrudcd through 0.2~tm membranc filters for eight 
Fig. 5.5 Typical pes profiles of encapsulating and surface-labelled 
liposomes 
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The liposomes encapsulating Fl antigen were reduced in size, from 250nm to 181nm in 
diameter, after 8 extrusion cycles. 
cycles the size of the liposomes was reduced to 181 run as the large liposomes were 
broken up to form smaller vesicles during the extrusion process. Overall, the 
polydispersity remained the same over eight cycles; the value was less than 0.1, 
suggesting that a homogenous suspension ofliposomes was obtained (fig. 5.6). 
5.3.2 Quantification of antigen in liposomes 
The amount of antigen in both liposome formulations was determined using the enhanced 
BCA protein assay protocol (section 2.8). Table 5.2 shows the protein assay results giving 
the amount of protein entrapped and indicates that only a small percentage (2.3 - 3.3%) of 
protein was entrapped or surface-bound. However, a large excess of protein was used in 
the starting material. 
5.3.3 Electron microscopy of liposomes 
Liposomes were examined by TEM using a negative stain (section 2.7.6.2). The 
micrographs showed the liposomes to be membranous structures of uniform size (fig. 5.7 
and 5.8); the liposomes encapsulating antigen collapsed as they dried onto the grid and 
folds in the lipid membrane were observed (fig. 5.7). Fig 5.8 shows surface-labelled 
liposomes; overall they are of a uniform size of approximately 200nm and in this 
micrograph the lipid membrane has not dried onto the grid to give a folded appearance. 
5.4 Examination of Fl antigen after encapsulation 
5.4.1 SDS-PAGE of PLG microspheres and liposomes 
PLO microspheres encapsulating F 1 antigen and 1iposomes encapsulating or surface-
labelled with antigen were examined by SDS-PAGE (section 2.5). The gel showed that 
the I7.5kDa FI antigen was present in all samples (fig. 5.9). F1 encapsulated in 811m 
micro spheres and both liposome formulations had the same molecular weight as non· 
encapsulated antigen; however, the Fl bands in the liposome formulations were very 
faint. The l11m PLG particles produced two bands on the SDS·P AGE gel. The upper band 
had a molecular weight of approximately 17.5kDa; the molecular weight of the lower 
band was approximately 15kDa, determined by image analysis (section 2.5.6). 
5.4.2 Immunological examination of encapsulated antigen 
Samples were run on an SDS-PAGE gel as described in section 5.4.1, proteins were then 
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Table 5.2 BCA protein assay of liposome formulations 
Liposome Extrusion Protein Protein in % Protein 
Temperature in starting lipos<;>me Encapsulated 
material (J,lg/ml) 
(mg/ml) 
Encapsulating F 1 56°C 4 130.95 3.27 
antigen 
Surface-labelled with 56°C 8 189.8 2.33 
Fl antigen 
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Fig. 5.9 SDS-PAGE of Fl after encapsulation in PLG 
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transferred to nitro-cellulose membrane (section 2.S.3) and probed with murine anti-FI 
polyclonal antibody. Fig. 5.10 showed that the 17.5kDa protein in the IJ..lm and SJ..lm 
microspheres remained antigenic; the lower protein band in the I J..lm formulation did not 
react with the antibody. In the liposome formulations. the 17.5kDa protein also remained 
antigenic but produced only a faint reaction. probably because only a small amount of 
protein was present in the sample. 
5.5 Discussion 
The aim was to produce PLG micro spheres and liposomes for use in immunisation of mice 
and examine these as alternative vaccine delivery vehicles. 
From the BeA protein assay results on PLG micro spheres encapsulating FI antigen in 
different buffers it was possible to determine the percentage of protein entrapped for all 
formulations and how much material was lost during the process. The results showed that 
FI in phosphate and pI buffers have higher entrapment efficiencies than FI encapsulated in 
distilled water. However. the in vitro release profiles showed that antigen is released more 
slowly from the distilled water formulations than from F I PLG particles in phosphate and 
pI buffers, therefore, a high efficiency of entrapment is not necessarily advantageous. Most 
of the antigen in phosphate and pI buffer formulations is released over a short time « 1 0 
days) after which the release was sustained over a period of 42 days. 
The PLG micro spheres were sized using a Coulter counter and the average size of the 
micro spheres was found to be as expected. However. electron micrographs for both 8~m 
and 1 J..lm micro spheres showed a considerable variation in size, although the average size 
was 0.8SJ..lm for the IJ..lm PLG micro particles and 9.S2J..lm for the SJ..lm microspheres. SEM 
would be the preferred method in future studies. In addition to this, future studies would 
include modifications of the manufacturing process or inclusion of a filtration step to 
attempt to produce a more homogeneous preparation. 
However. this variation in particle size might not be disadvantageous because particles 
<IO llm in size are taken up by the specialised M-cells in the PPs and may result in a potent 
mucosal and serological immune response All of the I ~lm PLG microspheres were 
Fig.S.10 Western blot ofFI after encapsulation in PLG 
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<1OJ.1m in diameter. The 8J.1m microspheres, however, may be disadvantaged by having a 
broad size range as evidence suggests that particles> 1 OJ.1m will not be taken up by the PPs 
in the GIT. 
Liposome preparations were more homogenous as indicated by sizing using pes; a narrow 
size distribution was observed and the polydispersity for all samples was <0.1. Electron 
micrographs confirmed these results and showed that the majority of liposomes, in both 
encapsulating and surface-labeled formulations, had a diameter of approximately 200nm. A 
large excess of protein was used as starting material in the liposome preparations and 
because the percent protein encapsulated is small, this is quite a wasteful process. 
However, it might be possible to recover non-encapsulated or surface-bound protein and 
this could be investigated in future studies. Further work could also include immunogold 
labelling to confirm that the antigen was surface-bound. 
SDS-PAGE and immunoblotting of encapsulated F 1 antigen demonstrated a 17. 5kDa band 
in all PLG microsphere and liposome formulations. The protein band in the liposome 
samples was very faint, it was difficult to load sufficient protein onto SDS-PAGE gels due 
to small amounts of protein entrapped or surface-labeled during preparation. 1 J.1m 
micro spheres produced two protein bands, the lower band proved to be non-antigenic 
when probed with anti-F 1 polyclonal antibody. The identity of this protein is unclear; the 
protein could be a breakdown product of Fl produced during the encapsulation process, 
however, some reaction with the anti-FI antibody would be expected if this were the case. 
Chapter 6 
Immunogenicity and protective efficacy of 
encapsulated antigen 
6.1 Introduction 
The Fl antigen confers protection against Y. pestis infection in a number of different 
animals species (Rust et al., 1971; Simpson et al., 1990), and high anti-Fl titres detected 
in individuals surviving plague infection (Shepherd et al., 1986; Williams et al., 1982) 
indicate that the Fl antigen may be a major protective antigen in humans. 
To overcome the limitations of the current vaccine, a new subunit vaccine should ideally 
induce prolonged protective systemic and mucosal immunity against Y. pestis, giving 
protection irrespective of the transmission route. Most of the work to date on the 
protective potency of the Fl antigen has been done with the protein subunit in appropriate 
adjuvants. 
Recent studies have highlighted the adjuvant properties ofPLG micro spheres (Jones et al., 
1995; Eldridge et al., 1991a) and liposomes (Gregoriadis et a/., 1989; Aramaki et al., 
1994) for use as vaccine delivery systems. In these cases, induction of both serological and 
mucosal responses has been observed following appropriate delivery. These two strategies 
for vaccine delivery both rely on concepts of controlled-release technology. Both are 
aimed at delivering an immunogen to immune effector cells (targeting), protecting vaccine 
antigens from harsh host environments, such as the gut, and to some extent timed-release 
delivery to mimic booster immunisations; short-term or long-term depot effect may be 
achieved, the latter giving either a continuous or pulsed release (Cox et al., 1997). In 
addition, liposomes can be used to fuse with the host cell membrane to facilitate 
intracellular delivery. Therefore, controlled-release systems may provide advantages over 
conventional adjuvant systems, such as antigens adsorbed onto Alhydrogel, by targeting 
antigens to sites where they will be more effective at inducing an immune response. 
Formulation of antigens into vaccine delivery systems may also improve the stability of 
vaccines, making them more useful in under-developed countries with respect to cost and 
shelf life. In addition, administration of vaccines orally or intranasally removes the trauma 
of injection and the reliance on medical staff to perform injections. 
Research has shown that oral vaccination of antigens incorporated into liposomes induces 
a secretory immune response (Childers c/ a/., 1987). However, there is little information 
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concerning size, concentration and form of liposomes that potentiate maximum induction 
of mucosal immune responses. 
In this study, Fl antigen was incorporated into both PLG micro spheres (Jones et ai, 1995) 
and liposomes (Gregoriadis et al., 1988; Aramaki et aI., 1994) and the immunogenicity of 
all formulations assessed. The immune responses to the antigen delivered in this way 
were characterised and compared with those induced by Alhydrogel-adsorbed antigens. 
The comparative efficacy of liposomes and PLG micro spheres in delivering the Fl 
antigen by the i.p., Ln. and oral routes was also assessed in this study. Protective potency 
was assessed by challenging groups of immunised mice sub-cutaneously with virulent Y. 
pestis GB strain. 
The protection afforded by Fl antigen against Y. pestis challenge can be augmented by 
co-immunisation with the V antigen of Y. pestis (Williamson et al., 1995). A recombinant 
V antigen (rV) was produced as a fusion protein with GST (CBD sector, DERA, Porton 
Down, Salisbury) and purified by affinity chromatography. The antigen was found to be 
protective against sub-cutaneous challenge with Y. pestis (Leary et al., 1995). Williamson 
et al. (1995) found that a combination vaccine of Fl and rV antigens gave increased 
protection up to a challenge dose of 109 cfu Y. pestis GB strain. An rFI antigen expressed 
in E. coli protected mice from bubonic and pneumonic plague after challenge with Y. 
pestis by the s.c.route or by aerosol respectively (Andrews et al., 1996). 
Therefore, further studies were performed in which Fl was co-encapsulated with rV 
antigen in liposomes and in PLG microspheres; the protective efficacy of the 
combinations was compared with that afforded by the F 1 alone after s.c. challenge with Y. 
pestis. 
6.2 Immune response to Fl in PLG microspheres and liposomes 
In all graphs, results are expressed as geometric means of ELISA titres observed from 
treatment groups of mice at each sample point. The Student's t test was used to determine 
whether observed differences in group mean titres were significant in samples taken at 
either day 28 or day 42. 
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6.2.1 Antibody titre hi mice immunised i.p. with Fl antigen in PLG microspheres 
Initial experiments were designed to compare the immunogenicity of F 1 in different 
encapsulation formulations with respect to encapsulation buffer and size. Mice were 
sampled at day 28 to assess the immune response after one i.p. dose of encapsulated 
antigen and to determine the influence of the different buffers used to prepare 
microspheres on the response. PLG microspheres prepared with distilled water and 
phosphate buffer induced the highest serum JgG responses, especially for Illm 
micro spheres (fig. 6.1) and the titres were significantly higher than titres produced by FI in I, 
, 
alhydrogel (P<0.02). Of the formulations tested, Illm PLG micro spheres produced in ,'. i '. 
phosphate buffer elicited the highest serum IgA response. An JgA response in stools was 
observed in all formulations after i.p. immunisation (fig. 6.2). 
From this preliminary comparison, there was little difference in antibody titre between the 
different formulations. However, PLG micro spheres produced with F 1 encapsulated in 
phosphate buffer were selected for further study to compare the effectiveness and influence 
of different delivery routes; making a direct comparison with the native Fl antigen and 
liposomes which were prepared in phosphate buffer. 
6.2.2 Immunogenicity of native and recombinant Fl antigen 
Serological and mucosal antibody responses in mice immunised i.p. with native or rFl 
antigen in Alhydrogel or the Greer vaccine given as multiple doses were compared to 
those induced by native F 1 antigen encapsulated into PLG micro spheres administered in a 
single i.p. dose. 
6.2.2.1 Serum antibody response 
Fl antigen entrapped in PLG microspheres stimulated high serum JgG antibody titres when 
given i.p. (fig. 6.3a), similar to the titre induced in mice immunised with Alhydrogel-
adsorbed antigens. Serum IgG titres did not vary significantly between the different 
formulations (P > 0.1). However, after day 28 the antibody titre had started to fall in mice 
immunised with Greer vaccine and PLG micro spheres, whereas the titre was sustained in 
groups immunised with native and rFI. It must be stressed, however, that mice vaccinated 
with PLG micro spheres received only one immunisation, whereas other groups were give 
three doses (fig 6.3a), in order to de~erminc whether the depot release etlcct of PLG 
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Fig. 6.2 Stool anti-Fl antibody titres 28 days after immunisation 
for mice immunised IP with Fl PLG formulations 
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Fig. 6.3 Serum antibody response to Fl antigen after immunisation 
of mice with Fl vaccine formulations 
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microparticles could sustain a similar immune response to Alhydrogel-adsorbed antigens 
after only one dose. 
Similar IgM titres were observed for all groups (fig6.3b); IgA titres were maximal at day 
14 and the titres decreased markedly after this (fig.6.3c). 
The serum IgG isotype was predominately IgGI for all vaccine formulations (fig. 6.4) and 
this did not change with time, apart from the 8Jlm PLG group, which by day 42 had 
developed a predominately IgG2a titre. 
6.2.2.2 Stool antibody response 
Stool IgG titres were similar for mice immunised with nFl, rFl and Greer vaccine. Fl in 
PLG micro spheres gave lower stool IgG response; however, stool IgA titres in the PLG 
microsphere samples were higher than those ofrFl and Greer vaccine (fig. 6.5). 
6.2.3 Immunogenicity of combined Fl and rV antigens in PLG microspheres 
The effect of combining Fl and rV on anti-Fl titres was investigated. Serum IgG titres in 
mice after one i.p. immunisation with Fl PLG micro spheres without and in combination 
with rV antigen PLG micro spheres were similar to the titres observed with the Fl antigen 
in Alhydrogel. There was no evidence of an additive effect by combining the two antigens 
(fig. 6.6a). 
Similar stool IgA titres were observed for all groups. However, the IgA response was 
essentially short-lived and had dropped by day 42 (fig. 6.6b). 
Antibody titres were not observed in samples of saliva. 
6.2.4 Long term antibody response to PLG microspheres 
The long-tenn serum and mucosal antibody response in mice immunised with one i.p. 
dose of Fl and rV PLG microspheres was compared to the same antigens adsorbed to 
Alhydrogel given as a single dose. Mice were sampled for six months after the final 
i mmunisations. 
Anti-FI serum IgG titres were similar for different formulations and titres were virtually 
constant throughout the experiment (fig. 6.7). IgA and IgG titres were determined in 
Fig.6.4 Serum IgG isotype to Fl antigen after immunisation of mice 
with Fl vaccine formulations 
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Fig. 6.5 Stool antibody response to Fl antigen after immunisation 
of mice with Fl vaccine formulations 
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Fig. 6.6 Immunogenicity of combined Fl and rV antigens in 
PLG microspheres to native Fl antigen after i.p. immunisation 
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nFl and rV/nFI antigens were given to groups of mice i.p. in Alhydroge\, 
PLG microsphere formulations were administered in PBS 
a). No data for rV/nFI in Alhydrogel (A 101-1) at dayl4 and day28 
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Fig. 6.7 Anti-Fl long-term antibody response to Fl and rV antigens 
encapsulated in PLG microspheres 
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stools and saliva. Antibodies were not detected in saliva. In stools, IgA was detected but 
the titres were more variable than those for serum IgG and titres were not sustained 
throughout the sampling period; a similar result was obtained for IgG titres in stools 
(results not shown). 
6.2.5 Comparison of oral and i.p. delivery of Fl in PLG microspheres 
Fl in l~m and 8~m micro spheres was given i.p. or orally to groups of 6-S week old mice, 
each group being given one dose. Antibody response was determined over 42 days and 
compared to the response induced by Fl in Alhydrogel (fig 6.S). 
Antigen given orally in PLG micro spheres gave limited serum antibody titres, and the 
response was lower than antigens given i.p. The serum antibody response elicited by l~m 
PLG micro spheres was virtually constant throughout the experiment, whereas with 8~m 
particles the titre started to fall at day 28. In addition, Fl given orally in Alhydrogel 
produced a serum response but this was significantly lower than F 1 in Alhydrogel given 
i.p. (P<O.Ol) (fig. 6.8a). 
An IgA response in stools was seen when the antigens were given i.p. and a weaker 
response was detected after oral administration ofFl antigen (fig. 6.Sb). 
To summarise the data so far, Fl antigen encapsulated in 1 or S~m PLG microspheres 
proved to be immunogenic when given as one dose. Initial studies showed an increased 
response in mice immunised with one dose of PLG microspheres when compared with 
non-encapsulated FI antigen. Further studies comparing nFl or rFl in Alhydrogei and 
Greer vaccine given in three doses with F 1 in PLG micro spheres administered as one dose, 
showed that serum IgG titres did not vary significantly (P>O.l), therefore antigen 
encapsulated in PLG microparticles can elicit a sustained response after only one dose. 
Stool IgA titres gave an indication of mucosal response and titres were higher in mice 
immunised with encapsulated antigen when given i.p.compared to oral administration. 
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Fig. 6.8 Comparison of oral and i.p. delivery of Fl in PLG 
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6.2.6 Antibody titre in mice immunised with Fl antigen in liposomes 
Mice immunised with one dose, i.p. or i.n., with Fl surface-labeled liposomes produced 
high serum IgG titres against Fl antigen (fig. 6.9); only minor differences in the serum IgG 
were observed and were not significantly different to the serum IgG response in mice 
immunised with Fl in Alhydrogel (P>O.I). Fl antigen produced a stool response when 
given in liposomes i.p. or orally but not when given i.n. (fig. 6.10). Oral administration of 
liposomes did not produce a serum IgG response (fig. 6.9). In this experiment, Fl was 
given orally in Alhydrogel and only a limited stool IgA response was observed (fig. 6.10). 
Fl given ip. produced a constant IgA response over the sampling period, whereas the titre 
was much lower at day 42 for Fl in liposomes given i.p. or orally. 
A limited IgA response was detected in saliva samples for all Fl formulations (fig. 6.11). 
The serum IgG isotype in mice immunised with liposomes, like PLG microspheres, was 
predominantly an IgG I response (fig. 6.12). 
Therefore, Fl antigen in liposomes stimulated a serum antibody response after only one 
dose given either i.p. or i.n., but not when given by oral gavage. However, there was a gut 
antibody response after i.p. or oral administration but not when liposomes were given i.n. 
6.3 Antibody-producing cells in spleen and Peyer's patches (PPs) 
The quantities of specific antibody-producing cells in spleens and PPs from ffilce 
irnmunised with vaccine formulations of Fl antigen of Y. pestis were determined by 
modified ELISA (section 2.8.1) in order to further examine the systemic and mucosal 
response stimulated by the different vaccine formulations. Table 6.1 summarises the 
amounts of antibody-producing cells in the tissues of mice immunised with non-
encapsulated antigen (table 6.1a), Fl encapsulated in PLG microspheres (table 6.lb) and 
antigen in liposomes (table 6.lc). The results show higher levels ofIgG-producing cells in 
both spleen and PPs in the groups immunised with F 1 antigen formulations when 
compared to the control groups; levels of IgA- and IgM-producing cells were lower than 
those of IgG-producing cells. IgA- and IgM-producing cells were also detected in some of 
the control groups, indicating either non-specific binding or a limited immune response to 
cmpty ("ghost") liposolllcs and PLG microsphcrcs. 
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Fig. 6.9 Anti-Fl serum IgG titres in mice immunised parenterally, 
intranasally or by gavage with liposomes 
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Fig.6.10 Anti-Fl stool IgA titres in mice immunised parenterally, 
intranasally or by gavage with liposomes 
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Fig.6.11 Anti-Fl IgA titres in saliva from mice immunised parenterally, 
intranasally or by gavage with liposomes 
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Fig. 6.12 Serum anti-Fl IgG isotype distribution in mice immunised 
with liposomes 
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Table 6.1 Antibody producing cells detected in spleen and Peyer's 
patches from mice immunised with vaccine formulations of 
Fl and V antigens of Y. pestis. 
Table 6.1a. Response to antigen in Alhydrogel or PBS 
Flin i.p. 3 S 0.91 0.07 0.27 v 
Alhydrogel pp 0.66 0.019 0.023 
Greer vaccine i.m. 3 S 0.91 0.12 0.72 
PP 0.66 0.21 0.25 
Flin i.p. S 0.63 0.17 0.95 
Alhydrogel PP 0.35 0.25 0.20 
Flin oral S 0.03 0.04 0.37 
Alhydrogel PP 0.02 0.11 0.06 
PBS/ Alhydrogel i.p. S 0.03 0.05 0.33 
control group PP 0.03 0.14 0.10 
PBS/ Alhydrogel oral S 0.01 0.01 0.09 
control group PP 0.0 0.05 0.02 
S spleen 
PP Peyer's patches 
Table 6.1h. Response to antigen in PLG microspheres 
Fl in l~mPLG i.p. S 0.98 0.07 0.35 
microspheres PP 0.82 0.19 0.13 
Fl in 81lm PLG i.p. S 0.55 0.03 0.21 
microspheres PP 0.36 0.15 0.15 
Ghost PLGs i.p. S 0.0 0.01 0.3 1 
PP 0.0 0.01 0.13 
S' spleen 
PP Peyer's patches 
Table 6.1c. Response to antigen in Iiposomes 
.... 
Fl surface-labelled i.p. 1 S 0.82 0.15 0.82 
liposomes pp 0.22 0.28 0.27 
Fl surface-labelled oral S 0.02 0.10 0.62 
liposomes pp 0.07 0.0 0.23 
Liposornes i.p. S 0.22 0.01 0.24 
encapsulating 
Fl antigen pp 0.17 0.13 0.09 
Liposornes oral S 0.02 0.07 0.43 
encapsulating antigen 
Fl antigen pp 0.04 0.24 0.13 
Ghost liposomes (a) i.p. S 0.0 0.02 0.21 
pp 0.15 0.15 0.13 
Ghost Iiposomes (a) oral S 0.01 0.03 0.36 
pp 0.02 0.24 0.18 
GhoSlliposomes (b) i.p. S 0.03 0.0 0.42 
pp 0.03 0.27 0.2 1 
GhoSllipos011lcS (b) oral S 0.0 0.02 0.09 
pp 0.0 1 0.06 0.02 
S spleen 
PI> Peyer's patches 
6.4 Multiple immunisations with FI and rVantigens 
Research has shown a combination of F 1 and rV antigen to be protective in mice when 
given s.c. in Freund's adjuvant (Williamson et al., 1995) and there was evidence of an 
additive effect. 
Previous experiments in this study have involved immunising mice with a single 6 - 10J.lg 
dose of encapsulated antigen or multiple doses of antigen in Alhydrogel. Therefore, the 
immunostimulatory effect of giving three doses of encapsulated antigen formulations by 
different delivery routes was assessed and the protective efficacy of these combination 
vaccine formulations was examined (Section 6.7). 
6.4.1 Serum antibody response to Fl antigen 
Consistently high levels of circulating antibody to FI antigen were detected in groups 
given antigens i.n. or i.p. in liposomes and PLG microspheres; the IgG titres were similar 
to titres observed in mice given F 1 in Alhydrogel. Response to PLG micro spheres given 
orally was poor. However, the formulation incorporating FI on the surface of liposomes 
and encapsulated rV antigen produced higher titres when given i.p. or i.n. than the 
liposome formulations in which both antigens were encapsulated. The titres elicited by 
liposomes given i.n. were higher than titres produced by antigens in PBS using the same 
immunisation route. These results suggest that multiple immunisations with antigens 
formulated in liposomes or PLG micro spheres produced sustained levels of circulating 
antibody (fig. 6.13). In addition, encapsulation of subunit antigens in PLG micro spheres or 
liposomes has an adjuvant effect when given i.n. compared to non-encapsulated antigens. 
6.4.2 Mucosal antibody response 
Only low levels of IgA antibodies were detected in stools (fig. 6.14). Antibodies were not 
detected in saliva. 
6.5 Summary of the immunogenicity of vaccine formulations 
FI antigen was immunogenic in PLG microspheres and liposomes; high circulating levels 
of antibody were observed after only one dose i.p. Antibody titres were similar to those 
obtained for FI in Alhydrogel and the comlllercial Greer vaccine where three doses were 
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Fig. 6.13 Anti-Fl serum IgG response to multiple immunisations 
with Fl and rV antigens 
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Fig. 6.14 Anti-Fl stool IgA response to multiple immunisations 
with Fl and rV antigens 
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given. Liposomes also produced a serum response after one dose by the i.n. route or i.p. 
IgG-producing cells were present in the spleens and PPs of animals immunised i. p. with all 
of the vaccine fonnulations examined. 
After one oral dose, PLG microspheres and liposomes stimulated only a poor serum IgG 
response. There was evidence of a gut mucosal response when liposomes were given i.p. 
or orally, however, PLG micro spheres produced a low stool antibody response after 
administration by oral gavage. In both cases, multiple dosing did not increase titres against 
orally administered antigens. Stool JgA titres from mice immunised with liposomes were 
not confinned by levels ofIgA in PPs of these animals. 
When encapsulated Fl and V antigens were co-administered, no additive effect on Fl 
antibody response was observed. The IgG serum response to these fonnulations was still 
evident after 168 days, but again no additive effect was achieved by combining 
encapsulated F 1 and V antigens. The systemic and mucosal response to antigens given 
orally was poor, even after three doses. In mice immunised i.p. with PLG micro spheres, 
IJ..lm particles induced a sustained response over 42 days but with 8J..lm particles antibody 
levels started to fall after 28 days. However, the levels were sustained if mice were given 
three doses of8J..lm particles i.p. 
6.6 Fl as a protective antigen 
6.6.1 Protective efficacy of F1 antigen in PLG microspheres 
Mice immunised i.p. with Fl in PLG micro spheres (single dose) were challenged at day 60 
after inullunisation with fhlly virulent Y. pestis (GB strain). The protective potency was 
assessed and compared with three doses of either the commercially available Greer whole-
cell vaccine or Fl antigen in Alhydrogel (Fig.6.1S). Mice immunised with Fl in Alhydrogel 
were 90% protected against sub-cutaneous challenge with up to 1 x I 05 cfu virulent plague 
bacilli. The whole-cell vaccine gave 100% protection against 1 x 103 cfu and 40% 
protection against 1 x 107 cfu challenge. Mice immunised i.p. with Fl encapsulated in PLG 
microspheres were protected against challenge with virulent Y. pestis; the 1.0llm 
micro spheres were more protective than the 8.0~tm PLG micropartic\es, giving 100% 
protection at a challenge dose of 1 x 10' cfu, 40% protection against 1 x 1 OS cfu, but no 
protection with 1 x 107 cfu virulent plague bacilli. FI in Alhydrogcl and the Greer whole-
cell vaccine were more protective at the higher challenge doses than the 1.0/1 111 PL(; 
en 
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Fig.6.15 Protective efficacy of Fl antigen in PLG microspheres 
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microspheres. However, the mice immunised with Fl in Alhydrogel and Greer whole-cell 
vaccine were given 2 to 3 doses of antigen before challenge, whereas mice receiving PLG 
micro spheres were only immunised at day o. A single dose of 1.0~m or 8.0~m PLG 
microspheres gave protection against sub-cutaneous challenge with lxl03 cfu plague 
bacilli; the 1.0~m PLG microspheres gave full protection whereas the 8.0~m microspheres 
gave partial (70%) protection. A single dose of 1.0~m PLG microspheres was as effective 
as three doses ofFl in Alhydrogel or the Greer whole-cell vaccine at the lowest challenge 
dose, but protection was not as effective at the higher challenge doses of lxlOs and lxl07 
cfu. 
6.6.2 Protective efficacy of Fl in Iiposomes 
Mice immunised with one dose of liposomes, i.p. or i.n., were challenged at day 60 with 
fully virulent Y. pestis GB strain as described for PLG microspheres. Mice immunised i.p. 
with a single dose of Fl surface-labeled Ii po somes gave a similar level of protection 
against Y. pestis at all three challenge doses as that given by one dose of the antigen 
adsorbed to Alhydrogel (fig.6.16). When given i.n., however, surface-labeled liposomes 
gave only limited protection at the lowest challenge dose. 
6.7 Comparison of the protective efficacy ofliposomes and PLG 
microspheres using Fl and rV combinations 
The most suitable Fl fonnulations detennined from the previous immunogenicity and 
protection studies (section 6.S and 6.7) were selected for a further protection study 
comparing these antigen delivery systems to the same antigens administered in Alhydrogel. 
Mice were immunised with combinations of Fl and rV antigens in liposome and PLG 
fonnulations to assess the protection given by co-immunisation and to detennine the effect 
of giving multiple immunisations by different routes. In this study, all mice were given 
three doses of antigen. Mice receiving liposomes or PLG microspheres were given 5~g of 
antigen per dose (there was insufficient antigen to give 10~g). Animals receiving antigens 
in Alhydrogel were immunised with three, IOllg doses. The results of this protection study 
are illustrated in fig. 6.17. 
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Fig.6.16 Protective efficacy of Fl in liposomes 
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Fig.6.17 Protective efficacy of Fl and rV in liposomcs and 
PLG microspheres 
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6.7.1 PLG microspheres 
There was 100% protection against the highest challenge dose of 1 x 10' cfu when 
immunised i.p. with the combination of FI and rV antigen in PLG micro spheres. The 
protective efficacy was lowered to 100% protection at 1 x lOs cfu when PLG 
micro particles were given i. n. Therefore, multiple immunisations with a combination of F I 
and rV antigens afforded greater protection than immunisation with one dose of F 1 in PLG 
microspheres (section 6.7.1). Antigens given orally in PLG micro spheres failed to protect 
against s.c. challenge. 
6.7.2 Liposomes 
The level of protection seen in mice immunised i.p. with three doses of combined Fl and 
rV antigens in liposomes was higher than in mice given a single dose of Fl antigen in the 
previous study (section 6.7.2). The results also showed that FI antigen surface-bound to 
liposomes gave better protection (87.5% at 1 x lOs cfu) than FI encapsulated in liposomes 
(12.5% at 1 x 10' cfu) when combined with liposomes encapsulating rV antigen and given 
Ln. and to a lesser extent i.p. 
The protective efficacies of all vaccine formulations examined in this study are summarised 
in table 6.2. 
6.8 Discussion 
Microencapsulated F I antigen proved to be an effective immunogen when administered 
i.p., giving high levels of circulating antibody (fig. 6.1). IgA and IgG were detected in 
faecal pellet supernates, giving evidence of a mucosal response with all formulations. 
When comparing serum IgG titres, it can be seen that when administered i.p., the 
microspheres gave serum IgG and stool IgA titres comparable to the non-encapsulated F 1 
antigen (fig. 6.3 and 6.5). 
The immunogenicity elicited by immunising mice with various vaccine formulations of the 
F I antigen of Y. pestis and combinations of nF I and rV antigens was compared Mice 
immunised with F I in PLG microspheres or liposomes developed high titres of circulating 
IgG when the antigens were givcn as one dose i p. Ilowcver, F 1 given orally as one dose 
Table 6.2 A summary of the protective efficacy of vaccine formulations 
of Fl and V antigens of Y. pestis 
Table 6.2a The protective efficacy of vaccine formulations in Alhydrogel or PBS 
comparing one dose with three doses of antigen(s) 
nFI in i.p. 3 100% 90% 10% 
Alhydrogel 
rFI in i.p. 3 100% 60% 10% 
Alhydroge\ 
Greer vaccine l.m. 3 100% 60% 40% 
nFI in i.p. 100% 100% 12.5% 
Alhydrogel 
nF\ and rV in i.p. 100% 100% 100% 
Alhydroge\ 
nFl and rV in i.p. 3 100% 100% 100% 
Alhydroge\ 
nFl and rV in oral 3 0% 0% 0% 
PBS 
nFI and rV in i.n. 3 37.5% 37.5% 0% 
PBS 
Untreated 0% 0% 0% 
control group 
~~()( ) 
Table 6.2b 
nFl in IJ.UTl PLG 
microspheres 
nFl in 8J.UTl PLG 
microspheres 
nFl and rV in 
IJ.UTl PLG 
microspheres 
nFl and rVin 
IJ.UU PLG 
microspheres 
nFl and TV in 
IJ.UU PLG 
microspheres 
nFl and rV in 
8J.UU PLG 
microspheres 
Untreated 
control group 
The protective efficacy of PLG microsphere vaccine formulations 
comparing one dose with three doses of antigen(s) 
i.p. 100% 40% 0% 
i.p. 70% 0% 0% 
i.p. 3 87.5% 100% 100% 
oral 0% 0% 0% 
i.n. 3 87.5% 100% 25% 
i.p. 100% 87.5% 100% 
0% 0% 0% 
Table 6.2c 
nFl surface-
labeJled 
liposomes 
Liposornes 
surface-labelled 
withnFl and 
encapsulating rV 
nFI surface-
labelled 
Iiposornes 
Liposornes 
surface-labelled 
with nFl and 
encapSUlating rV 
Liposornes 
surface-labelled 
with nFI and 
encapsulating rV 
Liposomes 
encapSUlating 
nF I and rV 
Liposomes 
encapsulating 
nF l and rV 
Ghost liposomes 
Untreated 
control group 
The protective efficacy of liposome vaccine formulations comparing 
one dose with three doses of antigen(s) 
i.p. 100% 
i.p. 62.5% 50% 12.5% 
i.n. 37.5% 0% 0% 
lop. 3 87.5% 100% 75% 
1.n . 3 87.5% 75% 12.5% 
i.p. 3 100% 87.5% 50% 
i.n. 3 62.5% 12.5% 0% 
1.p. 0% 0% 0% 
0% 0% 0% 
in PLG micro spheres did not elicit such an immune response in serum (fig. 6.8a). There 
was evidence of a gut mucosal response in faecal pellets when antigen was given i. p. but 
only a limited mucosal response was observed when the antigen was given by oral gavage 
(fig.6.8b). The presence of IgA in faecal pellets indicates the involvement of the gut 
associated lymphoid tissue (GALT) in the immune response to microparticles. Therefore, 
i. p. immunisation with microencapsulated subunit antigens effectively induced both 
systemic and mucosal immunity. Although the normal route by which antigen is taken up 
by the GALT is via the epithelial surface of the gut lumen, Peyer's patch tissue in the 
GALT can also be accessed via the serosal surface if antigen is administered i.p. 
(Williamson et al., 1996). However, the lack of IgA in faecal pellets after oral 
immunisation suggests that microencapsulated antigen was not processed in the normal 
way. 
When Fl antigen in liposomes were used to immunise mice, i.n. or i.p., high circulating 
antibody titres developed (fig. 6.9). The supemates from homogenised faecal pellets were 
assayed to determine whether a gut mucosal response had been produced and F 1 in 
liposomes given i.p. or by oral gavage produced IgA tit res indicative of a mucosal 
response. However, when given i.n. liposomes did not produce IgA titres in faecal pellet 
supemates (fig. 6.10). Therefore, like PLG micro spheres, liposomes can access immune 
inductive sites in the gut after i. p. immunisation. In addition, a gut mucosal response was 
induced after oral administration indicating liposome-entrapped antigens are processed in 
the normal way. However, immunisation via the oral route did not induce a serum 
response. Fl surface-labeled liposomes also gave higher titres 'of gut mucosal antibody 
when given i.p. compared to i.n., indicating that systemic immunity but not gut mucosal 
immunity was activated following a single i.n. dose of liposomes. Therefore, the delivery 
route and antigen localisation in liposomes, in addition to the number of immunisations , 
may affect the immune adjuvant effect. 
Multiple oral immunisations with F 1 alone or F I and V antigens combined did not 
overcome the poor antibody response observed after one dose of encapsulated antigen. 
The lack of response following oral immunisation of PLG microspheres may have been due 
to either the induction of oral tolerance, or destruction of antigen by stomach acid or 
digestion. Further doses of vaccine may be required to compensate for the loss of vaccine 
during passage through the GIT if oral delivery is to he ctlcctivc Enough vaccine needs to 
2()) 
be administered so that sufficient particulate antigen can be taken up by the PPs in the 
small intestine. In addition to this, other mucosal surfaces, such as lung and vaginal 
washings, would need to be sampled to provide evidence of a disseminated mucosal 
immune response .. However, the gut IgA response in mice fed antigen entrapped in 
liposomes suggested that unlike PLG particles, liposome-antigen formulations could be 
processed in the GIT via the epithelial surface in the gut lumen. 
The serum IgG antibody for all vaccine formulations examined was predominantly a Th2 
(IgG1) response indicating that the subunit antigens presented in these formulations were 
similarly processed by APes. 
The protection results showed that Fl in PLG microspheres when given i.p. gave effective 
protection against challenge with Y. pestis after only one dose, especially if the size of the 
PLG microspheres was restricted to 1.0J,1m. The protection was consistent with the Fl-
specific antibody response developed in mice. Previous studies found that the strong 
adjuvant activity of PLG micro spheres was dependent on the microspheres being no more 
than 10J,1m in diameter (Eldridge et al., 1991a; 1990). The protection given by IJ.lm PLG 
micro spheres after only one dose may be a direct result of this as all of the microparticles 
were <10J,1m in diameter (fig. 5.7). In addition to this, the depot release properties of the 
micro spheres mean that less antigen and so fewer doses may be necessary to give 
protection (Eldridge et 01., 1991a; Cohen et 01., 1994), even though in this study there was 
evidence that some of the F 1 antigen had broken down and a smaller protein was present 
in addition to Fl (section 5.4). 
When F 1 antigen in liposomes were used to immunise mice, high circulating antibody titres 
developed when Ii po some formulations were given i.p. and i.n. The protective efficacy of 
Fl in liposomes given i.p. and i.n. was compared with the antigen given i.p. in Alhydrogel. 
FI, when surface-labeled onto liposomes and given i.p, protected against challenge with up 
to 1 x 1 05 cfu plague bacilli and this was similar to the protective efficacy of F I given i. p. in 
Alhydrogel. The same liposomes given i.n., however, only gave 37.5% protection at the 
lowest challenge dose of I x lO'cfu. Therefore, although the serum titres were comparable 
to the liposomes given i.p., liposomes given i.n. are not as protective as liposomes given 
i.p. after one dose. More doscs may be requircd for i.n. administcrc'd liposolllcs to give 
2()·1 
protection against s.c. challenge. 
The protection results from multiple immunisations with a combination of FI and rV 
antigens showed that the greatest protection was afforded by antigens administered i.p., 
whether they were adsorbed to Alhydrogel or in PLG micro spheres and liposomes. The 
most effective liposome formulation was with FI antigen bound to the vesicle surface and 
rV encapsulated in the lipid vesicle. When this formulation was given i.n., it was more 
effective than Alhydrogel-adsorbed antigens given in the same way. This was possibly due 
to the way in which the antigen was presented on the surface of the liposome vesicle, 
which may have been of a similar conformation to FI and V antigens in vivo. 
The results showed that multiple immunisations of a combination of F 1 and rV in 
liposomes or PLG microspheres gave greater protection than FI antigen given alone as a 
single dose in the same vaccine delivery formulations. The most effective vaccine 
formul.ation overall against sub-cutaneous challenge was a combination of FI and V 
antigens administered i.p. as three doses in Alhydrogel. However, this study has shown the 
vaccine potential of encapsulated FI and V antigens given intra-nasally. A vaccine for use 
in humans that can be administered by a less invasive route would be a significant advance 
in vaccine development. Additionally, the aerosol challenge route should be investigated to 
determine protection against pneumonic plague infection. 
Chapter 7 
General Discussion 
7.1 Introduction 
The F 1 antigen of Yersinia pestis has been used in the diagnosis of plague over many years 
(Chen and Meyer, 1966; Balmanyar and Cavanaugh, 1976; Williams et a/., 1988) and 
identified as a protective antigen (Meyer et a/., 1974; Simpson et a/., 1990). However, it is 
of value to fully characterise the antigen, to understand how the antigen affords protection 
against plague and to examine methods that might be used to increase the protective 
efficacy against plague infection. 
7.2 Identification and purification of Fl 
This study succeeded in purifying large quantities of native F 1 by modification of an earlier 
extraction method (Baker et a/., 1952). Although the extraction method used by Baker, 
where cultures were grown on agar medium, has been used for many years for the 
preparation ofFI antigen from Y. pestis, other studies found that bacteria grown in liquid 
culture can yield substantial quantities of Fl comparable to Y. pestis grown on solid 
culture media (Englesberg and Levy, 1954). In addition to this, growth of Y. pestis in 
liquid culture proved to be a practical approach in developing a scaled-up method of 
producing large quantities of antigen (fig. 3.10). A recombinant Fl antigen was produced 
in an attempt to overcome the problems of having to culture large quantities of Y. pestis 
under category 3 containment, which would increase the cost of any resulting vaccine. 
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Abath et al. (1990) examined the immunochemicallocalisation of Fl antigen and found it 
to be localised on the cell surface. In this study, SDS-PAGE and Western blot analysis 
(section 3.2.1) identified a 17.5kDa protein as the Fl antigen. The antigen was found to be 
secreted into the culture supernatant or loosely associated with the outer membrane, but 
was not present in membrane fractions after homogenisation (section 3.2.2). As expected 
for Fl antigen, it was produced only when cultures were incubated at 37°C. The pH of 
larger-scale cultures was maintained at 7.4 as this was found to produce consistently 
higher yields of F 1 antigen from culture supernatants. 
Andrews el al. (1996) used a modification of Baker's method to purify F I; the mcthod 
employed in this study was similar to that of Andrews el at., except that culturc 
supernatants were always lIsed as starting material for purification of native F I. The yield 
of Fl antigen was maximised by repeated washing and centrifugation of the ammonium 
sulphate precipitated pellet. The resulting Fl antigen was >90% pure and free of any 
major contaminating proteins. Attempts to further purify the Fl antigen did not produce a 
purer product. However, ion exchange chromatography was found to be an effective way 
of concentrating the purified product. 
Lipopolysaccharide (LPS) was detected in purified protein samples (section 3.3.2.5) and, 
although removal of this potentially immunomodulatory component was not addressed in 
this study, it might be possible to remove endotoxin using a number of methods. On a gel 
filtration column, LPS from Y. pestis forms large aggregates of high molecular weight 
(Hartley et al., 1974) and would therefore be difficult to separate from native Fl antigen, 
which also forms large aggregates in solution and eluted close to the void volume of the 
gel filtration column used during the course of this study. Andrews et al. (1996) reduced 
levels of endotoxin in purified Fl using immobilised polymyxin B that bound LPS. 
However, LPS levels present in this study did not have an observed toxic effect in mice, 
therefore further reduction in LPS content may not be required. 
To improve the safety of an antigen for use as a vaccme component, further 
considerations would be to show that successive batches of antigen contained only pure 
product and any compounds used during purification and concentration are removed to 
acceptable limits. Standard procedures that exist for vaccine testing, include; (i) protein 
assay, SDS-PAGE and an antigenicity test, such as Western blot, to test protein purity and 
identity; (ii) sterility tests in appropriate media and at appropriate temperatures; (iii) the 
general safety of a vaccine component can be assessed by observation of immunised 
animals after administration of excessive doses; (iv) pyrogen testing by LAL assay for 
quantitation of endotoxin; and (v) assessment of potency by in vitro tests such as 
bactericidal assay and/or in vivo protection tests. These criteria can be specified for each 
vaccine component and must always fall within prescribed limits (Parkman and 
Hardegree, 1994). 
To overcome problems of growing large quantities of Y. pestis, recent studies have 
examined the production of a recombinant FI antigen. Oysten et al. (1995) produced a 
Salmonella aroA mutant expressing FI antigen, but the safety of such live vaccine vectors 
is questionable and enhancement of virulence in the vector by expression of foreign 
proteins needs to be addressed. i\. recombinant f:. coli strain expressing PI as a surface 
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antigen has been used as a source of Fl antigen and purified using methods similar to 
those used for native FI (Andrews et aI., 1996) but sequence analysis of the recombinant 
protein were not reported. In the present study, the cajl gene was successfully amplified 
and cloned into the GST vector. The recombinant strain of E. coli produced adequate 
amounts of fusion protein, but problems were encountered when trying to cleave rFI in 
large enough quantities for vaccine and production studies. The Fl-GST fusion protein 
constituted 43% of the total protein after 5h of induction but was found to be insoluble 
and only 32.7% of the protein in the sonicate supernatant starting material bound to the 
affinity column. The rFl product accounted for only 6.19% of the bound protein(section 
3.3.2.3). Attempts to solubilise the protein using Sarkosyl (section 3.3.2.4) resulted in 
recovery of 75% of the protein; however, when this material was applied to the 
glutathione affinity column, again low efficiency of binding was observed resulting in low 
yields of rFI (section 3.3.2.4), possibly due to the conformation of the rFI masking the 
glutathione binding site on the GST moiety of the fusion protein. Therefore, native Fl 
antigen was purified for vaccine and production studies but further study of a recombinant 
FI antigen is required to produce an antigen that is easily purified in large quantities. An 
alternative expression vector could be used or a recombinant E. coli capable of expressing 
the antigen in vitro (Andrews et al., 1996; Titball et al., 1997). Currently, there is no 
advantage in using a recombinant Fl instead of the native antigen which was purified in 
large quantities during the course ofthis study. 
7.3 Characterisation of Fl antigen 
The study was also successful in characterising the Fl antigen using novel methods to 
those previously used (Bennet and Tornabene, 1974; Glosnicka and Gruszkiewicz, 1980). 
The amino-acid sequence of Fl was predicted from the DNA sequence by Galyov et 
al.(1990). N-terminal sequencing of the first ten amino acids of both the native and 
recombinant antigens agreed with the predicted amino-acid sequence (section 4.2). 
When Baker et al. (1952) first purified the Fl antigen of Y. pestis, it was found to consist 
of a 15kDa subunit (protein only) and a 17kDa subunit (containing both protein and 
carbohydrate). Other researchers have supported this finding (Bennet and Tornabene, 
1974; Glosnicka and Gruszkiewicz, 1980) and therefore, FI has been referred to as a 
17.5kDa glycosylated protein. 
A number of approaches were investigated during this study to determine whether 
purified native Fl was glycosylated, as this might have an immunomodulatory effect on a 
subunit vaccine containing this protein. PAS-stained polyacrylamide gels did not show Fl 
to bear carbohydrate residues even when gels were heavily loaded with protein (section 
4.3.l). Similarly, Fl was not detected by enzyme immunoassay (section 4.3.2) designed 
to detect glycan residues in proteins. In addition to different growth media, high salt 
washes of whole cells and F 1 derived from culture supernatant were examined to 
determine whether growth conditions or close association ofFI with the outer membrane 
affected the glycosylated state of the antigen. In all cases, glycosylation was not detected. 
Samples of purified Fl were also analysed by mass spectroscopy using a number of 
approaches. The first of these methods, acetolysis, is a fairly crude method for detecting 
carbohydrate and is a useful first step before continuing with a more detailed mass 
spectroscopy study. Acetolysis provided evidence of hexose residues in Fl antigen, but 
this was not confirmed by further investigation involving tryptic digestion of the antigen 
prior to F AB-MS; Fl proved to be resistant to denaturation with urea and subsequent 
digestion with trypsin (section 4.3.3.2). This series of experiments provided no evidence 
of post-translational modification of Fl antigen. This result was confirmed by ESI-MS 
which showed purified culture-derived Fl to have a molecular weight of 15.363kDa 
(section 4.3.4). This agreed with the molecular weight predicted from the gene sequence 
(Galyov et al., 1990) and confirmed, therefo!e, that no post-translational modification of 
the antigen had occurred indicating that culture-derived Fl antigen from Y. pestis was not 
glycosylated. This is beneficial for vaccine production in that the native FI, as purified in 
this study and shown to be protective, was not glycosylated which will simplfy the quality 
control of the antigen considerably. 
The hexose residues detected by acetolysis may have arisen from contaminating 
endotoxin. LPS contamination might also explain why carbohydrate moieties were 
detected in earlier studies. However, earlier studies also employed different growth media, 
Y. pestis strains and methods of puri fication that may have contributed to the detection of 
carbohydrates or glycoproteins in these earlier studies. 
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7.4 Vaccine development 
The problem with using synthetic peptides or purified anJigens as vaccine candidates is 
that, compared with the intact organism, the level of induced antibody can be much lower, 
unless the method of presentation is correct. When proteins are released from their natural 
environment conformational changes may diminish their immunogenic activity, or at least 
modify it. Therefore, in addition to immunising with antigen adsorbed onto Alhydrogel 
(at p'resent the only adjuvant registered for use in humans), FI was successfully 
encapsulated into PLG micro spheres and liposomes to achieve higher levels of protective 
antibody. Using vaccine delivery vehicles such as these can modulate antigen processing, 
possibly leading to the development of vaccines which can elicit both systemic and 
secretory antibody responses. FI was also surface-labeled onto liposomes to assess 
whether this might mimic the in vivo conformation of the antigen and optimise the 
immune response. Liposomes and PLG micro spheres have adjuvant properties, therefore 
less antigen may be required to stimulate a potent immune response, thus potentially 
reducing the cost. In addition, immunisation via a mucosal surface, possible with both 
PLG micro spheres and liposomes, is much less invasive and easier to administer. 
7.4.1 PLG microspheres 
7.4.1.1 Microsphere formulation 
The model of antigen release from microspheres can be divided into three phases; an 
initial "burst" release of surface-located and poorly entrapped protein, followed by a 
period of minimal release while polymer degradation starts, and a third phase of 
degradation-dependent release, which continues until the microparticles are depleted of 
protein (O'Hagan et al., 1991). The immune response might be dependent on the 
physiological site at which protein is released and the rate of release. The study of 
microparticles with different release rates has shown that the more rapidly degrading 
polymer, Resomer RG506, was most effective for induction of high levels of salivary 
IgA, while the more slowly degrading polymer, RG 755, was most effective for the 
induction of serum IgG antibody (O'Hagan et al., 1994). In this study, microspheres were 
produced using RGS06 in an attempt to demonstrate a mucosal antibody response to 
determine whether this would result in increased protection against s.c. Y. pestis 
challenge. 
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7.4.1.2 Size-effect of PLG microspheres 
Tabata et al. (1996) examined the size-effect of PLG micro spheres on mucosal response 
using ovalbumin as a model antigen. After oral administration, the amount of 
microspheres taken up by PPs increased with increasing size up to 11 ~m, uptake decreased 
thereafter and finally became zero when their diameter reached >21 ~m. After being taken 
up into PPs, microspheres <5~m in diameter seemed to be translocated to the spleen, 
where released antigen produced a serum antibody response. However, larger 
micro spheres probably remained in the PPs leading to induction of IgA secretion. 
Therefore, size distribution of micro spheres could be a key factor in regulating the 
induction of a systemic and mucosal response. Tabata et al., (1996) determined the 
number of micro spheres in tissue sections by fluorescent microscopy and microspheres 
were separated according to size into fractions by counterflow centrifugal elutriation 
(CCE). 
Eldridge et al., (1990,1991b) found that oral administration of staphylococcal enterotoxin 
B in microspheres with diameter of 1-1 O~m stimulated a higher serum antibody response 
than that of free antigen; secretion of IgA in mucosal tisssues was also enhanced by 
microsphere administration if the size was restricted to <1 O~m. Therefore, IgA secretion 
may not be simply a case of larger microspheres being retained by PPs and stimulating 
production ofIgA. 
In this study, examination of microspheres by SEM showed a marked variation in size, 
but size variation was less in the l!lm sample than in the 8/J.m microsphere sample. In the 
1 ~m microspheres all particles sampled measured <2~m in diameter; the mean diameter 
for the 8Jlm microspheres was <lOJ.lm but some micro spheres in the sample were as large 
as 20~m in diameter. This may have disadvantaged the 8~m microsphere in that 
immunisation with these particles might not lead to a disseminated immune response 
because larger particles would not be taken up as efficiently by the PPs with subsequent 
translocation to the spleen. Antibody-secreting cells (ASCs) in spleens and PPs of mice 
immuniscd with PLG fom1ulations were examined. When mice were given one dose i.p. 
of I ~lm microspheres, increased levels of ASCs in both immune inductive sites were 
observed compared with one dose of FI in Alhydrogc1 given i.p. Larger microspheres 
found in the 8~LI11 sample would be expected to remain in PPs leading to [gA secretion, 
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however, increased levels ofIgA-secreting cells were not observed (section 6.4). 
7.4.2 Liposomes 
7.4.2.1 Liposome formulation 
Although the basic model of a liposomal vesicle comprises uni- or multi-lamellar bilayers 
of phospholipid, the possibilities for variations of this basic model are many. Clarke and 
Stokes (1992) investigated liposome stability in vitro with liposomes composed either of 
PC, CH and DCP or DPPC, CH and DCP. Both formulations demonstrated negligible 
release at 4°C, similar amounts of protein were released at 37°C and showed substantial 
resistance to disruption in the presence of acidic stomach contents. However, DPPC-
containing liposomes were more resistant to disruption in the prese~ce of bile. Mori et al. 
(1992) found that inclusion of DSPC and CH in the phospholipid bilayer.produced more 
rigid vesicles and increased the circulation time of liposomes in body fluids, such as 
serum. Phillips et al. (1996) examined the influence of phospholipid composition on 
antibody response to protein and peptide antigens encapsulated in liposomes. Vesicles 
composed of DPPC and DMPG were found to be the only effective adjuvant for the 
induction of s-IgA and circulating IgG antibody against Schistosoma mansoni 
glutathione-s-transferase after oral administration. 
Two liposome formulations were examined in this study, the first was similar in 
composition to vesicles used by Michalek et al., (1992) for oral immunisation; a 
homogeneous suspension ofliposomes (ca. 200nm) consisting ofDPPC, CH and DCP. In 
the second formulation, NHSP was added producing liposomes surface-labeled with Fl 
antigen; these vesicles also contained CH to make them more rigid and therefore more 
likely to withstand the harsh environment of the gut. Empty or "ghost" liposomes were 
produced as negative controls for immunogenicity and protection experiments. Both 
liposome-antigen formulations induced a serum IgG response after i.p. and i.n. dosing but 
not after oral immunisation. Liposomes given orally or i.p induced a limited IgA response 
in stools but i.n. immunisation did not induce a stool IgA response. However, surface-
labeled liposomes were found to be more effective at inducing a protective immune 
response to Y. pestis challenge. Therefore, although optimal antigen presentation in 
liposomes is unknown, whether they should consist of free antigen in liposome 
suspension (unincorporated), totally encapsulated or surface-labeled with antigen, the 
results of this study indicated that presentation of the antigen would seem to be an 
important factor in liposome design. 
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7.4.2.2 Size-effect of Iiposomes 
Michalek et al. (1992) examined the effect of liposome size on the secretory IgA response 
in rats and found that unilamellar vesicles of approximately 100nm in size induced higher 
levels of secretory IgA than a non-homogeneous suspension of multi-lamellar vesicles 
after gastric intubation of antigen. 
As with PLG microspheres, the size of the vesicles and release of antigen may affect the 
adjuvanticity of liposomes. Some researchers have incorporated soluble and particulate 
antigens in giant liposome vesicles with a mean diameter of S.S).lm and successfully 
encapsulated whole cells (Antimisiaris et aI., 1993) in such lipo~omes. Michalek et al 
(1992) fed rats with either a non-homogeneous suspension of liposomes ranging from 
150nm to 600nm in diameter or an homogeneous suspension of liposomes encapsulating 
antigen of approximately 100nm and found that the smaller liposomes induced higher 
levels of s-IgA. In this study, size variation was not studied in detail. Liposomes designed 
to withstand the harsh conditions of the gut and stimulation of a mucosal response were 
used for oral, Ln. and Lp. immunisation, based on the findings of previous studies (Clarke 
and Stokes, 1992). Homogeneous suspensions of liposomes encapsulating or surface-
labeled with antigen of approximately 200nm in diameter were examined. 
7.5 Immune response and protective efficacy in mice 
The immunogenicity and protective potency of Fl antigen, alone or in combination with 
rV antigen were assessed using different vaccine delivery methods and were compared 
with these antigens given to Balb/c mice in Alhydrogel or PBS depending on the delivery 
route.The ability of these vaccination regimens to elicit mucosal and systemic responses 
was assessed and protective potency was determined by challenging mice by the sub-
cutaneous route with virulent Y. pestis GB strain. 
Long term mucosal immunity would be advantageous in protecting against pneumonic 
plague. However, long-tenn systemic immunity would also be needed to prevent bubonic 
plague and reduce the number of vaccinations required. Essentially, mucosal antibodies 
are short-lived, whereas systemic antibody response is long-lived and this has 
implications for immunity to mucosal infection. Delivery systems such as PLG 
microsphcrcs and liposomcs have the potential to produce a more long-tcm1 mucosal and 
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systemic response because of their depot-release properties and can be administered by 
various, less invasive routes. 
7.5.1 PLG microspheres 
7.5.1.1 Intraperitoneal (i.p.) immunisation 
The adjuvant effect of PLG micro spheres following i.p. injection of mice was examined 
by Nakaoka et al., (1996) using ovalbumin (OVA) as a model system. A strong antibody 
response was induced compared with free OVA and the response was maintained over a 
period of 16weeks. Jones et al., (1995) encapsulated Bordetella pertussis fimbriae in 
microspheres of approximately 241-t.m in diameter, protein was released in vitro over 
42days, and mice immunised i.p. were protected against challenge with B. pertussis. 
Antibodies to encapsulated fimbriae were slightly lower than non-encapsulated fimbriae 
in Alhydrogel but both formulations protected against B. pertussis challenge. 
In the present study, the in vitro release of antigen from PLG micro spheres was sustained 
for a period of 42 days. There was an initial burst-release of antigen during the first five 
days, followed by a sustained level of release over the following 37 days (section 5.2.4). 
The immune response to Fl antigen released from PLG microspheres in vivo was 
assessed; a systemic response was observed up to 168 days after one dose i.p. 
immunisation, although in encapsulated formulations a decline in titre was observed. 
However, a sustained response was also observed in mice given one dose of FI in 
Alhydrogel i.p. Therefore, in addition to the amount of antigen released over a period of 
time, the immune response might also depend on the physiological site at which the 
antigen is released and the results indicated that the in vivo release of antigen was slower 
than the rate of release in vitro (42 days, section. 5.2.4). Other researchers have 
demonstrated that PLG microspheres form a depot at the injection site from which antigen 
is released over prolonged periods of time (Gupta et al., 1996) and this would also explain 
why in this study a sustained response was observed after only one dose. 
When Fl was gIven l.p. either Alhydrogel-absorbed or encapsulated in PLG 
microspheres, high circulating levels of IgG were observed which compared well with the 
commercial Greer vaccine. Titres were consistent over the 60day sampling period for F 1 
in Alhydroge\ (3 doses) but in mice given one dose of PLG particles i.p. or three doses of 
Greer vaccine i.Ill., titres were lower after 42 days for II-1m microspheres, 14 days for 81-lJl1 
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microspheres and after 28 days for Greer vaccine. Therefore, although three i.p. doses of 
non-encapsulated FI gave the most sustained serum IgG response, the I~m PLG 
microspheres gave a sustained response after only one dose. The number of IgG-
producing cells in spleens and PPs in mice given one dose of I ~m micro spheres i.p. was 
similar to that observed in mice given three doses of Fl in Alhydrogel i.p .. Therefore, 
antigen in 1 ~m PLG microspheres induced a response equal to that induced by non-
encapsulated antigen and only one dose is required if encapsulated antigen is administered 
i.p. Elevated stool IgA titres were used as a marker for mucosal response; however, 
increased stool IgA titres were not observed in mice given one dose ofPLG microspheres 
i.p. and combining microspheres containing Fl and V antigens did not have a synergistic 
effect. 
Immunisation of mice i.p. with one dose of 1 or 8Jlm formulations of PLG microspheres 
containing Fl protected against Y. pestiS challenge at 103 cfu, at higher challenge doses 
the 8Jlm microspheres did not protect, while l~m PLG micro spheres afforded some 
protection. After three doses i.p., both 1 or 8Jlm microspheres provided 100% protection 
against 107 cfu. Therefore, although the presence of much larger micro spheres in the 8~m 
formulation may have disadvantaged their uptake by PPs and subsequent translocation to 
the spleen and other immune inductive sites, this was apparently overcome by giving 
three doses of the 8~m PLG microsphere vaccine i.p .. 
7.5.1.2 Oral immunisation 
Oral delivery of 1 or 8~m PLG micro spheres did not augment the mucosal response; 
serum IgG and stool IgA titrcs were lower than those observed with antigens given i.p .. 
Additionally, elevated levels ofIgG and IgA secretion by ASCs from spleen and PPs were 
not observed. 
Oral immunisation of PLG encapsulated Fl antigen or a combination of Fl and V 
antigens resulted in at best only poor systemic and gut mucosal responses, irrespective of 
the number of doses given. By giving antigen in PLG microspheres of <lO~m orally it 
should be possible to elicit a mucosal response by delivery of antigen to ASCs by M cells 
in the GALT followed by a disseminated response via the common mucosal immune 
system to distant mllcosal tisslles (section 1.7.5). 
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O'Hagan et al. (1994) found salivary and serum IgA responses in mice dosed orally with 
OV A in PLO microspheres made with the R0506 resomer after two doses of 
encapsulated OVA. Jones et al. (1996) found that orally administered microencapsulated 
B. pertussis (2f.lm diameter) protected mice from respiratory infection and mounted an 
increased mucosal response compared with antigen adsorbed onto Alhydrogel given i.p. 
Although the same PLO resomer was used in this study as O'Hagan et al. (1994) and a 
similar microsphere formulation was used by Jones et al. (1996), the antibody response 
and protection afforded by oral administration of PLO formulations was poor and 
multiple doses or co-administration with V antigen did not improve the outcome (section 
6.8.1). 
7.5.1.3 Intranasal (i.n.)immunisation 
Almeida et al. (1993) examined nasal delivery of tetanus toxoid associated with PLO 
microspheres in rats, rabbits and guinea pigs. They observed that micro spheres with a 
mean diameter of 51 0-930nm entered the blood circulation from the rat nasal cavity. 
In the present study, Fl In If.lm PLO micro spheres were co-administered with 
microspheres containing V antigen in three doses. The antibody response and protective 
efficacy was higher than free antigens in PBS given i.n .. Even at the highest challenge 
dose, PLO micro spheres gave 25% protection compared with no protection afforded by 
the non-encapsulated antigens. It is possible that i.n. administration of PLO microspheres 
resulted in a protective immune response because antigen was delivered directly to lung 
macrophage and therefore to the BALT. This can then act as an inductive site for 
migration of IgA-committed B-cells to other mucosal tissues and at the same time 
stimulation of a systemic IgO response (de Haan et al., 1995). In addition, nasal 
administration ofPLO microspheres resulted in sustained levels of anti-Fl serum IgO. 
7.5.2 Liposomes 
7.5.2.1 I.P. immunisation 
J.P. immunisation with liposomes has not been extensively studied by other researchers as 
the main routes of administration are considered to be oral and i.n. However, this study 
found that i.p. immunisation stimulated high serum antibody titres, which were sustained 
over the 42day sampling period. There was also evidence of a gut mucosal response, 
dcmonstrated by stool Ig1\ titres but titres dcclined after day28. Salivaty IgA was also 
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measured but only a low response was observed that was not sustained. IgG and IgM-
producing cells were detected in spleen and PPs from mice immunised with surface-
labeled liposomes. Lower levels of ASCs were observed with liposomes encapsulating 
antigen. When mice were given three doses of FI and rV liposomes co-administered, 
serum IgG titres were at a similar level to those observed in mice given antigens in 
Alhydrogel. Protection was afforded against Y. pestis infection, especially when 
liposomes were surface-labeled with Fl antigen. After one dose of surface-labeled 
liposomes given Lp., 70% protection was observed with a challenge dose of 105cfu and 
when the number of immunisations was increased to three doses given i.p. before 
challenge, 100% protection was observed at 105cfu. 
7.5.2.2 Oral immunisation 
Clarke and Stokes (1992) examined intestinal and serum humoral response of mice to 
systemically and orally administered antigens in liposomes. They failed to demonstrate 
improved levels of intestinal IgA levels after feeding antigen in liposomes. The results 
obtained in this study confirmed this. Therefore, feeding antigen in liposomes does not 
enhance the serum humoral response or s-IgA response in the gut or saliva. 
The results for both PLG micro spheres and liposomes administered orally indicated that 
there was low or no intestinal absorption of liposomes or PLG microspheres. Therefore, 
the properties responsible for the adjuvant action of liposomes and PLG micro spheres 
administered parenterally may be inapplicable to the induction of an immune response in 
the intestine. Repeated doses of PLG microspheres and liposomes failed to overcome low 
immunogenicity and protection afforded by oral administration of liposomes and PLG 
microparticles; no protection against Y. pestis infection was observed even after three 
doses. A reason for the low response could be induction of oral tolerance to Fl antigen. 
Thomas et al. (1992) evaluated the Fl antigen as a potential oral immunogen in mice and 
found that intragastric intubation of Fl antigen failed to show an elevated immune 
response and protection against Y. pestis infection. The observations made in this study 
agreed with these findings even when the antigen is protected by encapsulation in PLG 
microspheres or liposomes. Either the antigen did not survive proteolysis or the quantity 
absorbed was too low to stimulate antibody production and therefore induced oral 
tolerance. 
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7.5.2.3 LN. immunisation 
Abraham (1992) demonstrated that l.n. administration of bacterial polysaccharide in 
liposomes enhanced the antigen-specific pulmonary secretory response compared with 
non-encapsulated polysaccharide, therefore acting as an adjuvant for Ln. administration 
of a poorly immunogenic antigen. Aramaki et at (1994) investigated the effects of 
liposomes on the systemic and mucosal immune response following nasal administration 
in Balb/c mice using BSA-associated liposomes as a model and determined BSA-specific 
serum and salivary IgA levels. Levels were found to be significantly elevated after two 
doses of i.n administered liposomes. Antigen localisation was found to be important; 
mucosal response was activated by liposomes surface-labeled with BSA and a systemic 
response was activated by Ii po somes surface-labeled with or encapSUlating BSA. High 
salivary IgA levels were observed when BSA was coupled to the outer surface of 
liposomes and no increase in this parameter was observed in liposomes encapSUlating 
BSA. 
This study showed that after Ln. administration of liposomes, a sustained serum IgG 
response was induced but no s-IgA was observed in stools or saliva. Liposomes surface-
labeled with F 1 antigen induced the highest titres and also gave enhanced protection 
against Y. pestis challenge compared with liposomes encapsulating antigen; this did not 
change when three doses of antigen were given and increased protection was observed in 
groups receiving liposomes encapsulating rV and surface-labeled with Fl antigens. 
Therefore, antigen localisation would seem to be an important factor following nasal 
administration of liposomes. The protective efficacy was lower when this formulation was 
administered i.n. compared with antigens adsorbed to Alhydrogel given Lp. However, Ln. 
administered liposomes were more protective than Fl and V antigens given 1.n. in PBS, 
giving 75% compared with 37.5% protection at 10scfu Y. pestis (tables 6.2a and 6.2c). 
In future studies of both liposomes and PLG microspheres, other mucosal sites, for 
example, lung and vaginal washes, could be sampled to assess a number of distant 
mucosal sites and to determine the s-IgA response, thereby further characterising the 
mucosal response to encapsulated antigens administered parenterally or to a mucosal 
surface. 
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7.6 Implications of the present study for vaccine development 
The killed whole cell plague vaccine is, at present, the only widely used vaccine that 
protects against plague infection. However, protection is limited and it is questionable 
whether it will protect against respiratory infection. Therefore, an improved vaccine 
giving protection against plague infection by the s.c. and respiratory route is required. 
In the present study, Fl antigen protected against infection with virulent Y. pestis, but a 
combination vaccine of Fl and rV antigens in Alhydrogel afforded greater protection. 
Anderson et al. (1996) found that rV gave protection against infection with both capsule 
positive and negative strains of Y. pestis. Although naturally occuring Fl-negative strains 
are rare, some cases have been reported (Friedlander et al., 1995; Winter, 1960). The 
present study succeeded in evaluating Fl antigen alone or co-administered with rV 
antigen as a potential vaccine against Y. pestis infection. 
Comparison of Lp., Ln. and oral delivery showed that i.p. administered antigens induced 
high levels of circulating antibody and provided effective protection against s.c. 
challenge. The most effective formulation was Fl and rV co-administered in three doses 
i.p. in Alhydrogel, which gave full protection at the highest challenge dose. Antigens 
delivered intra-nasally in liposomes or PLG micro spheres induced high serum IgG titres 
and protected against s.c. Y. pestis challenge but the gut mucosal response was poor. 
Encapsulated antigens afforded increased protection against s.c. challenge compared with 
Fl and rV antigens delivered intranasally in PBS. Orally immunised mice mounted only a 
poor systemic and mucosal response and this was reflected in the protective efficacy of 
oral formulations. 
Therefore, i.n. administration of encapsulated antigens by delivering antigen to the BAL T 
stimulated a protective response, but a gut mucosal response was not observed. The 
current hypothesis is that IgA committed B cells migrate to distant mucosal sites via the 
common mucosal Immune system. However, there IS some evidence of 
subcompartmentalisation of the common mucosal immune system (Mestecky et af. 1994) 
(fig. 7.1) where the highest levels of JgA secretion would occur locally at the site of 
immunisation. IgA-secreting B cells could then disseminate into the different 
compartments of the mucosal immune system and the site more distant from the site of 
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immunisation would have diminished amounts or no antibody response to the antigen. 
This may be the reason why a poor gut response to i.n. administered antigens was 
observed. If higher levels of antibody were present at the immunisation site, it follows 
that better protection would be afforded at the natural site of infection. Therefore, with 
pneumonic plague i.n. immunisation may be the preferred route of immunisation. 
PLG microspheres are considered suitable for oral delivery of peptides (O'Hagan et al., 
1994) and the reasons for a poor oral response, possibly due to oral tolerance, should be 
investigated in future studies. Previous studies have shown that parenteral priming 
followed by oral boosting can produce increased antibody levels in animal models (Keren 
et al., 1988 ). This sort of immunisation schedule may also overcome the problem of oral 
tolerance. Similarly, parenteral priming followed by Ln. administration of encapsulated 
antigens may increase protection against Y. pestis infection. 
This study showed that there was no advantage in using encapsulated Fl and rV antigens 
compared with antigens injected i.p. in Alhydrogel against sub-cutaneous Y. pestis 
infection. However, encapsulation of antigenic pep tides or proteins can be used for 
vaccine development and may be more effective when infection is by other routes, such 
as, i.n. or by aerosol. The immune responses induced to PLG micro spheres and liposomes 
were similar to that induced by non-encapsulated antigens especially after three doses and 
protection was afforded by both methods. However, in liposome formulations antigen 
presentation would seem to be important. Further work should include an aerosol 
infection model to determine whether encapsulated antigens give increased protection 
over injection of non-encapsulated Fland rV antigens against respiratory infection. 
However, the results of this study did show that i.n. administration of liposomes and PLG 
micro spheres were more protective against Y. pestis s.c. challenge than Fl and rV in PBS 
administered by the same route and so might be a possible vaccine to protect against both 
s.c. and aerosol challenge. Additionally, i.p. immunisation could not be transferred 
directly to use in humans and other routes, such as i.m. or s.c. need to be investigated. 
Additionally, to further augment the protective Immune response with encapsulated 
antigens, especially with respect to increased s-IgA, further work could include cytokines 
or the cholera toxin B subunit (CTB) as adjuvants. Cytokines have been shown to be 
involved in many aspects of the immune response including activation, proliferation and 
<Ii ffcrentiation of Band T lymphocytes, the activation of mononuclear phagocytcs and 
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Fig. 7.1 Subcompartmentalisation of the common 
mucosal immune system 
Inductive sites 
Tonsils 
Nasal lymphoid tissue 
BALT 
GALT upper gut (ileum ) 
lower gut (rectum) 
Effector sites · 
Nasal mucosae 
Upper respiratory tract 
Lacrimal 
Salivary . glands 
Mammary 
Small intestine 
Large intestine 
Genital tract 
Higher levels of mucosal antibody are achieved locally at the site of 
immunisation and a reduced response at distant mucosal effector sites 
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attraction of cells such as macrophage to the site of infection (Taylor, 1995). Certain 
cytokines have the ability to stimulate the production of a particular antibody isotype, for 
example, interleukin-5 (IL-5) can augment IgA secretion. Williamson et a/., 1996 
demonstrated increased protection against Y. pestis infection when microencapsulated FI 
and rV antigens were co-administered i.p. with CTB. Therefore, it might be possible to 
modify the immune response using encapsulated antigen combined with adjuvants such as 
cytokines or CTB as an improved method of vaccine delivery. 
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Renaturation buffer 
SOmM Tris 
20% Glycerol 
pH adjusted to 7.4 with 6M HC!. 
TAE buffer 
121g Tris/HCI 
28.6ml glacial acetic acid 
SOml O.SMEDTA 
Appendix 1 
Duffers used 
This was made up in SOOml distilled water and the pH adjusted to 8.0 
TDE buffer 
89mM Tris 
89mM boric acid 
2.SmMEDTA 
pH 8.2 
TE buffer 
10mM Tris/lICI 
ImM EDT A 
pIl8.0 
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